Emerging Threats and Innovative Responses: Novel Bacterial Taxa in Immunocompromised Patients

Abstract

This article synthesizes current research on the discovery, clinical impact, and management of novel bacterial taxa in immunocompromised patients. It explores the foundational knowledge of these emerging pathogens, details advanced methodological approaches for their identification, addresses diagnostic and therapeutic challenges, and evaluates novel treatment strategies. Aimed at researchers, scientists, and drug development professionals, this review highlights the critical intersection of microbial evolution, clinical microbiology, and the urgent need for innovative solutions to combat antimicrobial resistance in vulnerable populations.

The Uncharted Microbiome: Discovering Novel Bacterial Taxa in Vulnerable Hosts

Immunocompromised patients represent a critical niche for the emergence and propagation of novel bacterial taxa and pathogenic entities. This whitepaper delineates the complex interplay between host immunity deficits and microbial adaptation, drawing upon recent advances in molecular diagnostics and multi-omics profiling. Within this vulnerable host environment, conventional pathogen definitions are being recalibrated through frameworks such as the damage-response model, where commensal-pathogen boundaries blur and opportunistic taxa exploit immunological voids. The analysis synthesizes evidence from respiratory, gastrointestinal, and systemic infections across cancer, transplant, and critical care settings, highlighting the discovery of novel microbial communities and their functional contributions to disease pathogenesis. This refined understanding of host-microbe dynamics in immunocompromised hosts offers transformative potential for risk stratification, targeted antimicrobial therapy, and innovative treatment strategies that leverage or restore protective microbiota functions.

The expanding population of immunocompromised hosts—including transplant recipients, individuals with hematologic malignancies, those receiving immunosuppressive therapies, and critically ill patients—has created unprecedented selective environments for microbial adaptation and emergence of novel pathogens [1] [2]. Traditional concepts of microbial pathogenesis are being fundamentally reshaped by observations in these patients, where the damage-response framework provides a more nuanced understanding of host-microbe interactions than rigid classifications of virulence [3]. In this framework, microbial pathogenesis represents an outcome of host-microbe interaction where the amount of damage to the host defines disease states ranging from commensalism to lethal infection [3].

The clinical significance of this niche is substantial; immunocompromised patients experience infection-related mortality rates up to threefold higher than immunocompetent individuals, with nosocomial infections affecting 20-50% of critically ill patients [4] [5]. Advances in next-generation sequencing technologies have revealed that this vulnerable population not only experiences infections with uncommon pathogens but also harbors novel microbial communities with distinct functional profiles that influence disease progression and outcomes [6] [7] [5]. This whitepaper examines the evidence for immunocompromised patients as a niche for novel bacterial taxa, detailing the mechanisms of emergence, diagnostic approaches, and therapeutic implications.

Microbial Niches in the Immunocompromised Host

Anatomical Sites of Pathogen Emergence

Table 1: Primary Anatomical Niches for Novel Pathogen Emergence in Immunocompromised Hosts

Anatomical Site	Key Microbial Alterations	Clinical Consequences	Supporting Evidence
Lower Respiratory Tract	Enrichment of Pneumocystis jirovecii, Aspergillus fumigatus, Klebsiella pneumoniae, SARS-CoV-2	Severe pneumonia with frequent co-infections (36.5%), high 28-day mortality	[6] [5]
Gastrointestinal Microbiota	Enterobacteriaceae expansion, loss of commensal anaerobes (Ruminococcaceae, Lachnospiraceae)	Impaired systemic immunity, increased nosocomial infections	[4]
Intratumoral Microenvironment	Distinct microbial community subtypes (IMCS) with varying metabolic profiles	Modulation of cancer progression, influence on metastasis and treatment response	[7]
Systemic Circulation	Pathogen translocation from disrupted mucosal barriers	Bloodstream infections with opportunistic pathogens	[4]

Novel Bacterial Taxa and Community Structures

Recent investigations have revealed novel bacterial assemblages in immunocompromised hosts that diverge significantly from those in immunocompetent individuals. In colorectal cancer liver metastasis (CRLM), intratumoral microbial community subtypes (IMCSs) demonstrate distinct taxonomic and functional profiles [7]. These include:

• IMCS1: Characterized by sugar metabolism-related liver metastasis with T cell activation and moderate proliferation/invasion (median DFS: 22 months)
• IMCS2: Dominated by protein metabolism with natural killer cell activation and high proliferation/invasion (median DFS: 12 months)
• IMCS3: Defined by lipid metabolism with a pauci-immune phenotype and the highest proliferation/invasion (median DFS: 10 months) [7]

At the genus level, significant alterations include increased abundance of Odoribacter, Leptothrix, Clavibacter, and Caulobacter in CRLM patients, while Agrobacterium, Fusobacterium, Methylobacterium, and Faecalibacterium are depleted compared to non-metastatic colorectal cancer [7]. The species Faecalibacterium prausnitzii, typically considered beneficial, is significantly reduced in metastatic disease, suggesting its potential protective role [7].

In critically ill patients, gut microbiota dynamics demonstrate progressive enrichment of Enterobacteriaceae, which inversely correlates with overall microbiota diversity (Shannon index) and is linked to impaired neutrophil function and increased susceptibility to nosocomial infections [4]. This Enterobacteriaceae expansion occurs independently of antibiotic exposure, illness severity, or admission diagnosis, suggesting intrinsic host immune deficits as the primary driver [4].

Diagnostic Approaches and Experimental Methodologies

Advanced Sequencing Technologies

Table 2: Comparison of Diagnostic Platforms for Pathogen Detection in Immunocompromised Hosts

Methodology	Target Range	Sensitivity	Turnaround Time	Key Advantages	Limitations
Broad-spectrum tNGS (bstNGS)	1872 microorganisms (1124 bacterial, 218 fungal, 474 viral, 56 parasitic species)	96.33% vs mNGS, 91.15% vs culture	~36 hours	Higher diagnostic accuracy (90.67%) than mNGS (86.00%) and culture (49.33%)	Requires specialized probe design
Metagenomic NGS (mNGS)	Virtually any microorganism	82.00% pathogen detection in LRTI	~48 hours	Hypothesis-free approach	Host nucleic acid contamination; unstable AMR gene detection
16S rRNA Gene Sequencing	Bacterial identification only	Varies with bacterial load	24-72 hours	Cost-effective for microbiota profiling	Limited to bacterial taxa; no functional data
Standard Microbiological Testing	Culturable pathogens only	46.00% pathogen detection in LRTI	48-72 hours	Provides antibiotic susceptibility	Limited sensitivity; prior antibiotic use affects yield

Laboratory Workflows for Pathogen Identification

Figure 1: Experimental Workflow for Pathogen Detection via Sequencing Technologies

Broad-Spectrum Targeted NGS (bstNGS) Protocol

The bstNGS methodology represents a significant advancement for comprehensive pathogen detection in immunocompromised hosts [6]. The detailed protocol includes:

• Sample Processing: Bronchoalveolar lavage fluid (BALF) samples are collected within 48 hours of clinical presentation and subjected to simultaneous DNA and RNA extraction using commercial kits designed to minimize host nucleic acid carryover.

• Library Construction: Nucleic acids are converted into sequencing libraries through fragmentation, end-repair, adapter ligation, and amplification steps optimized for low microbial biomass samples.

• Target Enrichment: Libraries undergo capture-based enrichment using custom-designed probes covering 1872 microbial species (1124 bacteria, 218 fungi, 474 viruses, 56 parasites) during a 4-hour hybridization process [6].

• Sequencing and Analysis: Enriched libraries are sequenced on the Gene+ Seq-100 platform, generating single-end 100bp reads with a minimum output of 5 million reads per sample. Quality control thresholds include Q20 ≥95% and Q30 ≥88%. Bioinformatics processing involves:

  • Adapter trimming and quality filtering using fastp (v0.23.1)
  • Host sequence subtraction via alignment to human genome (hg38)
  • Microbial classification using BWA alignment to a curated pathogen database
  • Threshold determination: RPM ≥6 for common bacteria, RPM ≥0.5 for fungi/mycobacteria [6]

Microbiota-Immune Metasystem Analysis

For investigating integrated host-microbe interactions, a multi-omics approach is required:

• Longitudinal Sampling: Serial collection of fecal specimens (via rectal swabs) at ICU admission, day 3, and day 7 for 16S rRNA gene sequencing (V4 region) on Illumina MiSeq platform [4].

• Immune Profiling: Parallel blood collection for single-cell mass cytometry analysis of systemic immune responses using a panel of 35 metal-tagged antibodies targeting leukocyte differentiation and functional markers [4].

• Data Integration: Multi-Omics Factor Analysis (MOFA) to identify latent factors linking microbiota dynamics with immune phenotypic changes and clinical outcomes [4].

Research Reagent Solutions

Table 3: Essential Research Reagents for Investigating Pathogens in Immunocompromised Hosts

Reagent Category	Specific Products/Assays	Research Application	Technical Considerations
Nucleic Acid Extraction	QIAamp UCP Pathogen DNA Kit, QIAamp UCP Pathogen Mini Kit	Selective isolation of microbial nucleic acids with host background depletion	Critical for low microbial biomass samples; DNase treatment for RNA workflows
Library Preparation	Ovation RNA-Seq System, Ovation Ultralow System V2	cDNA synthesis and library construction from low-input samples	Optimized for challenging clinical specimens with high host contamination
Target Enrichment	Geneplus custom capture probes (1872 pathogens)	Selective amplification of microbial targets from complex samples	4-hour hybridization; covers bacteria, fungi, viruses, parasites
Immunological Assays	Metal-tagged antibody panels (35-marker), CMV CMI assays	Single-cell immune profiling and pathogen-specific T-cell function	Mass cytometry enables deep immunophenotyping; functional assays predict reactivation risk
Microbial Culture	Selective media for vancomycin-resistant enterococci, fungal cultures	Isolation and expansion of low-abundance pathogens	Essential for antibiotic susceptibility testing but limited sensitivity

Mechanisms of Pathogen Emergence and Adaptation

Ecological Disruption and Niche Exploitation

In immunocompromised hosts, the breakdown of colonization resistance creates ecological opportunities for novel pathogen emergence. The gut microbiota normally provides a barrier effect through multiple mechanisms including resource competition, production of inhibitory metabolites, and maintenance of physiological conditions that suppress pathobiont expansion [8] [4]. Critical illness and immunosuppression trigger profound dysbiosis characterized by:

• Loss of Anaerobic Fermenters: Depletion of commensal families Ruminococcaceae and Lachnospiraceae that produce short-chain fatty acids with immunomodulatory properties [4]
• Enterobacteriaceae Expansion: Progressive enrichment of Enterobacteriaceae (median ~10-fold increase in relative abundance) that inversely correlates with overall microbiota diversity [4]
• Reduced Community Stability: Increased microbiota volatility with >41% of critically ill patients showing doubling of Enterobacteriaceae between consecutive sampling time points [4]

This dysbiosis is not merely a consequence of antibiotic exposure but represents an intrinsic aspect of critical illness, as progressive Enterobacteriaceae enrichment occurs independently of antibiotic spectrum or duration in multivariable analysis [4].

Metabolic Adaptation and Immune Evasion

Novel bacterial taxa in immunocompromised hosts exhibit distinct metabolic profiles that enable persistence in compromised host environments. In colorectal cancer liver metastasis, intratumoral microbial communities show subtype-specific metabolic programming:

• IMCS1: Enriched for sugar metabolism pathways with concomitant T cell activation
• IMCS2: Dominated by protein metabolism associated with natural killer cell activation
• IMCS3: Characterized by lipid metabolism linked to pauci-immune phenotypes and worst prognosis [7]

Functional metagenomic prediction using PICRUSt2 reveals differential abundance of key enzymatic pathways in pathogens from immunocompromised hosts, including:

• Increased pyruvate kinase (carbohydrate metabolism)
• Elevated oxaloacetate decarboxylase (TCA cycle)
• Enhanced immunity-related proteins [7]

These metabolic adaptations interface with immune evasion strategies, particularly in patients with impaired myeloid function. Intestinal Enterobacteriaceae enrichment is coupled with systemic immune alterations including hypofunctional and immature neutrophils, creating a self-reinforcing cycle of impaired host defense [4].

Figure 2: Mechanisms of Novel Pathogen Emergence in Immunocompromised Hosts

Therapeutic Implications and Future Directions

Microbiota-Directed Interventions

The recognition of immunocompromised patients as a niche for novel pathogens has stimulated development of innovative therapeutic approaches aimed at restoring protective microbiota functions:

• Barrier Effect Reinforcement: Identification of seven commensal bacterial species that confer resistance against vancomycin-resistant enterococci (VRE) proliferation through synergistic interactions with resident microbiota [8]

• Predictive Biomarkers: Development of microbiota-based risk stratification tools that predict infection vulnerability in high-risk populations such as leukemia patients receiving intensive chemotherapy [9]

• Fecal Microbiota Transplantation: Successful application of FMT in common variable immunodeficiency patients with intestinal dysbiosis, demonstrating feasibility in selected immunocompromised hosts [3]

Diagnostic-Driven Antimicrobial Stewardship

Advanced molecular diagnostics enable more precise antimicrobial strategies in immunocompromised hosts:

• Pathogen-Targeted Therapy: bstNGS detection of causative pathogens in respiratory infections is associated with improved antibiotic treatment outcomes (89.68% vs 62.50% benefit; OR 7.53, 95% CI 1.41-45.30) compared to non-detection [6]

• Antiviral Stewardship: Implementation of CMV-specific cell-mediated immunity assays to guide preemptive therapy and prevent unnecessary antiviral exposure in transplant recipients [2]

• Resistance Management: Genomic sequencing of multidrug-resistant pathogens (e.g., Staphylococcus aureus, Candida auris) to identify vulnerabilities and inform combination therapies [9]

Immunocompromised patients constitute a definitive niche for the emergence and selection of novel bacterial taxa and adapted pathogens. The convergence of host immune deficits, ecological disruption of resident microbiota, and microbial metabolic adaptation creates an environment where the traditional boundaries between commensals and pathogens dissolve according to the damage-response framework. The research methodologies and evidence synthesized in this whitepaper provide a roadmap for investigating these complex host-microbe dynamics, emphasizing integrated multi-omics approaches that connect microbial community shifts with systemic immune function. As diagnostic technologies continue to advance, particularly through targeted sequencing and single-cell immune profiling, the capacity to identify novel pathogens, understand their mechanisms of emergence, and develop targeted interventions will transform the management of infections in this vulnerable population. This evolving paradigm positions the immunocompromised host not merely as a setting for opportunistic infections, but as a crucial environment for discovering fundamental principles of host-microbe interactions and microbial evolution.

The study of novel bacterial taxa—newly identified and characterized bacterial species—has profound implications for clinical microbiology, especially in the management of immunocompromised patients. The discovery of these organisms is accelerating due to advanced molecular techniques like whole-genome sequencing (WGS), revealing a previously hidden diversity of bacteria associated with human disease [10]. Immunocompromised individuals, with their altered host defenses, provide a unique niche for these novel pathogens to establish infection and cause significant morbidity and mortality.

Understanding the epidemiology and clinical significance of these novel taxa is critical. These organisms can be resistant to conventional therapies, associated with atypical presentations, and complicate treatment decisions. This whitepaper synthesizes current data on the prevalence of novel bacterial taxa and quantifies their impact on patient outcomes, providing researchers and drug development professionals with the evidence base and methodological frameworks needed to advance this field.

Epidemiology of Novel Bacterial Taxa

Prevalence in Clinical Settings

The isolation of novel bacterial taxa from clinical specimens is more common than previously recognized. Prospective studies systematically applying advanced identification methods have quantified this phenomenon.

Table 1: Prevalence of Novel Bacterial Taxa in Clinical Isolates

Source / Study	Study Design / Population	Total Isolates Analyzed	Novel Taxa Identified	Prevalence / Key Findings
NOVA Study (2014-2022) [10]	Prospective; clinical specimens not identifiable by routine methods (MALDI-TOF & 16S rRNA)	61 isolates	35 novel species	57% (35/61) of unidentifiable isolates represented novel species
Ibid. [10]	Ibid.	61 isolates	7 clinically relevant novel species	11.5% (7/61) of unidentifiable isolates were both novel and clinically relevant
2024 Taxonomic Update [11]	Literature review of novel taxa from human clinical specimens in 2024	N/A	Multiple novel species	New clinically significant species described: Staphylococcus brunensis, Providencia huashanensis

The NOVA study algorithm, which utilizes WGS for isolates that cannot be characterized by conventional methods like MALDI-TOF MS and partial 16S rRNA gene sequencing, found that over half of such problematic isolates represented novel bacterial species [10]. Among these, a significant proportion (7 out of 35 novel species) were assessed by infectious disease specialists as being clinically relevant, meaning they were associated with the patient's signs and symptoms of infection. These strains were predominantly isolated from deep tissue specimens or blood cultures, underscoring their invasive potential [10].

Gram-positive organisms, particularly within the genera Corynebacterium and Schaalia, were the most frequently identified novel taxa in the NOVA study. Other novel species were found in genera including Anaerococcus, Clostridium, Desulfovibrio, Peptoniphilus, Neisseria, and Pseudomonas [10]. Continuous updates to taxonomic classifications, such as the recent description of Staphylococcus brunensis and Providencia huashanensis, further expand the list of clinically significant novel pathogens [11].

The Human Microbiome as a Reservoir

The human gut microbiome is a significant reservoir for novel bacterial taxa. Cultivation-based studies have shown that a substantial portion of commensal gut bacteria isolated from human fecal samples represent previously unknown species.

Table 2: Novel Taxa in the Human Gut Microbiome (HiBC Study)

Parameter	Findings
Total Strains in Collection	340 strains
Total Species Represented	198 species
Previously Unknown Species	29 novel taxa
Key Novel Species	Ruminococcoides intestinale, Blautia intestinihominis
Ecological Impact	Novel taxa from HiBC increased microbiome coverage in metagenomic analyses by 3.75 ± 3.99% on average, representing >10% of the microbiota in 380 individuals [12].

The Human intestinal Bacteria Collection (HiBC) study isolated 340 strains representing 198 species, of which 29 were previously unknown and have been taxonomically described [12]. Some of these novel species, such as Ruminococcoides intestinale, are not merely rare curiosities but can be dominant members of an individual's gut microbiota, with a mean relative abundance of 2.84% in positive metagenomic samples [12]. This highlights that novel taxa can be constitutive and potentially key components of the human microbiome.

In immunocompromised hosts, a disrupted gut microbiome (dysbiosis) can lead to loss of colonization resistance, allowing otherwise commensal novel taxa or antimicrobial-resistant pathogens to expand and translocate across the intestinal barrier, causing bloodstream infections and other invasive diseases [13]. This is particularly relevant for carbapenem-resistant Enterobacteriaceae (CRE), where the gut serves as a major reservoir [13].

Clinical Significance and Impact on Outcomes

Association with Clinical Conditions

The clinical relevance of a novel bacterium is determined by correlating its isolation with the patient's clinical presentation. In the NOVA study, of the 47 cases with available medical records, the novel bacterial isolate was considered clinically relevant in 15 (approximately 32%) cases [10]. In a subset of these (3 out of 15), the culture was monomicrobial, providing stronger evidence for the pathogen's role in disease.

Novel taxa can also have complex associations with health and disease states, as demonstrated by metagenomic studies of isolated strains. For example:

• Health-Associated Novel Taxa: Ruminococcoides intestinale encodes numerous proteins that are significantly more prevalent in the gut microbiomes of healthy controls compared to individuals with Crohn's disease (CD) or ulcerative colitis (UC). These include proteins involved in anti-inflammatory pathways, such as the ABC transporter for spermidine and enzymes for biotin biosynthesis [12].
• Disease-Associated Novel Taxa: In contrast, the novel species Blautia intestinihominis showed a more complex association. While many of its proteins were enriched in healthy controls compared to CD patients, a large number (1,450 proteins) were significantly more prevalent in UC patients compared to healthy controls, suggesting a potential role in exacerbating this specific inflammatory condition [12].

Impact on Patient Management

The identification of a novel bacterial taxon presents direct challenges to patient management:

• Diagnostic Delays: Conventional identification methods like MALDI-TOF MS and 16S rRNA gene sequencing often fail to provide a definitive identification for novel organisms, necessitating more complex and time-consuming WGS analysis [10]. This can delay the final microbiological diagnosis.
• Uncertain Pathogenicity: The lack of prior clinical data makes it difficult to definitively ascertain the organism's role as a pathogen, colonizer, or contaminant. This decision often requires expert multidisciplinary consultation [10].
• Unclear Antimicrobial Susceptibility Profiles: Without a history of clinical use against the novel species, antibiotic susceptibility patterns are unpredictable. While WGS can detect known resistance genes, phenotypic testing remains essential for guiding therapy [10].

Essential Methodologies for Identification and Analysis

Accurate identification and quantification of novel bacterial taxa are foundational to epidemiological and clinical studies. The following protocols are critical in this field.

The NOVA Pipeline for Novel Organism Verification

The NOVA (Novel Organism Verification and Analysis) study provides a robust algorithm for identifying novel taxa in clinical isolates that cannot be characterized by routine diagnostics [10].

Experimental Protocol:

• Sample Inclusion: Bacterial isolates that yield no reliable identification by MALDI-TOF MS (score < 2.0) and show ≤99.0% nucleotide identity (≥7 mismatches/gaps) to any correctly described species in 16S rRNA gene sequence databases (e.g., NCBI BLAST) are included [10].
• DNA Extraction: Genomic DNA is extracted using standardized kits (e.g., EZ1 DNA Tissue Kit on EZ1 Advanced Instrument, Qiagen) [10].
• Whole Genome Sequencing (WGS): Libraries are prepared (e.g., NexteraXT) and sequenced on platforms such as Illumina MiSeq or NextSeq500. Sequencing reads are trimmed (using tools like Trimmomatic v0.38) and assembled into contigs (e.g., with Unicycler v0.3.0b) [10].
• Genomic Analysis:
  • Annotation: Assembled genomes are annotated with tools like Prokka v1.13 [10].
  • Species Delineation: The assembled genome is used for taxonomic assignment. This involves:
    • rMLST Analysis: Analysis of ribosomal multilocus sequence typing [10].
    • Digital DNA-DNA Hybridization (dDDH): Using the Type (Strain) Genome Server (TYGS) with a 70% dDDH cutoff value (method 2) as a species boundary benchmark [10].
    • Average Nucleotide Identity (ANI): Calculation of OrthoANIu values with a threshold of ≥96% for species-level identity [10].

The following diagram illustrates the logical workflow of the NOVA algorithm:

Rapid Identification and Quantification from Blood

For sepsis, a novel rapid method enables the identification and quantification of unknown pathogenic bacteria directly from blood within four hours of collection [14]. This is critical for assessing the severity of infection and monitoring therapeutic efficacy.

Experimental Protocol:

• Bacterial Isolation from Blood: A 2 mL whole blood sample is centrifuged at low speed (100 × g for 5 minutes) to pellet red blood cells. The supernatant fraction (500 μL), containing bacteria in the plasma and buffy coat, is collected and pelleted [14].
• DNA Extraction: The pellet is subjected to mechanical (using small beads) and enzymatic (Proteinase K) lysis to maximize DNA yield and maintain consistent efficiency across bacterial species [14].
• Nested Real-time PCR with Tm Mapping:
  • Primary PCR: The DNA template is amplified using seven bacterial universal primer sets with mixed 1st PCR forward primers (to account for sequence variations in the target region and ensure accurate quantification across species) [14].
  • Nested PCR: The primary PCR product is used as a template for a second, quantitative real-time PCR targeting a highly conserved region (e.g., region 3 amplicon). Fluorescence acquisition is set at 82°C to dissociate primer-dimer artifacts [14].
  • Standards: Quantification standards (E. coli DNA solutions of known concentration, measured by flow cytometry) are run in parallel to generate a standard curve [14].
• Identification and Quantification:
  • Identification (Tm Mapping): The seven amplicons from the primary PCR are analyzed for their melting temperatures (Tm). The seven Tm values are plotted to create a unique, species-specific "Tm mapping shape," which is compared against a database for identification [14].
  • Quantification: The pathogen's concentration is determined from the standard curve (Ct value of the region 3 amplicon) and then corrected based on the 16S rRNA operon copy number of the identified bacterium, yielding the final absolute bacterial count [14].

Absolute Bacterial Quantification Methods

Moving beyond relative abundance to absolute quantification is essential for understanding true microbial dynamics in a sample [15]. Different methods are suited to different biological questions.

Table 3: Key Methods for Absolute Bacterial Quantification

Method	Principle	Major Applications	Key Advantages	Key Limitations
Flow Cytometry [15]	Staining and single-cell enumeration by light scattering/fluorescence	Feces, aquatic, soil	Rapid; differentiates live/dead cells; flexible parameters	Background noise; requires gating strategy
16S qPCR [15]	Quantitative PCR of the 16S rRNA gene	Feces, clinical (lung), soil	High sensitivity; cost-effective; compatible with low biomass	Requires standard curve; PCR biases; 16S copy number variation
ddPCR [15]	Partitioning of sample into nanodroplets for endpoint PCR	Clinical (lung, bloodstream), feces, soil	Absolute quantification without standard curve; high precision for low concentrations	Requires dilution for high-concentration templates
Spike-in with Internal Reference [15]	Adding known quantity of foreign DNA/ cells before DNA extraction	Soil, sludge, feces	Easy incorporation into high-throughput sequencing; high sensitivity	Spiking amount and time point critical for accuracy
16S qRT-PCR [15]	Quantitative reverse-transcription PCR of 16S rRNA	Clinical (joint infection), food safety	Targets metabolically active cells (rRNA)	Unstable RNA; an approximation of protein synthesis

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Reagents and Kits for Studying Novel Taxa

Reagent / Kit	Function in Workflow	Key Feature / Rationale
EZ1 DNA Tissue Kit (Qiagen) [10]	Automated genomic DNA extraction from bacterial isolates	Provides high-quality, pure DNA for downstream WGS applications.
NexteraXT DNA Library Prep Kit (Illumina) [10]	Preparation of sequencing libraries for WGS	Enables efficient, tagmentation-based library construction for Illumina platforms.
Eukaryote-made Thermostable DNA Polymerase [14]	Enzyme for bacterial universal PCR in quantification assays	Free from bacterial DNA contamination, eliminating false positives in sensitive detection of low-biomass pathogens.
Mixed 1st PCR Forward Primers [14]	Primers for the initial amplification step in universal bacterial PCR	Accounts for natural sequence variation in the 16S rRNA gene target, ensuring unbiased amplification and accurate quantification across species.
Proteinase K + Lysis Beads [14]	Comprehensive disruption of bacterial cells during DNA extraction	Mechanical (beads) and enzymatic (Proteinase K) action maximizes DNA yield from diverse bacterial species with varying cell wall structures.
Fluorescent Cell Stains (for Flow Cytometry) [15]	Staining nucleic acids for bacterial enumeration	Allows for rapid, direct counting of total bacterial cells; some dyes can distinguish live/dead cells (e.g., using membrane integrity).

The landscape of clinical bacteriology is being reshaped by the ongoing discovery of novel bacterial taxa. Epidemiological studies reveal that these organisms are not rare, but constitute a substantial fraction of clinically relevant isolates that evade routine identification. In immunocompromised patients, they represent a significant source of morbidity and present unique challenges in diagnosis and management due to the lack of historical data on their pathogenicity and antimicrobial susceptibility.

Addressing these challenges requires a multifaceted approach: the adoption of advanced molecular methods like WGS for definitive identification; the development and implementation of rapid quantitative diagnostics for direct patient sample testing; and a deepened understanding of the ecological role these taxa play within the human microbiome, particularly in states of dysbiosis. Future research must focus on correlating genomic data with clinical outcomes to build a comprehensive knowledge base. This will ultimately guide the development of novel therapeutic and microbiome-based interventions, thereby improving care for the vulnerable immunocompromised host.

The discovery and accurate classification of novel bacterial taxa from human clinical specimens are fundamental to advancing diagnostic microbiology and understanding emerging pathogens, particularly in immunocompromised patient populations. Taxonomic revisions, while sometimes challenging to implement, enhance our comprehension of microbial pathogenesis and epidemiology [16]. This guide synthesizes documented novel species and taxonomic revisions from recent literature, providing a structured resource for researchers, scientists, and drug development professionals engaged in this dynamic field. The following sections present summarized data, detailed experimental protocols, and essential research tools to support laboratory investigations.

Summarized Data on Novel and Revised Taxa

The tables below consolidate novel taxa of clinical significance and notable taxonomic revisions published in recent years, providing a quick reference for researchers.

Table 1: Novel Bacterial Taxa from Clinical Specimens (2022-2024)

Scientific Name	Gram Reaction	Source	Key Clinical Relevance/Phenotype
Staphylococcus brunensis sp. nov. [11]	Positive	Not Specified	Clinically significant novel species.
Streptococcus suis subsp. hashimotonensis subsp. nov. [11]	Positive	Not Specified	Can be delineated by possession of Lancefield group A antigen.
Providencia huashanensis sp. nov. [11]	Negative	Not Specified	Clinically significant; harbors multiple antimicrobial resistance genes.
Stenotrophomonas forensis sp. nov. [11]	Negative	Specimen transport medium	A distinct component within the Stenotrophomonas maltophilia complex.
Bartonella tamiae sp. nov. [11]	Negative	Not Specified	Officially recognized agent of the first culture-confirmed bartonelloses in Thailand.
Streptococcus toyakuensis sp. nov. [16]	Positive	Not Specified	Exhibits multi-drug resistance.
Vibrio paracholerae sp. nov. [16]	Negative	Not Specified	Associated with diarrhea and sepsis; co-circulated with pandemic V. cholerae.
Staphylococcus taiwanensis sp. nov. [16]	Positive	Blood	Isolated from a female patient with gastric cancer experiencing fever and chills; oxacillin-resistant.
Arsenicicoccus cauae sp. nov. [16]	Positive	Blood	Isolated from a 17-month-old male with fever, diarrhea, vomiting, and abdominal pain; clinical significance not firmly established.
Streptococcus ilei sp. nov. [16]	Positive	Ileostomy effluent	Isolated from a male patient with a loop ileostomy; clinical significance not established.

Table 2: Significant Taxonomic Revisions (2022-2024)

Revised Taxonomic Status	Previous Classification	Key Clinical Note
Return of Chlamydophila caviae to the Chlamydia genus [11]	Chlamydophila caviae	Reversion to original genus.
Creation of novel Metaclostridioides genus for Clostridioides mangenotii [11]	Clostridioides mangenotii	Reclassification based on genetic analysis.
Reclassification of two Kocuria spp. into two subspecies of Kocuria rosea [11]	Separate Kocuria species	Consolidation into a single species with subspecies.
Reassignment of Fusobacterium nucleatum subspecies to species F. animalis and F. vincentii [16]	Fusobacterium nucleatum subsp.	Elevation of subspecies to full species status.
Reassignment of non-toxigenic C. diphtheriae biovar Belfantii to Corynebacterium belfantii [16]	Corynebacterium diphtheriae	Reassignment of an outlier with unusual phenotypes.

Experimental Protocols for Taxonomic Characterization

The methodology for validly describing a novel prokaryotic taxon is strictly defined by the International Committee on Systematics of Prokaryotes. The following workflow details the key experimental protocols.

Workflow for Taxonomic Validation

The following diagram outlines the primary pathway for the discovery and validation of novel bacterial taxa, from initial isolation to final publication.

Detailed Methodologies

• Phenotypic Characterization: This initial step involves a battery of tests to determine the isolate's morphological, biochemical, and metabolic properties. Standard tests include Gram staining, assessment of cellular morphology, catalase and oxidase reactions, motility, and sporulation. Metabolic profiling utilizes systems like the BIOLOG Gen III or API strips to analyze carbon source utilization and enzymatic activities. Growth characteristics under different temperatures, oxygen tensions, and salinity are also determined [16].
• Genomic DNA Extraction and Whole-Genome Sequencing (WGS): High-quality genomic DNA is extracted from a pure culture of the type strain using standardized kits or manual protocols. Whole-genome sequencing is performed on both short-read (e.g., Illumina) and long-read (e.g., PacBio, Oxford Nanopore) platforms to achieve a high-quality, complete genome assembly. As of January 2018, WGS data of the type strain is mandatory for valid publication of a novel taxon [16].
• Phylogenomic Analysis: The genome sequence is used for definitive classification. The 16S rRNA gene sequence is extracted from the genome and compared to databases (e.g., EzBioCloud, SILVA) to find closely related species. However, the cornerstone of modern taxonomy is genome-based analysis. This includes calculating Average Nucleotide Identity (ANI) and digital DNA-DNA Hybridization (dDDH) values against known type strains. ANI values below ~95-96% and dDDH values below ~70% support the designation of a novel species [16].
• Culture Collection Deposition: The proposed type strain must be deposited in at least two recognized culture collections in different countries. This ensures the organism is available to the scientific community for future study. Examples of such collections include the American Type Culture Collection (ATCC) and the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (DSMZ) [16].
• Publication and Validation: The novel taxon can be effectively published in the International Journal of Systematic and Evolutionary Microbiology (IJSEM) or in another journal with subsequent inclusion in an IJSEM Validation List. The manuscript must provide evidence that all requirements of the International Code of Nomenclature of Prokaryotes have been met, including culture collection accession numbers and the GenBank genome accession number [16].

The Scientist's Toolkit: Key Research Reagents & Materials

Table 3: Essential Research Reagents and Materials for Taxonomic Studies

Item	Function in Taxonomic Workflow
Culture Media (e.g., Blood Agar, Columbia Agar)	Supports the initial isolation and pure culture of novel bacteria from clinical specimens, enabling observation of colonial morphology and hemolytic patterns [16].
Biochemical Profiling Kits (e.g., API, BIOLOG)	Provides standardized, miniaturized tests for assessing metabolic capabilities, which forms a core part of the phenotypic characterization of a novel isolate [16].
DNA Extraction Kits	Facilitates the reliable and pure extraction of genomic DNA, which is a prerequisite for high-quality whole-genome sequencing and subsequent genomic analyses [16].
Whole-Genome Sequencing Platforms (Illumina, PacBio)	Generates the comprehensive genomic data required for phylogenomic analysis, calculation of ANI/dDDH values, and fulfillment of the mandatory sequencing requirement for publication [16].
Phylogenetic Analysis Software (e.g., MEGA, RAxML)	Used to construct phylogenetic trees based on 16S rRNA gene sequences and core genomes, visually illustrating the evolutionary relationship of the novel isolate to known taxa [16].
Public Databases (e.g., GenBank, EzBioCloud)	Provides reference sequences for comparative analysis and serves as the mandatory repository for depositing the genome sequence of the proposed type strain [16].
Culture Collections (e.g., ATCC, DSMZ)	Provides a permanent, public repository for the deposition of type strains, making them available for validation and further study by the global scientific community [16].

The ESKAPE pathogens—an acronym for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—represent a group of multidrug-resistant bacteria that pose a grave threat to global health. These organisms are notorious for their ability to "escape" the bactericidal effects of conventional antibiotics, leading to life-threatening nosocomial infections, particularly in immunocompromised patients [17]. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have classified most ESKAPE pathogens as critical or serious threats, urgently requiring new antibiotics [17] [18]. The challenge is further compounded by the fact that these pathogens are merely the tip of the iceberg. Within clinical settings, particularly in specimens from immunocompromised hosts, microbiologists are increasingly isolating bacterial strains that defy conventional identification methods, many of which represent novel bacterial taxa with undefined pathogenic potential [16] [10]. This whitepaper details the core ESKAPE pathogens, explores the experimental pipelines for discovering novel taxa, and presents the expanding list of high-priority pathogens that threaten patient care.

The Core ESKAPE Pathogens: Clinical Profiles and Resistance Mechanisms

ESKAPE pathogens are a major cause of life-threatening, hospital-acquired infections and correspond with the highest risk of mortality, with the majority of their isolates being multidrug-resistant (MDR) [17] [19]. Their clinical significance is driven by a combination of intrinsic and acquired resistance mechanisms.

Gram-Positive ESKAPE Pathogens

• Enterococcus faecium: This Gram-positive coccus is a frequent cause of healthcare-associated infections in immunocompromised patients. It often exhibits resistance to β-lactam antibiotics and vancomycin, earning the designation vancomycin-resistant Enterococcus (VRE). These strains display a profound ability to develop and share resistance through horizontal gene transfer and can code for virulence factors that result in thicker biofilms, allowing them to grow on medical devices such as urinary catheters and prosthetic heart valves [17].
• Staphylococcus aureus: A Gram-positive coccus commonly found as part of the human skin microbiota, S. aureus can cause severe infections when it enters wounds or the bloodstream. Methicillin-resistant S. aureus (MRSA) strains are resistant to β-lactam antibiotics and are a leading cause of morbidity and mortality. Similar to E. faecium, S. aureus can form biofilms on implanted medical devices, making treatment exceedingly difficult. Some strains also secrete potent exotoxins that can cause toxic shock syndrome or necrotic hemorrhagic pneumonia [17] [18].

Gram-Negative ESKAPE Pathogens

• Klebsiella pneumoniae: This Gram-negative rod-shaped bacterium is particularly adept at accepting resistance genes via horizontal gene transfer. It is commonly resistant to phagocyte treatment due to its thick, adhesive biofilm. Of grave concern is the emergence of carbapenem-resistant K. pneumoniae (CRKP), for which there are very few effective antibiotics in development [17].
• Acinetobacter baumannii: A Gram-negative coccobacillus prevalent in hospitals, A. baumannii can thrive in a wide range of temperatures, pHs, and dry environments. It can develop resistance to all known antimicrobials, partly due to its Gram-negative outer membrane and efflux pumps. It is often the first to develop new β-lactamases and can acquire families of efflux pumps from other species [17]. Carbapenem-resistant A. baumannii (CRAB) is now widespread, with mortality rates from hospital-acquired infections reaching ≥50% [20].
• Pseudomonas aeruginosa: A ubiquitous, Gram-negative rod-shaped bacterium, P. aeruginosa is a versatile hydrocarbon degrader that can survive in extreme environments, including the lungs of patients with late-stage cystic fibrosis. Multi-drug resistant (MDR) strains that express β-lactamases combined with upregulated efflux pumps are particularly difficult to treat [17].
• Enterobacter spp.: This family of Gram-negative, rod-shaped bacteria can cause urinary tract and bloodstream infections. Some species have demonstrated a striking ability to adapt to disinfectants like benzalkonium chloride (BAC). Colistin and tigecycline are among the only antibiotics currently effective against some resistant strains, with few new options in development [17].

Table 1: Core Resistance Mechanisms and Clinical Threats of ESKAPE Pathogens

Pathogen	Gram Stain	Key Resistance Mechanism(s)	Common Infection Types	Notable Resistance Profiles
Enterococcus faecium	Positive	Target site modification, acquired resistance genes [17]	Healthcare-associated infections, urinary tract infections, bacteremia [17]	Vancomycin-Resistant Enterococci (VRE) [17]
Staphylococcus aureus	Positive	Production of modified PBP2a (e.g., mecA gene), biofilm formation [18]	Skin/soft tissue infections, pneumonia, bloodstream infections, bone infections [17]	Methicillin-Resistant S. aureus (MRSA) [17] [19]
Klebsiella pneumoniae	Negative	Production of β-lactamases (e.g., ESBL, carbapenemases), biofilm formation [17] [18]	Pneumonia, urinary tract infections, bloodstream infections [17]	Carbapenem-Resistant K. pneumoniae (CRKP) [17]
Acinetobacter baumannii	Negative	Efflux pumps, acquisition of new β-lactamases, porin loss [17] [18]	Pneumonia, bloodstream infections, wound infections [17]	Carbapenem-Resistant A. baumannii (CRAB) [20]
Pseudomonas aeruginosa	Negative	Upregulated efflux pumps, β-lactamase production, innate membrane permeability [17]	Pneumonia (especially in CF), bloodstream infections, UTIs, surgical site infections [17]	Multi-Drug Resistant P. aeruginosa (MDR-PA) [17]
Enterobacter spp.	Negative	Expression of drug-inactivating enzymes, efflux pumps [17] [18]	Urinary tract infections, bloodstream infections [17]	Multi-Drug Resistant Enterobacter [17]

Beyond ESKAPE: The Challenge of Novel Bacterial Taxa

The ESKAPE list is static, but the microbial world is constantly evolving. Advances in genomic technologies are accelerating the discovery of novel bacterial taxa from clinical specimens, revealing a hidden diversity of potential pathogens. These novel organisms often emerge from under-explored ecological niches and pose a significant challenge for clinical microbiologists and infectious disease specialists [16] [10].

Experimental Pipeline for Novel Pathogen Identification

The identification of novel bacterial taxa requires a systematic approach that moves beyond conventional microbiological techniques. The NOVA (Novel Organism Verification and Analysis) study provides a robust pipeline for this purpose, integrating routine diagnostics with whole-genome sequencing (WGS) [10].

Key Reagents for the Identification Workflow

Table 2: Research Reagent Solutions for Novel Pathogen Identification

Reagent / Tool	Function in Workflow	Specific Example / Note
MALDI-TOF MS	Rapid identification of bacterial isolates based on protein spectral fingerprints.	Bruker Daltonics system; a score of ≥2.0 indicates reliable species identification [10].
16S rRNA PCR Reagents	Amplification of the ~800 bp segment of the 16S rRNA gene for Sanger sequencing.	Critical for isolates not identifiable by MALDI-TOF MS; ≤99.0% identity to known species triggers WGS [10].
DNA Extraction Kit	High-quality genomic DNA extraction for downstream sequencing.	EZ1 DNA Tissue Kit (Qiagen) used in the NOVA pipeline [10].
Whole Genome Sequencing	Provides comprehensive genomic data for high-resolution taxonomic analysis.	Illumina technology (MiSeq, NextSeq); libraries prepared with NexteraXT or Illumina DNA prep [10].
Bioinformatics Tools	Genome assembly, annotation, and phylogenetic analysis.	Unicycler (assembly), Prokka (annotation), TYGS and OrthoANIu for digital DNA-DNA hybridization and Average Nucleotide Identity calculations [10].

The Expanding List: Documented Novel Taxa from Clinical Specimens

The application of the NOVA pipeline and similar approaches has led to the identification of a growing number of novel bacterial taxa from clinical settings. These organisms often originate from deep tissue specimens or blood cultures, indicating their potential to invade sterile sites and cause disease [10].

Table 3: Novel and Clinically Relevant Bacterial Taxa Identified from 2017-2024

Novel or Revised Taxon	Year	Gram Reaction	Clinical Source / Relevance
Corynebacterium belfantii [16]	2018	Positive	Reassignment of non-toxigenic C. diphtheriae biovar Belfantii; clinical significance under investigation.
Enterobacter bugandensis [16]	2018	Negative	Considered the most pathogenic species within the genus; cause of neonatal sepsis.
Lawsonella clevelandensis [16]	2017	Positive	Strictly anaerobic organism associated with various abscess formations, including vascular graft infections.
Streptococcus toyakuensis [16]	2023	Positive	Noteworthy for exhibiting multi-drug resistance; isolated from human clinical specimens.
Vibrio paracholerae [16]	2023	Negative	Associated with diarrhea and sepsis; co-circulated with pandemic V. cholerae for decades.
Corynebacterium sp. nov. (6 strains) [10]	2024	Positive	Isolated from various deep tissue and blood culture specimens; clinical relevance assessed for each.
Schaalia sp. nov. (5 strains) [10]	2024	Positive	Predominant novel genus identified; isolated from diverse clinical samples.
Citrobacter sp. nov. [10]	2024	Negative	One new species identified, expanding the diversity of this clinically relevant genus.

Discussion: Implications for Research and Drug Development

The continuous discovery of novel bacterial taxa, alongside the persistent threat of ESKAPE pathogens, underscores a critical and expanding frontier in public health and biomedical research. For researchers and drug development professionals, this reality demands a dual-focused strategy.

First, the fight against the known ESKAPE pathogens must intensify. The global burden is staggering; in 2019 alone, antibiotic resistance was directly linked to 1.27 million deaths worldwide [18]. Surveillance studies continue to show alarmingly high rates of multidrug resistance among ESKAPE isolates. For instance, a 2025 study in Nepal found that 52.3% of ESKAPE isolates were MDR, with significant proportions isolated from Intensive Care Units (ICUs) [19]. The pipeline for novel antibiotics against these pathogens, while active, is insufficient. Machine learning approaches, such as the ESKAPE Model that predicts antibacterial activity of molecules against these pathogens, represent a promising avenue for accelerating discovery [21].

Second, the scientific community must develop frameworks to proactively address the threat of novel pathogens. The finding that 7 out of 35 novel strains in the NOVA study were clinically relevant demonstrates that the diversity of human pathogens is greater than previously recognized [10]. This has direct implications for diagnostic development, antimicrobial stewardship, and empirical therapy guidelines. The research toolkit must, therefore, evolve to include robust genomic surveillance and rapid whole-genome sequencing as standard practice in reference laboratories. Understanding the pathogenic potential, resistance gene carriage, and transmission dynamics of these emerging taxa is essential for preparing for the next wave of antimicrobial resistance threats.

The list of high-priority bacterial pathogens is not a fixed document but a dynamic entity. The ESKAPE organisms—E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter spp.—remain formidable adversaries due to their sophisticated resistance mechanisms and high associated mortality. However, as this whitepaper has detailed, they are only part of the story. The application of advanced genomic techniques is systematically revealing a hidden landscape of novel bacterial taxa isolated from clinical specimens, particularly from immunocompromised patients. These discoveries, facilitated by pipelines like the NOVA study, expand the list of pathogens of concern and highlight an ongoing need for vigilant surveillance, agile diagnostic methods, and innovative therapeutic development. The scientific and public health response must be as evolving and adaptable as the microbial threats it aims to counter.

In the context of novel bacterial taxa research, particularly concerning immunocompromised patients, the concepts of "sources" and "reservoirs" require precise epidemiological definitions. A reservoir is defined as one or more epidemiologically connected populations or environments in which a pathogen can be permanently maintained and from which infection is transmitted to a defined target population [22]. For clinical researchers, the "target population" is typically humans or a specific patient group, while "nontarget populations" encompass all other susceptible hosts or environments that could constitute the reservoir [22]. Critically, a reservoir is confirmed when infection within the target population cannot be sustained after all transmission between target and nontarget populations has been eliminated [22]. This framework is essential for understanding the origin of novel bacterial taxa, which may emerge from complex reservoir systems before causing infection in immunocompromised hosts.

The Clinical Landscape: Identifying Novel Taxa in Patient Populations

The systematic identification of novel bacterial taxa from clinical specimens reveals a significant diversity of previously undescribed pathogens with implications for immunocompromised patients. The NOVA (Novel Organism Verification and Analysis) study, a prospective study integrated into routine diagnostic processes, provides a robust framework for detecting and characterizing these organisms [10]. This methodology has identified 35 bacterial strains representing potentially novel species, with predominant genera including Corynebacterium (6 strains) and Schaalia (5 strains) [10]. These findings demonstrate that clinical microbiology laboratories regularly encounter novel organisms that conventional identification methods cannot characterize.

Table 1: Novel Bacterial Taxa Identified in Clinical Specimens (NOVA Study)

Genus	Number of Novel Strains	Specimen Types (Predominant)	Clinical Relevance Assessment
Corynebacterium	6	Deep tissue, blood cultures	7 of 35 novel strains deemed clinically relevant
Schaalia	5	Various clinical specimens	Clinical impact on antibiotic use investigated
Anaerococcus	2	Deep tissue specimens	Isolated from immunocompromised hosts
Clostridium	2	Blood cultures	Potential significance for vulnerable patients
Desulfovibrio	2	Diverse anatomical sites	Relevance to patient care assessed
15 Other Genera	1 each	Various sterile and non-sterile sites	Varied clinical significance

The anatomical distribution of these novel isolates provides crucial insights into their potential pathogenic roles. Among the 61 isolates (including 35 novel species and 26 difficult-to-identify organisms) analyzed in the NOVA study, predominant specimen sources were blood cultures (n=9) and deep tissue specimens [10]. Of 47 cases with available medical records, 15 were classified as clinically relevant, with 3 exhibiting monomicrobial growth in culture—a significant finding suggesting true pathogenic potential rather than mere colonization [10]. This distribution pattern is particularly relevant for immunocompromised patients, who may lack robust immune defenses to prevent novel organisms from deep tissue invasion and bloodstream infection.

Methodological Framework: Experimental Protocols for Detection and Analysis

The NOVA Study Algorithm for Novel Organism Identification

The NOVA study established a rigorous algorithmic approach for identifying novel bacterial taxa that cannot be characterized through conventional diagnostic methods [10]. The protocol integrates seamlessly with routine diagnostic workflows while implementing specific criteria for triggering whole genome sequencing (WGS) analysis:

Table 2: NOVA Study Algorithm Decision Points

Step	Method	Decision Criteria	Action
1	MALDI-TOF MS	Score <2.0, divergent results on first/second hit, or no validly published species	Proceed to 16S rRNA gene sequencing
2	Partial 16S rRNA Gene Sequencing	≤99.0% nucleotide identity (≥7 mismatches/gaps) compared to correctly described species	Include in NOVA study for WGS analysis
3	DNA Extraction	EZ1 DNA Tissue Kit using EZ1 Advanced Instrument	Prepare for WGS
4	Whole Genome Sequencing	Illumina technology (MiSeq or NextSeq500)	Generate comprehensive genomic data
5	Genomic Analysis	rMLST and TYGS with 70% dDDH cutoff	Confirm novel species status

This methodological pipeline represents a standardized approach for clinical microbiology laboratories to systematically identify and characterize novel bacterial taxa, with particular utility for analyzing isolates from immunocompromised patients who may harbor unusual pathogens.

Taxonomic Profiling and Genomic Analysis Techniques

Taxonomic profiling of metagenomic samples employs several computational approaches for classifying sequencing reads, each with distinct advantages for novel organism detection [23]:

• Genome-based approach: Reads are aligned to reference genomes, providing high detection accuracy and enabling analysis of genes in genomic context with medium computational cost [23].
• Gene-based approach: Reads are aligned to reference genes, allowing detection of the pangenome but with higher computational cost and lower detection accuracy [23].
• k-mer-based approach: Databases and sample DNA are broken into strings of length k for comparison, offering low computational cost but no gene detection or genomic comparison capabilities [23].

For absolute quantification of microbial communities—particularly important when assessing pathogen load in immunocompromised patients—digital PCR (dPCR) anchoring provides a rigorous framework [24]. This method combines the precision of dPCR with high-throughput 16S rRNA gene amplicon sequencing to measure absolute abundances rather than relative proportions, enabling more accurate assessment of microbial load changes in different gastrointestinal locations and other body sites [24].

Diagram 1: NOVA Study Workflow for Novel Bacterial Species Identification

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful identification and characterization of novel bacterial taxa from clinical specimens, particularly from immunocompromised patients, requires specific research reagents and methodological tools. The following table summarizes essential components of the research toolkit based on established protocols from the NOVA study and complementary methodologies:

Table 3: Research Reagent Solutions for Novel Bacterial Taxa Identification

Reagent/Equipment	Specific Example	Function in Protocol
MALDI-TOF MS System	Bruker Daltonics GmbH	Initial species identification using protein mass fingerprinting
DNA Extraction Kit	EZ1 DNA Tissue Kit (Qiagen)	High-quality DNA extraction for downstream genomic analyses
Sequencing Platform	Illumina MiSeq/NextSeq500	High-throughput whole genome sequencing
Library Prep Kit	NexteraXT or Illumina DNA prep	Preparation of sequencing libraries from extracted DNA
Assembly Software	Unicycler v0.3.0b	Genome assembly from trimmed sequencing reads
Annotation Tool	Prokka v1.13	Rapid annotation of prokaryotic genomes
Taxonomic Analysis	rMLST	Ribosomal multilocus sequence typing for classification
Digital PCR System	Microfluidic dPCR platform	Absolute quantification of microbial loads

The integration of these tools enables a comprehensive workflow from specimen collection to novel species confirmation. Particularly critical for immunocompromised patients is the ability to detect low-abundance pathogens that may be present in complex microbial communities, necessitating sensitive quantification methods like dPCR alongside specific identification through WGS [24].

Ecological and Clinical Implications: Reservoirs and Transmission Dynamics

Understanding the reservoir dynamics of novel bacterial taxa is essential for developing effective infection control strategies, particularly in healthcare settings serving immunocompromised patients. The epidemiological framework distinguishes between three primary intervention approaches: target control (directed solely within the target population), blocking tactics (interrupting transmission between source and target populations), and reservoir control (managing infection within the reservoir itself) [22]. Each approach requires different levels of understanding of reservoir structure and function, with reservoir control being the most demanding but potentially most effective for novel pathogens.

The identification of specific reservoir systems informs clinical management strategies. For example, in the case of Mycobacterium bovis in the United Kingdom, a complex reservoir system exists, making identification of the most important infection source for cattle highly controversial [22]. Similar complexity likely exists for many novel bacterial taxa identified in clinical settings, particularly those with environmental reservoirs or multi-host transmission cycles. This complexity underscores the importance of the ecological perspective when investigating novel bacterial infections in immunocompromised patients, as effective prevention may require intervention at the reservoir level rather than solely at the patient level.

Diagram 2: Reservoir Dynamics and Intervention Points for Novel Bacterial Pathogens

The systematic identification of novel bacterial taxa from clinical specimens, particularly from immunocompromised patients, reveals a hidden diversity of potential pathogens with complex ecological origins. Through rigorous application of whole genome sequencing technologies and standardized analytical pipelines, clinical researchers can now characterize these previously undescribed organisms and begin to understand their reservoir dynamics. The finding that 7 of 35 novel strains in the NOVA study were clinically relevant underscores the importance of this work for patient care [10]. As our understanding of microbial reservoirs grows, so too does our ability to develop targeted interventions that protect vulnerable patient populations from novel infectious threats. Future research should focus on elucidating the specific transmission pathways between environmental and animal reservoirs and human hosts, particularly for immunocompromised individuals who may serve as sentinel cases for emerging bacterial threats.

Beyond Conventional Diagnostics: Advanced Tools for Identifying Novel Pathogens

In the study of human pathogens, particularly within immunocompromised patient populations, accurate microbial identification is paramount. The discovery of novel bacterial taxa in these hosts is a critical frontier in infectious diseases, as it directly influences diagnosis, treatment, and patient outcomes [3] [25]. For over a decade, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) and 16S ribosomal RNA (rRNA) gene sequencing have been cornerstone technologies in clinical microbiology laboratories, revolutionizing the identification of bacteria and fungi [26]. However, their limitations become acutely apparent when confronted with novel, rare, or highly similar microorganisms. This guide details the specific constraints of these standard methods, provides experimental protocols for their application, and outlines advanced pathways for the verification of novel organisms, all within the context of researching the unique microbiomes of immunocompromised hosts.

Core Limitations of Standard Identification Methods

The challenges of MALDI-TOF MS and 16S rRNA sequencing are multifaceted, ranging from database dependency to analytical sensitivity, which can hinder the detection of novel pathogens in immunocompromised patients.

Limitations of MALDI-TOF MS

MALDI-TOF MS operates by comparing the protein spectrum of an unknown microorganism to a library of reference spectra. Its primary weaknesses stem from this foundational principle.

• Database Dependency and Novel Organisms: The accuracy of MALDI-TOF MS is directly tied to the comprehensiveness and quality of its database. Commercial databases, while extensive, have finite entries. For instance, one review noted that the FDA-cleared libraries for the VITEK MS and MALDI Biotyper systems cover 332 and 294 bacteria and yeast species or species groups, respectively [26]. When an organism not present in the database is encountered, the system will typically yield "no identification" or, less commonly, a misidentification. A 2024 study explicitly designed to find novel organisms reported that 35 out of 61 unidentifiable clinical isolates were confirmed to be novel species after further analysis, highlighting the gap in existing databases [27].
• Difficulty with Closely Related Species: The technique can struggle to discriminate between species that are genetically or phenotypically very similar, as their protein profiles may be nearly identical. This is particularly problematic for organisms like members of the Aeromonas genus or the Streptococcus mitis group, where precise identification has significant clinical implications [26] [28].
• Technical Challenges with Certain Microbes:
  • Molds: The identification of filamentous fungi by MALDI-TOF MS is widely recognized as challenging. A 2024 meta-narrative review concluded that the lack of a comprehensive and standardized database for mold species is a major limitation, often relegating MALDI-TOF MS to a verification role rather than a primary identification tool [29].
  • Yeasts and Mycobacteria: These organisms have robust cell walls that require specialized extraction protocols, such as formic acid/acetonitrile treatment or mechanical disruption, to generate high-quality spectra for reliable identification [30].

Table 1: Key Limitations of MALDI-TOF MS in Clinical Microbiology

Limitation Category	Specific Challenge	Impact on Identification
Database Scope	Limited entries for rare, novel, or environmental species [26] [27]	Results in "no identification" for legitimate pathogens
Taxonomic Resolution	Poor discrimination of closely related species (e.g., A. hydrophila vs. A. caviae) [28]	Potential for misidentification and inappropriate treatment
Specimen Preparation	Requires rigorous extraction for yeasts and molds; spectra can vary with culture media [30]	Increases hands-on time, reduces reproducibility
Low Biomass Samples	Insufficient microbial material for analysis [31]	Low sensitivity in sterile body fluids like ascites

Limitations of 16S rRNA Gene Sequencing

While 16S rRNA sequencing is a powerful molecular tool, it is not a panacea and possesses several intrinsic limitations that can obscure the discovery of novel taxa.

• Variable Discriminatory Power: The 16S rRNA gene is highly conserved, which is both a strength and a weakness. It reliably identifies organisms at the genus level, but its resolution at the species level is inconsistent. A 2015 study on Aeromonas found that 16S rRNA sequencing correctly identified only 43.1% (28/65) of isolates to the species level, performing worse than MALDI-TOF MS (92.3%) and far worse than housekeeping gene sequencing [28].
• Challenges with Polymicrobial and Low-Biomass Specimens:
  • Polymicrobial Infections: Traditional Sanger sequencing of the 16S rRNA gene cannot reliably deconvolute mixtures of bacteria, as it produces overlapping chromatograms. While next-generation sequencing (NGS) can overcome this, the bioinformatic analysis becomes more complex [32].
  • Low Biomass: In specimens with very few bacterial cells, such as ascitic fluid from patients with spontaneous bacterial peritonitis, 16S rRNA sequencing has shown little to no improvement over traditional culture. A 2024 study found that the microbial composition in these samples was often indistinguishable from negative controls due to reagent contamination and the extremely low bacterial load [31].
• Contamination and Turnaround Time: The high sensitivity of PCR makes 16S rRNA sequencing vulnerable to contamination from environmental DNA or reagents. Furthermore, the turnaround time is significantly longer than MALDI-TOF MS. A clinical review reported a mean turnaround time of 8 days for positive 16S rRNA NGS tests, compared to minutes for MALDI-TOF MS and days for culture [32].

Table 2: Key Limitations of 16S rRNA Sequencing in Clinical Microbiology

Limitation Category	Specific Challenge	Impact on Identification
Genetic Resolution	Inability to distinguish between some clinically distinct species [28]	Stops at genus-level identification or provides ambiguous results
Analytical Sensitivity	Poor performance in low-bacterial-biomass samples (e.g., ascites, CSF) [31]	Low diagnostic yield in certain clinical syndromes
Sample Complexity	Difficulty with polymicrobial infections using Sanger sequencing [32]	Requires NGS for resolution, increasing cost and complexity
Operational Logistics	Long turnaround time (mean 8 days for positives) and risk of contamination [31] [32]	Delays diagnosis and complicates result interpretation

Experimental Pathways for Novel Organism Investigation

When conventional methods fail, a systematic, multi-step investigative pathway is required to confirm and characterize a novel organism.

A Structured Algorithm for Verification

The NOVA (Novel Organism Verification and Analysis) study provides a robust algorithm for this process [27]. The workflow begins with routine MALDI-TOF MS analysis. If no reliable identification (score < 2.0) is achieved, the isolate proceeds to partial 16S rRNA gene sequencing (~800 bp). If the 16S rRNA sequence has ≤ 99.0% nucleotide identity (representing 7 or more mismatches) to any correctly described species, the isolate is considered a candidate novel species and proceeds to Whole Genome Sequencing (WGS) for definitive analysis.

Diagram 1: Workflow for novel organism verification.

Detailed Experimental Protocols

Protocol 1: MALDI-TOF MS with Full Extraction for Yeasts/Fungi [30]

• Culture: Grow isolate on appropriate solid medium (e.g., blood agar) for 24-72 hours.
• Harvesting: Collect 1-5 colonies and transfer to a microcentrifuge tube.
• Washing: Add 300 µL of ultrapure water and mix thoroughly. Add 900 µL of absolute ethanol and vortex.
• Centrifugation: Pellet cells by centrifugation (e.g., 13,000 x g for 2 minutes). Discard supernatant.
• Protein Extraction: Dry pellet briefly. Resuspend in 25-50 µL of 70% formic acid. Add an equal volume of 100% acetonitrile. Vortex thoroughly.
• Clarification: Centrifuge at 13,000 x g for 2 minutes.
• Spotting: Transfer 1 µL of the supernatant to a polished steel target plate. Allow to dry.
• Overlay: Overlay the spot with 1 µL of α-cyano-4-hydroxycinnamic acid (HCCA) matrix solution and allow to dry.
• Analysis: Load target into the mass spectrometer and acquire spectra using manufacturer's parameters. Compare spectra to commercial and/or in-house databases.

Protocol 2: 16S rRNA Gene Sequencing and Analysis [28] [32]

• DNA Extraction: Use a commercial kit (e.g., InstaGene Matrix, MagMAX Microbiome Ultra Kit) to extract genomic DNA from a pure culture.
• PCR Amplification: Set up a 30-50 µL PCR reaction mixture containing:
  • Template DNA (20 ng)
  • PCR buffer
  • dNTPs
  • Forward and reverse primers targeting hypervariable regions (e.g., V1-V4, V3-V4)
  • DNA polymerase (e.g., EF-Taq, HF-Taq)
  • Run PCR with cycling conditions: initial denaturation (95°C for 2-5 min); 35 cycles of denaturation (95°C for 30 sec), annealing (55°C for 30 sec), extension (72°C for 1 min); final extension (72°C for 5-10 min).
• Purification: Purify PCR amplicons using a multiscreen filter plate or magnetic beads.
• Sequencing: Perform Sanger sequencing with a BigDye Terminator kit or prepare a library for NGS on a platform like Illumina MiSeq.
• Bioinformatic Analysis:
  • For Sanger data: Trim primers, check chromatogram quality, and perform BLAST search against the NCBI 16S rRNA database.
  • For NGS data: Use a pipeline (e.g., in QIIME2) for quality trimming (DADA2), chimera removal, and clustering into Operational Taxonomic Units (OTUs). Assign taxonomy using a naïve Bayesian classifier trained on a reference database (e.g., RefSeq).

The Scientist's Toolkit: Essential Research Reagents and Materials

Successfully navigating from unknown isolate to novel pathogen requires a suite of specific reagents and technologies.

Table 3: Key Research Reagent Solutions for Microbial Identification

Item	Function/Brief Explanation	Example Products/Technologies
MALDI-TOF Matrix	A chemical (e.g., CHCA) that absorbs laser energy to facilitate ionization of microbial proteins.	α-cyano-4-hydroxycinnamic acid (HCCA) [30]
Protein Extraction Reagents	Disrupts microbial cell walls to release ribosomal proteins for mass spectral analysis.	Formic Acid, Acetonitrile [28] [30]
16S rRNA Primers	Oligonucleotides designed to amplify conserved regions of the 16S rRNA gene for sequencing.	27F/1492R; V4 region primers (e.g., 515F/806R) [31] [28]
High-Fidelity DNA Polymerase	Enzyme for accurate PCR amplification of genetic targets with low error rates, crucial for sequencing.	HF-Taq, EF-Taq [28]
Next-Gen Sequencing Kit	Reagents for preparing sequencing libraries from amplified 16S rRNA genes or whole genomic DNA.	Illumina MiSeq Reagent Kit v2 [31] [27]
Bioinformatics Platforms	Software for analyzing sequence data, performing taxonomic classification, and phylogenetic analysis.	QIIME2, Pathogenomix PRIME, TYGS, rMLST [31] [27]

Discussion: Implications for Immunocompromised Host Research

The limitations of MALDI-TOF MS and 16S rRNA sequencing have profound consequences for research and clinical care in immunocompromised patients. This population is uniquely susceptible to infections by a wide spectrum of organisms, including those that are rare, opportunistic, or not yet characterized [3] [25]. The failure to identify a pathogen using standard methods in a symptomatic immunocompromised host can represent a critical missed opportunity.

The research community's response has been the development of integrated algorithms, like the NOVA pipeline, that leverage Whole Genome Sequencing (WGS) as a definitive solution [27]. WGS provides the resolution needed for accurate species designation through calculations of digital DNA-DNA hybridization (dDDH) and Average Nucleotide Identity (ANI), overcoming the resolution limits of 16S sequencing [27]. Furthermore, metagenomic NGS (mNGS), a hypothesis-free approach that sequences all nucleic acids in a sample, is emerging as a powerful diagnostic tool for this patient group. It can identify a broad spectrum of microorganisms (bacteria, viruses, fungi) simultaneously, which is particularly valuable in culture-negative scenarios [3]. As one editorial notes, this places advanced sequencing "at the forefront of scientific and applied understanding of the role of the microbiome" in immunocompromised hosts [3]. The ongoing discovery and validation of novel bacterial taxa from clinical samples, as documented in annual reviews, underscores that the landscape of human pathogens is still being fully mapped, and immunocompromised patients are a key population in which this discovery process occurs [16].

Within clinical bacteriology, the accurate identification of bacterial isolates is paramount for diagnosing infections and guiding treatment, particularly in immunocompromised patients who are vulnerable to a broader spectrum of pathogens. Conventional identification methods, however, frequently fail to characterize novel or rare bacterial species. This whitepaper details the Novel Organism Verification and Analysis (NOVA) algorithm, a systematic pipeline based on whole-genome sequencing (WGS) that enables the detection and verification of novel bacterial taxa. We provide an in-depth technical guide to the NOVA protocol, present quantitative data on its application in discovering 35 novel clinical isolates, and frame its significant utility within research focused on immunocompromised hosts, where uncovering novel pathogens is critical for patient management and understanding the microbiota's role in disease.

Reliable species identification of cultured isolates is the foundational step in the workflow of clinical microbiology, as it provides essential guidance for treatment [10] [27]. While most clinical pathogens are well-characterized, a small but significant number of bacterial isolates cannot be identified using standard methods like Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) or partial 16S rRNA gene sequencing. This gap is often due to a lack of sufficient reference data or the presence of truly novel, uncharacterized organisms [10].

This challenge is particularly acute in the context of immunocompromised patients. Individuals with weakened immune systems are susceptible to infections from a wider range of organisms, including those typically considered commensals or of low pathogenicity. The inability to identify a pathogen in such a patient can lead to delayed or inappropriate therapy, with potentially severe consequences. The NOVA study was established precisely to address this diagnostic dilemma by creating a robust pipeline for the systematic analysis of unidentifiable clinical isolates using WGS [10] [33].

The NOVA Algorithm: A Step-by-Step Technical Workflow

The NOVA algorithm is integrated directly into the routine diagnostic process, providing a clear pathway for isolates that resist standard identification. The following diagram and table outline the logical workflow and decision points of the pipeline.

Table 1: Key Decision Points in the NOVA Algorithm

Step	Method	Success Criteria	Failure Criteria (Proceed to Next Step)
1. Initial ID	MALDI-TOF MS	Reliable identification (score ≥ 2.0, consistent results) [10]	Score < 2.0, divergent results, or no valid species-level ID [10]
2. Molecular ID	Partial 16S rRNA Gene Sequencing	≥ 99.0% nucleotide identity to a described species (≤6 mismatches/gaps) [10]	≤ 99.0% nucleotide identity (≥7 mismatches/gaps) [10]
3. Genomic ID	Whole Genome Sequencing (WGS)	N/A	Isolate qualifies for NOVA study

Initial Identification and Inclusion Criteria

The NOVA pipeline is triggered when routine methods fail. The initial identification via MALDI-TOF MS is considered unsuccessful if the score is below 2.0, if there are divergent results between the first and second hit, or if the suggested species is not validly published [10]. Such isolates subsequently undergo partial 16S rRNA gene sequencing of approximately 800 bp. The resulting sequence is compared to the National Center for Biotechnology Information (NCBI) database using BLAST. The critical threshold for inclusion in the NOVA study is ≤ 99.0% nucleotide identity (corresponding to seven or more mismatches/gaps) compared to the closest correctly described bacterial species [10]. A species is considered "correctly described" only if it is validly published in the List of Prokaryotic names with Standing in Nomenclature (LPSN) [10] [27].

Whole Genome Sequencing and Bioinformatic Analysis

Isolates that meet the inclusion criteria are subjected to WGS, which forms the core of the NOVA algorithm.

• DNA Extraction and Sequencing: DNA is extracted using the EZ1 DNA Tissue Kit and EZ1 Advanced Instrument (Qiagen). Whole genome sequencing is performed on Illumina platforms (MiSeq or NextSeq500) following library preparation with NexteraXT or the Illumina DNA prep kit [10] [27].
• Genome Assembly and Annotation: Raw reads are trimmed using Trimmomatic (v0.38) and assembled into contigs using Unicycler (v0.3.0b). The assembled genomes are then annotated with Prokka (v1.13) to identify coding sequences and other genomic features [10].
• Species Identification: The assembled genomes are analyzed using two primary methods:
  • The Type (Strain) Genome Server (TYGS): This service is used for high-throughput digital DNA-DNA hybridization (dDDH). A 70% dDDH cutoff (method 2) is applied as the species boundary criterion [10] [27].
  • Average Nucleotide Identity (ANI): OrthoANIu is used to calculate ANI values between the isolate and known species. An ANI value of ≥96% is typically used to suggest that two strains belong to the same species. The calculation of ANI values is automated using a custom script [10].

Key Findings and Quantitative Results from the NOVA Study

The application of the NOVA algorithm in a prospective study from 2014 to 2022 led to the analysis of 61 bacterial isolates that were unidentifiable by conventional methods [10] [33]. The results demonstrate the power of this pipeline in expanding our knowledge of microbial diversity in clinical settings.

Table 2: Summary of Novel Bacterial Species Identified via the NOVA Algorithm

Category	Count	Details
Total Novel Species	35 isolates	Representing potentially novel bacterial taxa [10]
Predominant Genera	Corynebacterium (6), Schaalia (5)	Gram-positive bacilli common to human skin and mucosa [10] [33]
Other Novel Species	2 each: Anaerococcus, Clostridium, Desulfovibrio, Peptoniphilus1 each: Citrobacter, Dermabacter, Helcococcus, Lancefieldella, Neisseria, Ochrobactrum (Brucella), Paenibacillus, Pantoea, Porphyromonas, Pseudoclavibacter, Pseudomonas, Psychrobacter, Pusillimonas, Rothia, Sneathia, Tessaracoccus [10]	Diverse genera including both Gram-positive and Gram-negative organisms
Sample Origin	27/35 from deep tissue or blood cultures [10]	Indicates isolation from typically sterile sites, suggesting pathogenic potential
Clinical Relevance	7/35 strains assessed as clinically relevant [10]	Directly linked to infection in patients

Strain Characterization and Clinical Relevance

Among the 61 isolates analyzed, 35 (57%) were identified as novel species, while the remaining 26 were difficult-to-identify but known organisms, mainly those classified very recently [10]. The novel strains were predominantly Gram-positive (69%) and isolated from critical sites; 27 of the 35 novel strains came from deep tissue specimens or blood cultures [10] [33]. This is a significant finding, as isolation from a sterile site is a strong indicator of pathogenic potential.

An integral part of the NOVA study was the retrospective evaluation of clinical relevance by infectious disease specialists. This assessment was based on clinical signs and symptoms, the presence of concomitant pathogens, the known pathogenic potential of the genus, and overall clinical plausibility [10]. This process confirmed that seven of the 35 novel strains were clinically relevant, meaning they were likely causative agents of infection [10] [33]. This establishes a direct link between the newly discovered organisms and disease, a connection that is rarely documented so clearly.

The following table details key reagents, software, and databases essential for implementing the NOVA algorithm.

Table 3: Research Reagent Solutions for the NOVA Pipeline

Item	Function / Purpose	Specification / Example
EZ1 DNA Tissue Kit	Genomic DNA extraction from bacterial isolates.	Qiagen [10]
Illumina Sequencing System	High-throughput whole genome sequencing.	MiSeq or NextSeq500 platforms [10]
NexteraXT / Illumina DNA Prep	Library preparation for WGS.	Ensures DNA is properly formatted for sequencing [10]
Trimmomatic	Bioinformatics tool for read trimming.	Removes low-quality sequences and adapters (v0.38) [10]
Unicycler	Bioinformatics tool for genome assembly.	Assembles trimmed reads into contigs (v0.3.0b) [10]
Prokka	Bioinformatics tool for genome annotation.	Rapidly annotates prokaryotic genomes (v1.13) [10]
TYGS	Online tool for prokaryotic species identification.	Performs dDDH analysis with a 70% species cutoff [10]
OrthoANIu	Algorithm for calculating Average Nucleotide Identity.	Used with a ~96% species boundary [10]
LPSN Database	Reference for validly published prokaryotic names.	https://www.bacterio.net [10]

Discussion: Implications for Research in Immunocompromised Patients

The NOVA algorithm represents a significant advancement in diagnostic clinical microbiology and has profound implications for research involving immunocompromised patients. The identification of 35 novel species, seven of which were clinically relevant, underscores the vast diversity of undescribed bacteria that can interact with humans, often as opportunistic pathogens [10] [33].

For immunocompromised populations, the landscape of potential pathogens is markedly expanded. Commensal organisms from genera like Corynebacterium and Schaalia—which were the most commonly identified novel taxa in the NOVA study—are frequently underestimated but can cause significant disease if they breach barrier sites and enter the bloodstream [33]. The ability to precisely identify these organisms using WGS is crucial for understanding their epidemiology, pathogenic mechanisms, and susceptibility profiles. This, in turn, can inform more targeted antimicrobial therapy and improve patient outcomes.

Furthermore, the NOVA pipeline contributes directly to the growing catalog of human bacterial pathogens. Initiatives to compile comprehensive lists of these pathogens are vital for defining the "normal" versus "pathogenic" microbiome in vulnerable hosts [16]. By making genomic and clinical data publicly available, studies like NOVA provide indispensable resources for the scientific community to better understand the clinical and ecological role of novel microorganisms [10]. As the field moves forward, integrating such high-resolution genomic identification into routine practice will be key to unraveling the complex interactions between immunocompromised hosts and their microbiota.

Whole-Genome Sequencing as the Gold Standard for Species Identification

Within the context of research on novel bacterial taxa in immunocompromised patients, the precise identification of pathogenic species is not merely an academic exercise but a critical component of clinical diagnosis, infection control, and therapeutic decision-making. Traditional phenotypic methods and even proteomic technologies like MALDI-TOF MS often fail to provide the resolution needed to distinguish between closely related species, a common scenario with emerging pathogens in complex patient populations [34] [35]. Whole-genome sequencing (WGS) has emerged as the undisputed gold standard for microbial species identification, offering unparalleled resolution and reproducibility [36] [35]. This technical guide details the experimental protocols, analytical frameworks, and practical applications of WGS that enable its superior performance, particularly in the identification of novel and rare bacterial taxa in immunocompromised hosts.

The Case for WGS as the Gold Standard

The limitations of conventional methods become starkly apparent when dealing with genetically similar organisms. For instance, the Klebsiella pneumoniae complex comprises several closely related species, including K. pneumoniae, K. quasipneumoniae, and K. variicola, which are frequently misidentified by standard biochemical and proteomic methods [34]. In a defining case study, a K. quasipneumoniae subsp. similipneumoniae isolate from a hospitalized patient with liver cancer was consistently misidentified as K. variicola or K. pneumoniae by two different MALDI-TOF MS systems. Only WGS provided an accurate species and subspecies classification, which was critical for understanding the pathogen's resistance and virulence profile [34]. Similarly, studies on Aeromonas species, which are increasingly recognized as human pathogens, have shown that MALDI-TOF MS misidentifies approximately 12.2% of isolates, especially for species not well-represented in database libraries [35].

The quantitative genomic measure that forms the bedrock of species identification via WGS is the Average Nucleotide Identity (ANI). A threshold of ≥96% ANI is widely accepted for delineating prokaryotic species boundaries, providing an objective and quantitative measure that is robust and reproducible [35]. This genomic standard overcomes the ambiguities of phenotypic assays and the database limitations of protein-based methods.

Table 1: Comparative Performance of Bacterial Identification Methods

Method	Principle	Resolution	Key Limitation	Application in Novel Taxa Research
Phenotypic/Biochemical	Metabolic profile	Genus to species level	Ambiguous results due to overlapping characteristics [35]	Poor; cannot identify novel taxa
MALDI-TOF MS	Protein spectral fingerprint	Species level (with curated databases)	Misidentification of closely related species; database-dependent [34] [35]	Limited; requires pre-existing database entries
Whole-Genome Sequencing (WGS)	Total DNA sequence analysis	Subspecies and strain level	Higher cost and bioinformatics requirement [36]	Excellent; enables discovery and classification

Experimental Protocol for WGS-Based Identification

A standardized workflow is essential for generating high-quality, reproducible genomic data suitable for definitive species identification. The following protocol, synthesized from multiple studies, outlines the key steps.

Sample Preparation and Sequencing

• Genomic DNA Extraction: Using a commercial DNA purification kit, extract high-quality genomic DNA from a pure bacterial culture. Assess the DNA's integrity via agarose gel electrophoresis (e.g., 1% gel). Determine concentration and purity using spectrophotometry (NanoDrop, A260/280 ratio ~1.8-2.0) and fluorometry (Qubit) for accurate quantification [35] [37].
• Library Preparation: For short-read sequencing on platforms like Illumina NovaSeq or MiSeq, use a DNA library preparation kit such as the Ion Xpress Plus Fragment Library Kit or Nextera XT DNA Library Preparation Kit, following the manufacturer's instructions [34] [37]. This step fragments the DNA and ligates platform-specific adapters.
• Sequencing: Perform paired-end sequencing (e.g., 2x150 bp) to generate reads with overlapping ends, which facilitates more accurate genome assembly [34].

Bioinformatics Analysis for Species ID

• Quality Control (QC) and Trimming: Assess the quality of raw sequencing reads (FASTQ files) using tools like FastQC (v0.11.9). Remove adapters, duplicates, and low-quality sequences using Trimmomatic (v0.39) or similar tools [34] [37]. The global GA4GH WGS QC Standards provide a unified framework for ensuring consistent and reliable data quality across institutions [38].
• De Novo Genome Assembly: Assemble the quality-trimmed reads into contigs using a de novo assembler such as SPAdes (v3.11.1) or Unicycler (v0.48) [34] [37]. Assess assembly quality with metrics like genome coverage, contig count (N50, N90), and GC content using QUAST (v5.2.0) [35] [37].
• Species Identification via ANI:
  • Tool: Use fastANI (v1.3) to calculate the Average Nucleotide Identity between the assembled genome and reference genomes [35].
  • Reference Databases: Well-curated databases like the Genome Taxonomy Database (GTDB) or the Type Strain Genome Server (TYGS) are essential for accurate annotation [36].
  • Interpretation: An ANI value of ≥96% indicates that the query genome belongs to the same species as the reference genome [35].
• Complementary Analyses: For a comprehensive characterization, especially in outbreak settings, further analysis is recommended.
  • Multilocus Sequence Typing (MLST/cgMLST): Determine the sequence type (ST) and strain relatedness using tools like Kleborate, pyMLST, or PubMLST [34] [37].
  • Resistance and Virulence Gene Screening: Identify antimicrobial resistance (AMR) genes and virulence factors using the ABRicate pipeline with databases such as CARD and VFDB, using thresholds of ≥80% for both coverage and identity [34] [37].

The following workflow diagram visualizes this multi-stage process from sample to final report.

The Scientist's Toolkit: Essential Research Reagents and Software

Successful implementation of WGS for species identification relies on a suite of validated laboratory reagents and bioinformatics tools.

Table 2: Key Research Reagent Solutions for WGS-Based Identification

Item	Function/Description	Example Products/Tools (from search results)
DNA Extraction Kit	Purifies high-quality, high-molecular-weight genomic DNA from bacterial cultures.	Qiagen Bacterial DNA Isolation Kit [37], Wizard Genomic DNA Purification Kit [35]
Library Prep Kit	Fragments DNA and attaches platform-specific adapters for sequencing.	Nextera XT DNA Library Prep Kit [37], Ion Xpress Plus Fragment Library Kit [35]
Sequencing Platform	High-throughput system for generating short- or long-read DNA sequence data.	Illumina NovaSeq/MiSeq [34] [37], Ion Torrent S5 [35]
QC & Trimming Tool	Assesses read quality and removes low-quality bases/adapters from raw data.	FastQC [35], Trimmomatic [34]
Assembly Software	Reconstructs the genome sequence from millions of short sequencing reads.	SPAdes [34], Unicycler [37], CLC Genomics Workbench [35]
Species ID Tool	Calculates genomic similarity to reference genomes for taxonomic assignment.	fastANI [35], GTDB-Tk [36], TYGS [36]
Specialized Databases	Curated collections of reference genomes and gene sequences for comparison.	Genome Taxonomy Database (GTDB) [36], CARD [34] [37], VFDB [34] [37]

Application in Clinical Research: A Case Study in Immunocompromised Hosts

The critical importance of WGS is exemplified by its application in diagnosing infections in immunocompromised patients, where atypical or novel pathogens are more prevalent. The case of the 67-year-old male with liver cancer underscores this point [34]. The initial misidentification of the causative agent obscured the true nature of the multidrug-resistant K. quasipneumoniae infection. WGS not only provided the correct species and subspecies designation (K. quasipneumoniae subsp. similipneumoniae) but also revealed its full genetic profile: the presence of the extended-spectrum beta-lactamase gene bla_SHV-18 and a suite of virulence factors (e.g., entA, entB, fepC, ompA) [34]. This genomic intelligence is indispensable for tailoring infection control measures and understanding the pathogenesis of emerging taxa in susceptible hosts.

Furthermore, WGS is pivotal for tracking the transmission of multidrug-resistant organisms in hospital environments. A study on vancomycin-resistant enterococci (VRE) in a tertiary care center used WGS to uncover a polyclonal population structure, identify plasmid replicons co-associated with resistance genes, and profile the virulome of clinical isolates [37]. This high-resolution view is unattainable with non-genomic methods and is essential for effective hospital surveillance.

Whole-genome sequencing has unequivocally established itself as the gold standard for bacterial species identification. Its superior resolution, objectivity, and comprehensive data output overcome the significant limitations of traditional phenotypic and proteomic methods. For researchers and clinicians investigating novel bacterial taxa in immunocompromised patients, WGS is not just a superior diagnostic tool but a fundamental research technology. It enables the accurate delineation of species, provides insights into resistance and virulence mechanisms, and facilitates the real-time surveillance needed to combat emerging infectious threats in high-risk clinical settings. The ongoing standardization of workflows and quality controls will only solidify its role as the cornerstone of modern microbial systematics and clinical microbiology.

Phylogenetic-Based Orthology Analysis for Uncovering Pathogenicity Determinants

The rapid global rise in antimicrobial resistance and the emergence of novel bacterial pathogens pose a significant threat to public health, with immunocompromised patients being disproportionately affected. This technical guide details the application of phylogenetic-based orthology analysis (OA) for the systematic discovery of novel, widespread genetic determinants of bacterial pathogenicity. By comparing the proteomes of pathogenic and non-pathogenic bacterial strains across a broad phylogenetic spectrum, researchers can identify hierarchical orthologous groups (HOGs) statistically associated with virulence. The integration of this approach with machine learning models and functional genomics provides a powerful, data-driven framework for identifying potential diagnostic markers and therapeutic targets, offering a critical pathway to address infections in vulnerable patient populations.

Immunocompromised patients, including those with HIV/AIDS, cancer, diabetes, or organ transplants, and those in intensive care units, represent a population at exceptionally high risk for infections from multidrug-resistant (MDR) bacteria. In these individuals, the distinction between mere colonization and active infection by MDR pathogens is often blurred, with colonization frequently serving as a precursor to severe, systemic infections that are notoriously difficult to treat [39]. The World Health Organization has prioritized several MDR bacteria—including carbapenem-resistant Enterobacterales and Klebsiella pneumoniae—which demonstrate continuously increasing incidence and are associated with high mortality rates in these vulnerable groups [39] [40].

Conventional methods for bacterial characterization and susceptibility testing, such as serotyping and phage typing, have provided valuable service. Serotyping classifies bacteria based on surface antigens (O, H, and K antigens) and has been fundamental in distinguishing pathogenic variants, such as the O157:H7 serotype of Escherichia coli [41]. Similarly, phage typing, a phenotypic method that uses bacterial lysis patterns by bacteriophages, has been historically used for strain differentiation during outbreak investigations [42]. However, these methods are increasingly being supplemented or replaced by genotypic methods like whole-genome sequencing, which offer higher resolution and greater discriminatory power for epidemiological characterization [42] [43]. The limitations of traditional approaches underscore the need for advanced, genomics-driven methods like orthology analysis to uncover the fundamental genetic underpinnings of pathogenicity, thereby accelerating the development of novel interventions.

Core Principles of Phylogenetic-Based Orthology Analysis

Orthology analysis is a computational method used to identify orthologous genes—genes in different species that originated from a common ancestral gene via a speciation event. These genes often retain their original function over evolutionary time, making their identification crucial for understanding shared biological processes across taxa.

• Hierarchical Orthologous Groups (HOGs): In a phylogenetic context, HOGs represent sets of genes that evolved from a single gene in the last common ancestor of the considered taxa. HOGs are defined at each level of the phylogenetic tree, providing a multi-resolution view of gene evolution. Identifying HOGs that are significantly enriched in pathogenic strains compared to non-pathogenic ones can directly point to genes essential for virulence.
• Strain Annotation and Curation: The foundation of a robust analysis is high-quality, curated data. Initiatives like the Bacterial Pathogenicity Dataset (BacSPaD) provide standardized pathogenicity annotations—labeling strains as "pathogenic to humans" (HP) or "non-pathogenic to humans" (NHP)—which are essential for meaningful comparative analysis [44].
• Integration with Protein Domain Analysis: Correlating identified HOGs with known protein domains strengthens the biological interpretation of results. The presence of domains linked to well-characterized virulence factors (e.g., toxin domains, adhesion domains) in pathogen-associated HOGs provides supporting evidence for their potential role in disease mechanisms.

Experimental Workflow and Methodologies

The following section outlines the key experimental and bioinformatic protocols for executing a comprehensive orthology analysis.

Large-Scale Comparative Proteomics

A comprehensive study designed to identify pathogenicity determinants analyzed the proteomes of 734 bacterial strains spanning 514 species and 91 families, creating a robust dataset for comparative analysis [44].

Protocol: Proteome Comparison and HOG Identification

• Data Acquisition: Gather protein sequence data for a wide array of bacterial strains with curated pathogenic status (HP vs. NHP). Public repositories like NCBI GenBank can serve as primary sources.
• Orthology Inference: Use specialized software tools, such as the OMA (Orthologous MAtrix) standalone package, to infer hierarchical orthologous groups (HOGs) across the entire phylogenetic spectrum of the dataset [44].
• Statistical Association Testing: Employ statistical tests (e.g., Fisher's exact test) to identify HOGs that show a significant association with the "pathogenic to humans" (HP) label. This controls for false discoveries and highlights the most promising candidates.
• Functional Annotation: Annotate the resulting significant HOGs using databases like Gene Ontology (GO) and Pfam to identify enriched biological processes, molecular functions, and protein domains.

The following diagram illustrates the core bioinformatic workflow of this analysis.

Genomic Analysis of Virulence-Associated Loci

For in-depth investigation of specific pathogens, whole-genome sequencing and comparative genomics are indispensable. This approach allows for the detailed characterization of virulence genes, such as hemolysins, adhesins, cytotoxins, proteases, and siderophore systems, which are central to bacterial pathogenicity [45].

Protocol: Genomic Characterization of a Bacterial Pathogen * Case Study: Aeromonas hydrophila strain LP-2, a highly virulent pathogen in aquaculture. 1. Genome Sequencing and Assembly: Perform whole-genome sequencing using next-generation platforms (e.g., Illumina, PacBio). Assemble the reads into a complete genome. 2. Phylogenetic Positioning: Use Multilocus Sequence Typing (MLST) and core-genome phylogeny to determine the strain's phylogenetic group (e.g., high-risk ST251 clone for A. hydrophila) [45]. 3. Virulence Gene Identification: Use BLAST-based tools and databases (e.g., VFDB) to identify and catalog known virulence genes within the genome. 4. Phenotypic Virulence Assays: * Hemolytic Assay: Culture the bacterium on blood agar plates to confirm hemolytic capability. * Protease Activity Assay: Use agar plates containing skim milk; a clear zone around the colony indicates protease production. * Siderophore Production Assay: Use Chrome Azurol S (CAS) agar plates; a color change from blue to orange indicates siderophore production, demonstrating iron acquisition capability [45]. 5. Gene Deletion Studies: Construct targeted gene knockout mutants (e.g., for siderophore biosynthesis genes) to validate the role of specific genes in virulence through phenotypic re-assessment.

Data Integration and Interpretation

Quantitative Results from Orthology Analysis

A large-scale analysis identified 4,383 HOGs that were statistically associated with the HP label. These HOGs were linked to critical biological functions that facilitate pathogenicity [44].

Table 1: Key Functional Categories of Pathogenicity-Associated HOGs

Functional Category	Role in Pathogenicity	Examples / Notes
Stress Tolerance	Enables survival under host-induced stress (e.g., oxidative, osmotic).	Includes heat shock proteins (e.g., Hsp31 with glyoxalase activity) [44].
Metabolic Versatility	Allows utilization of diverse nutrient sources in host environments.	Could involve pathways for nutrient scavenging.
Antibiotic Resistance	Directly confers resistance to antimicrobial agents.	Genes for antibiotic inactivation, efflux pumps.
Known Virulence Factors (VFs)	Directly damages host tissues or subverts host defenses.	Toxins, adhesins, invasins. Analysis confirms known VFs [44].

Integration with Molecular Diagnostics

Orthology analysis can directly inform the development of rapid molecular diagnostics. For instance, PCR analysis of the 16S-23S rRNA Internal Transcribed Spacer (ITS) region, followed by microchip gel electrophoresis (MGE), allows for species-level identification of Gram-negative bacteria directly from positive blood culture bottles in as little as 1.5 hours [46]. This method has demonstrated 90% accuracy in identifying species from monomicrobial blood cultures and can be simultaneously used to detect resistance genes like CTX-M extended-spectrum β-lactamase (ESBL) [46]. The HOGs identified through orthology analysis provide a rich source of potential targets for such PCR-based assays.

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents and Resources for Orthology and Pathogenicity Research

Reagent / Resource	Function / Application	Specific Examples / Notes
OMA Standalone Software	Inference of hierarchical orthologous groups (HOGs) from genomic data.	Critical for the core phylogenetic analysis [44].
BacSPaD Database	Provides curated strain-level pathogenicity annotations (HP/NHP).	Forms the basis for reliable phenotype-genotype correlations [44].
API 20E System	Biochemical identification of bacterial species.	Used for initial phenotypic characterization [43].
Specific Antisera	Serotyping based on O (LPS), H (flagellar), and K (capsular) antigens.	Essential for traditional classification and strain differentiation [41].
Chromocult Coliform Agar	Differential culture medium for detecting β-d-glucuronidase activity.	Used to distinguish E. coli O157:H7 (negative) from other E. coli [43].
Chrome Azurol S (CAS) Agar	Detection of siderophore production, a key virulence factor for iron acquisition.	Used in phenotypic validation [45].
Microchip Gel Electrophoresis (MGE)	Rapid sizing of PCR amplicons for bacterial identification and resistance gene detection.	Enables results in ~5 min vs. 2 hours for traditional gel electrophoresis [46].

Advanced Integration: Machine Learning for AMR Prediction

Machine learning (ML) represents a powerful extension to orthology analysis, capable of modeling the complex, non-linear interactions between genetic features that lead to antimicrobial resistance (AMR).

Key Considerations for ML Integration:

• Model Interpretability: For clinical and biological relevance, models must be transparent and explainable, revealing which genes or mutations drive the predictions [47] [48].
• Data Set Suitability: Model performance depends on large, well-curated genomic data sets with corresponding phenotypic AMR profiles. Control for population structure in the training data is critical to avoid spurious associations [47].
• Multidrug Resistance Prediction: Advanced models are moving beyond single-drug prediction to classify multidrug resistance, more accurately reflecting the clinical reality of MDR infections [47].

Phylogenetic-based orthology analysis provides a powerful, systematic framework for moving beyond traditional, phenotype-limited bacterial typing methods. By integrating large-scale comparative genomics with phenotypic data and advanced machine learning, this approach facilitates the discovery of novel, widespread pathogenicity determinants. For researchers focused on the pressing challenge of MDR infections in immunocompromised patients, this methodology offers a clear path to identify essential virulence and resistance factors. These discoveries are critical for developing the next generation of rapid diagnostics and targeted therapeutics, ultimately improving outcomes for this highly vulnerable patient population.

In the study of novel bacterial taxa in immunocompromised patients, bioinformatics pipelines are indispensable for transforming raw sequencing data into actionable biological insights. Immunocompromised individuals, such as hematopoietic stem cell transplantation (HCT) recipients, are at high risk for severe infections and dysbiosis, creating a unique environment where novel or hard-to-detect bacteria may thrive [49] [50] [51]. Advanced sequencing technologies and sophisticated computational workflows now enable researchers to comprehensively investigate these complex microbial communities, from initial genome reconstruction to detailed taxonomic classification and functional analysis. This technical guide examines the core principles, methodologies, and applications of bioinformatics pipelines within this critical research context, providing researchers and drug development professionals with the foundational knowledge needed to advance our understanding of host-microbe interactions in vulnerable populations.

Genome Assembly Strategies and Methodologies

Sequencing Platform Selection

The foundation of any successful genome assembly begins with selecting appropriate sequencing technologies, each offering distinct advantages and limitations. Research comparing Illumina MiSeq, Ion Torrent PGM, and Roche 454 GS FLX+ platforms demonstrates significant differences in output quality that directly impact downstream analyses [52]. Illumina MiSeq generates the highest throughput with up to 13.5 Gb on the MiSeq PE300 and the fastest run time, but produces relatively shorter reads. Roche GS FLX+ yields the longest reads (up to 600 bp) but struggles with homopolymer errors and has higher costs with lower throughput. Ion Torrent PGM offers lower homopolymer error rates than Roche GS FLX+ but yields lower throughput and shorter reads [52].

Table 1: Comparison of Sequencing Platforms for Bacterial Genomics

Platform	Read Length	Throughput	Error Profile	Best Application
Illumina MiSeq	Short (up to 300bp)	High (up to 13.5Gb)	Low error rate, substitution errors	High-confidence variant calling
Oxford Nanopore	Long (>10kb)	Medium to High	Higher error rate, random errors	Scaffolding, structural variants
Roche GS FLX+	Long (up to 600bp)	Low to Medium	Homopolymer errors	16S rRNA amplicon sequencing
Ion Torrent PGM	Short to Medium	Medium	Homopolymer errors	Moderate-cost sequencing

For comprehensive genome assembly, especially for novel bacterial taxa, a hybrid approach that combines multiple technologies often yields superior results. A recent study on root commensal bacteria from Lotus japonicus demonstrated that hybrid assemblies using both Oxford Nanopore long-reads and Illumina short-reads produced genomes with substantially greater contiguity and markedly reduced contamination compared to Illumina-only assemblies, while maintaining equivalent levels of genome completeness [53].

Specialized Assembly Pipelines for Challenging Samples

Sequencing and assembling genomes from bacteria in immunocompromised hosts presents unique challenges, particularly for obligate intracellular bacteria (OIB) that are dependent on their eukaryotic hosts for survival. Members of the Chlamydia, Anaplasma, Rickettsia, and Coxiella genera are clinically relevant in immunocompromised patients but are difficult to study due to the inability to separate bacterial sequences from host DNA [54].

The ATCC's specialized assembly pipeline for OIBs addresses this challenge through an initial classification stage that invokes an extensive custom-designed host genome database to reduce confounding eukaryotic DNA sequences. Both short-read Illumina and long-read Oxford Nanopore Technologies (ONT) reads are trimmed according to quality standards before host DNA depletion, followed by standard bacterial assembly procedures. This method has proven successful for assembling Chlamydia, Pisirickettsia, and Rickettsia species, which are particularly relevant in immunocompromised patient populations [54].

OIB Assembly Workflow: Specialized pipeline for obligate intracellular bacteria

Quality Assessment and Validation

Regardless of the assembly strategy implemented, rigorous quality assessment is essential for generating reliable reference genomes. The NCBI Prokaryotic Genome Annotation Standards provide validated thresholds for genome quality, including minimum completeness of 90%, less than 5% genomic contamination, and the presence of at least one complete copy of the required ribosomal genes (5S, 16S, and 23S) [53]. Assembly contiguity metrics such as N50 and L50 provide additional important measures of assembly quality, with higher N50 values indicating more contiguous assemblies.

For the Lotus japonicus root commensal bacteria project, these quality standards enabled the production of 152 high-quality annotated bacterial genomes from initial low-quality drafts. The hybrid assembly strategy demonstrated consistent GC content with Illumina-only assemblies (Wilcoxon's test p-value: 0.6322) while dramatically improving contiguity and reducing contamination [53].

Taxonomic Classification Approaches

16S rRNA Amplicon Sequencing Analysis

16S ribosomal RNA gene amplicon sequencing remains a widely used method for taxonomic profiling of bacterial communities, particularly in clinical samples from immunocompromised patients. This approach involves sequencing hypervariable regions of the 16S rRNA gene, which serve as phylogenetic markers for bacterial identification [52] [55].

The analytical process requires three fundamental steps: (1) merging of read pairs into longer single reads, (2) quality control and read trimming, and (3) taxonomic assignment. Bioinformatic tools for these analyses generally follow one of two approaches: Operational Taxonomic Unit (OTU) clustering, which groups sequences with typically less than 3% variance from each other, or Amplicon Sequence Variant (ASV) inference, which resolves sequences down to single-nucleotide differences over the sequenced gene region [55].

Bioinformatics Pipelines for Taxonomic Assignment

Multiple bioinformatic pipelines are available for 16S rRNA amplicon analysis, each with distinct methodologies and output characteristics. Research comparing QIIME2, Bioconductor, UPARSE, and mothur has demonstrated that while all are capable of discriminating samples by treatment conditions, they yield significant differences in diversity estimates and relative abundance of specific taxa [52] [55].

Table 2: Comparison of Bioinformatics Pipelines for 16S rRNA Analysis

Pipeline	Clustering Method	Strengths	Limitations	Impact on Diversity
QIIME2	ASV (DADA2, Deblur)	High resolution, reproducibility	Computational intensity	Higher alpha diversity
Bioconductor	ASV (DADA2)	R ecosystem integration	Programming knowledge required	Higher alpha diversity
UPARSE	OTU (97% similarity)	Fast processing, chimera removal	Lower resolution	Reduced alpha diversity
mothur	OTU (97% similarity)	Extensive documentation, validation	Less modern algorithm	Reduced alpha diversity

In a comparative study of human fecal samples, all pipelines showed consistent taxa assignments at both phylum and genus levels, but significant differences emerged in relative abundance estimates. For example, Bacteroides abundance varied considerably across pipelines: QIIME2 (24.5%), Bioconductor (24.6%), UPARSE-Linux (23.6%), UPARSE-Mac (20.6%), mothur-Linux (22.2%), and mothur-Mac (21.6%) [55]. These findings highlight the critical importance of maintaining consistent pipeline usage throughout a study and caution against direct comparisons between studies using different bioinformatic approaches.

Whole Genome-Based Taxonomic Classification

For more precise taxonomic classification, especially for novel bacterial taxa, whole-genome sequencing approaches provide superior resolution compared to 16S rRNA amplicon sequencing. Tools like GTDB-tk (Genome Taxonomy Database Toolkit) utilize whole-genome nucleotide comparisons for taxonomic classification, offering more accurate phylogenetic placement than single-gene approaches [53].

In the Lotus japonicus root commensal bacteria study, whole-genome based taxonomic classification revealed 19 distinct taxa at the family level with a predominance of Burkholderiaceae, Rhizobiaceae, Pseudomonadaceae, and Caulobacteraceae. The genome-based approach provided revised taxonomic classifications compared to previous 16S ribosomal gene marker analysis, with a considerable number of genomes reliably identified at the species level (n = 58), vastly improving the taxonomic assignment available for the collection [53].

Applications in Immunocompromised Patient Research

Pathogen Detection in Bloodstream Infections

Bioinformatics pipelines play a crucial role in detecting pathogens in immunocompromised patients with bloodstream infections (BSI), a severe complication that can lead to sepsis. Next-generation sequencing (NGS) combined with specialized analytical approaches enables comprehensive detection of microorganisms in clinical samples, outperforming traditional blood culture methods that can only detect culturable pathogens and show low positivity rates in febrile neutropenia (less than 30%) [50].

A study of immunocompromised children with BSI established diagnostic indices for NGS-based pathogen identification. The Bacterial Reads per million reads (BR) index represents the number of bacteria-derived sequences, while the P1 index indicates the relative abundance of dominant bacteria. Threshold values of BR > 200 and P1 > 0.5 were established to determine causative pathogens, successfully identifying causative organisms in 7 of 12 patients with BSI [50]. Notably, in patients with catheter-related BSI, NGS detected causative bacteria in plasma samples up to 7 days before clinical onset, highlighting the potential for early diagnosis in vulnerable populations.

NGS for BSI Diagnosis: Workflow for pathogen detection in bloodstream infections

Microbial Dynamics Post-Fecal Microbiota Transplantation

Fecal microbiota transplantation (FMT) has emerged as an effective therapy for refractory or recurrent Clostridium difficile-associated disease (CDAD) in immunocompromised patients, with attack rates as high as 25% in hematopoietic stem cell transplantation (HCT) recipients [51]. Bioinformatics pipelines enable detailed investigation of taxonomic and functional changes following FMT through shotgun metagenomic sequencing of serial stool samples.

Research in HCT recipients has revealed that while recipient stool assumes donor-like taxonomic and functional composition immediately following FMT, this concordance diminishes over time. Analysis of strain-level dynamics showed alterations in gene content, including loss of virulence and antibiotic resistance genes, accompanied by long-term bacterial divergence at the species and strain levels [51]. These findings suggest that FMT alone cannot induce long-term donor-like alterations of the microbiota in HCT recipients, indicating that environmental and host factors play significant roles in shaping bacterial composition.

Visualization Tools for Sequence Analysis

Effective visualization of sequence features and analysis results is essential for interpreting complex datasets. SeqVISTA provides a graphical tool for sequence feature visualization that presents a holistic, interactive view of features annotated on nucleotide or protein sequences [56]. The tool integrates results from diverse sequence analysis tools and enables researchers to view the totality of sequence annotations and predictions, which may be more revealing than individual analyses.

For genome-wide analyses and comparisons, Jalview offers cross-platform capabilities for multiple sequence alignment editing, visualization, and analysis [57]. These visualization tools are particularly valuable for identifying genomic features in novel bacterial taxa isolated from immunocompromised patients, facilitating the discovery of potential virulence factors, resistance genes, or unique adaptations to the immunocompromised environment.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for Bacterial Genomics

Reagent/Kit	Manufacturer	Function	Application Context
E.Z.N.A. Stool DNA Kit	Omega Bio-Tek	Fecal DNA extraction	Microbiome studies in immunocompromised patients [52]
QIAamp DNA Stool Mini Kit	Qiagen	Fecal DNA extraction	Human gut microbiota studies [55]
AMPure XP beads	Beckman Coulter	DNA purification	HMW DNA extraction for long-read sequencing [53]
TissueLyser II	Qiagen	Mechanical homogenization	Sample preparation for DNA extraction [55]
Nextera XT Library Prep Kit	Illumina	Library preparation	16S rRNA amplicon sequencing [55]
Quant-iT PicoGreen dsDNA Reagent	Thermo Fisher	DNA quantification	Accurate DNA concentration measurement [52]

Bioinformatics pipelines for genome assembly and taxonomic classification provide powerful approaches for investigating novel bacterial taxa in immunocompromised patients. From specialized assembly strategies for challenging intracellular pathogens to sophisticated taxonomic classification methods, these computational workflows enable comprehensive characterization of microbial communities in vulnerable patient populations. The integration of multiple sequencing technologies, rigorous quality control measures, and appropriate bioinformatic tools is essential for generating reliable, high-quality data that can advance our understanding of host-microbe interactions in immunocompromised states. As these methodologies continue to evolve, they will undoubtedly yield new insights into the complex dynamics of bacterial populations in immunocompromised patients, potentially leading to improved diagnostic approaches and therapeutic interventions for this vulnerable population.

Navigating Diagnostic and Therapeutic Challenges in Complex Cases

Overcoming Diagnostic Hurdles in Polymicrobial Infections

Polymicrobial infections (PMIs), characterized by the simultaneous presence of multiple microbial species at an infection site, represent a significant diagnostic challenge in modern clinical microbiology. Worldwide, PMIs account for an estimated 20–50% of severe clinical infection cases, with biofilm-associated and device-related infections reaching 60–80% in hospitalized patients [58]. The accurate identification of all causative pathogens is critical, particularly for immunocompromised patients where PMIs are associated with 2-fold higher case-fatality rates compared to monomicrobial infections [58]. The diagnostic process is further complicated by the rising prevalence of antimicrobial resistance (AMR) and the potential presence of novel bacterial taxa that conventional methods fail to detect.

The intricate microbial interactions within PMIs substantially alter disease pathophysiology, severity, and therapeutic response. In immunocompromised hosts, such as those with malignancies or undergoing immunosuppressive therapy, the pathogen landscape is notably diverse. A recent prospective study of immunocompromised host pneumonia (ICHP) in cancer patients revealed that 36.5% of cases involved coinfections, with these patients requiring vasoactive drugs at significantly higher rates (39.1% vs. 16.0%) and experiencing increased 28-day all-cause mortality [5]. This underscores the urgent need for advanced diagnostic approaches that can comprehensively characterize complex microbial communities to guide appropriate antimicrobial therapy and improve patient outcomes.

Current Diagnostic Limitations and the Novel Taxa Perspective

The Shortcomings of Conventional Diagnostic Methods

Traditional culture-based methods, while foundational in microbiology, exhibit critical limitations in detecting PMIs. These methods often suffer from low sensitivity, particularly for slow-growing, low-abundance, or unculturable pathogens, resulting in false negatives and incomplete pathogen profiles [58]. Conventional techniques typically focus on a narrow spectrum of anticipated pathogens, overlooking potentially significant co-infecting organisms and their contributions to disease pathogenesis. Studies indicate that traditional culture-based approaches can miss up to 30–40% of co-pathogens in polymicrobial samples, leading to suboptimal empiric therapy and worsened clinical outcomes [58].

The limitations of conventional methods are particularly problematic when dealing with novel or rare bacterial taxa. The Novel Organism Verification and Analysis (NOVA) study highlighted this challenge by systematically analyzing bacterial isolates that could not be characterized by conventional identification procedures like MALDI-TOF MS and partial 16S rRNA gene sequencing [59]. Using Whole Genome Sequencing (WGS) as a reference method, researchers identified 35 bacterial strains representing potentially novel species, with Corynebacterium sp. (n = 6) and Schaalia sp. (n = 5) as the predominant genera [59]. Critically, 27 of these 35 strains were isolated from deep tissue specimens or blood cultures, and 7 were determined to be clinically relevant, demonstrating the wide range of undescribed pathogens yet to be defined [59].

Table 1: Prevalence and Detection Challenges of Polymicrobial Infections Across Clinical Settings

Infection Type	PMI Prevalence	Common Pathogen Combinations	Key Diagnostic Challenges
Intra-Abdominal Infections	>80% following GI perforation [58]	Escherichia coli (60-70%), Bacteroides fragilis (30-40%) [58]	Complex anaerobic/aerobic interactions; fastidious organisms
Diabetic Foot Infections	60-80% [58]	S. aureus, Streptococcus spp., Pseudomonas aeruginosa, Enterobacteriaceae, anaerobes [58]	Biofilm formation; diverse microbial communities with varying abundance
Ventilator-Associated Pneumonia	40-70% [58]	MDR Gram-negative organisms (Acinetobacter baumannii, P. aeruginosa) [58]	Antimicrobial resistance patterns; pathogen prioritization
Immunocompromised Host Pneumonia	36.5% [5]	Pneumocystis jirovecii (20.3%), SARS-CoV-2 (8.9%), Aspergillus fumigatus (8.2%) [5]	Atypical pathogens; colonization vs. infection distinction
Cystic Fibrosis Lung Infections	>70% in adults [58]	S. aureus, H. influenzae, P. aeruginosa, Burkholderia cepacia complex [58]	Chronic biofilm-associated communities; evolving microbial populations

Advanced Diagnostic Technologies and Methodologies

Metagenomic Next-Generation Sequencing (mNGS)

Metagenomic next-generation sequencing represents a paradigm shift in PMI diagnosis by enabling culture-free, unbiased detection of entire microbial communities from clinical samples. This approach simultaneously identifies bacteria, viruses, fungi, and parasites through high-throughput sequencing of all nucleic acids present in a sample, followed by sophisticated bioinformatic analysis.

A compelling case study demonstrates the power of mNGS in diagnosing complex PMIs. An immunocompromised patient with severe community-acquired pneumonia (SCAP) and sepsis had bronchoalveolar lavage fluid (BALF) analyzed via mNGS, which detected six pathogens: Pneumocystis jirovecii, Klebsiella pneumoniae, Primate bocaparvovirus 1, Cytomegalovirus, Elizabethkingia anophelis, and Candida albicans [60]. This comprehensive pathogen profile enabled tailored antimicrobial therapy, leading to the patient's successful recovery despite the initial failure of conventional meropenem treatment [60]. The study highlighted mNGS's ability to identify mixed infections that conventional microbiological tests (CMTs) often miss, providing valuable guidance for clinical treatment decisions [60].

The typical workflow for BALF mNGS analysis includes: (1) nucleic acid extraction using kits designed to minimize host carryover; (2) library preparation with the Ovation Ultralow System v2; (3) high-throughput sequencing on platforms like Illumina NextSeq 550; (4) bioinformatic processing to remove low-quality and human reads; (5) microbial classification against comprehensive pathogen databases [5]. For pathogen identification, thresholds are defined relative to negative controls, with minimum reads-per-million (RPM) ratios or absolute cutoffs applied (e.g., ≥3 RPM for most bacteria and fungi) [5].

Multiplex Molecular Detection Platforms

For simultaneous detection and quantification of multiple pathogen targets, multiplex molecular platforms offer a complementary approach to mNGS. TaqMan Array Cards (TAC) represent one such technology, enabling the parallel analysis of 35 or more pathogen targets in a single run. This method has been successfully applied to wastewater surveillance but has direct clinical applications for PMI diagnosis [61] [62].

The TAC workflow involves: (1) sample processing using concentration methods like skim milk flocculation; (2) nucleic acid extraction; (3) setting up reactions with AgPath-ID One-Step RT-PCR reagents; (4) running the custom TAC on platforms like QuantStudio 7 Flex; (5) analyzing results with Cq values <40 considered positive [61] [62]. This approach provides semi-quantitative data on pathogen abundance with turnaround times potentially under 2 hours, significantly faster than mNGS.

Whole Genome Sequencing for Novel Taxa Identification

For the specific identification of novel bacterial taxa in immunocompromised patients, Whole Genome Sequencing (WGS) serves as the gold standard. The NOVA study established a pipeline for analyzing bacterial isolates that cannot be characterized by conventional methods [59]. The methodology includes: (1) initial isolation attempts using MALDI-TOF MS; (2) partial 16S rRNA gene sequencing when MALDI-TOF fails; (3) whole genome sequencing of unidentifiable isolates; (4) phylogenetic analysis using the Type (strain) genome server (TYGS); (5) determination of clinical relevance through chart review [59].

This approach proved highly successful, identifying 35 novel clinical isolates across diverse genera, with the majority isolated from deep tissue specimens or blood cultures [59]. The study highlights that WGS-based identification is particularly valuable for detecting and characterizing novel pathogens in immunocompromised patients, where unusual or fastidious organisms are more prevalent.

Experimental Protocols for PMI Research

In Vitro Co-infection Model Protocol

Studying pathogen interactions in PMIs requires sophisticated experimental models. The following protocol adapts established methods for investigating virus-bacteria co-infections, such as between SARS-CoV-2 and Staphylococcus aureus [63]:

• Cell Culture Maintenance: Maintain Vero E6 cells in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) without antibiotics. Passage cells at 90-100% confluence using 0.25% Trypsin/EDTA.

• Pathogen Preparation:

  • Virus: Use SARS-CoV-2 strains (e.g., USA-WA1/2020) amplified on Vero E6 cells, aliquoted, and stored at -80°C.
  • Bacteria: Streak S. aureus strain USA300 on Tryptic Soy Agar (TSA) and incubate at 37°C for 16-18 hours. Prepare bacterial suspension in Tryptic Soy Broth (TSB).

• Co-infection Assay:

  • Seed Vero E6 cells in 12-well plates and incubate until 70-80% confluent.
  • Infect cells with SARS-CoV-2 at appropriate MOI in infection medium (DMEM with 2% FBS).
  • Incubate for 24 hours at 37°C, 5% CO₂.
  • Add S. aureus at determined MOI and continue incubation.
  • Harvest samples at various time points for simultaneous quantification of viral and bacterial replication.

• Analysis Methods:

  • Viral quantification via plaque assay or RT-qPCR.
  • Bacterial quantification by colony-forming unit (CFU) counts.
  • Optional host RNA extraction using RNeasy Mini Kit.
  • Optional protein analysis using RIPA buffer with protease inhibitors.

This protocol allows monitoring of replication kinetics for both pathogens in the same sample, with optional extraction of host RNA and proteins for mechanistic studies [63].

Research Reagent Solutions for PMI Investigation

Table 2: Essential Research Reagents for Polymicrobial Infection Studies

Reagent/Kit	Manufacturer	Primary Function	Application Notes
DNeasy PowerSoil Pro Kit	Qiagen	Co-extraction of DNA and RNA from complex samples	Effective for BALF, tissue; reduces host background [5]
Ovation RNA-Seq System	Tecan Genomics	cDNA generation and amplification from low-input RNA	Maintains representation in transcriptomic studies [5]
AgPath-ID One-Step RT-PCR	Applied Biosystems	Multiplex pathogen detection	Compatible with TaqMan Array Cards [61]
AllPrep PowerViral Kit	Qiagen	Simultaneous DNA/RNA purification	Optimized for viral pathogen detection [62]
Illumina NextSeq 550	Illumina	High-throughput sequencing	75-bp single-end reads for mNGS [5]
QIAcuity Four dPCR	Qiagen	Absolute quantification of pathogens	Digital PCR for precise copy number determination [62]

Data Interpretation and Clinical Translation

Distinguishing Colonization from Infection

A critical challenge in PMI diagnosis, particularly with sensitive molecular methods like mNGS, is differentiating true pathogens from colonizers or contaminants. Clinical metagenomics requires careful interpretation integrating multiple data sources [60] [5]. The following criteria should be considered:

• Quantitative thresholds: Bacteria/viruses should demonstrate coverage depth >10× that of background microbiota; fungi require >5× that of other fungal species [5].
• Clinical-radiological correlation: Presence of characteristic symptoms with compatible CT patterns (e.g., ground-glass opacities suggesting Pneumocystis; cavitary lesions suggesting Aspergillus) [5].
• Supporting biomarkers: Elevated levels of relevant biomarkers (e.g., serum galactomannan for Aspergillus; elevated CRP and PCT for bacterial infections) [5].
• Microbial abundance: Relative abundance of the microbe in the microbial community and comparison to negative controls.

This integrated approach was successfully applied in the ICHP study, where pathogen attribution required collaborative determination by multiple clinicians evaluating microbiological data, imaging findings, and clinical symptoms [5].

Mathematical Modeling of Co-infection Dynamics

Mathematical models are increasingly important for understanding complex interactions in PMIs. A systematic review of mechanistic models of virus-bacteria co-infections in humans revealed that most models (42 of 72 studies) focus on evaluating control strategies and interventions [64]. However, a significant limitation exists: 79% (57 of 72) of these studies relied on non-empirical sources (assumed or borrowed values) for critical parameters like increased susceptibility to secondary pathogens following primary infection [64].

Future models need more empirical parameterization to reliably predict PMI dynamics. Promising approaches include:

• Within-host models that mechanistically describe interactions between viruses and bacteria
• Multi-scale models integrating within-host and between-host dynamics
• Network models capturing complex microbial community interactions
• Machine learning approaches leveraging high-dimensional mNGS data

Emerging Technologies and Research Needs

The field of PMI diagnostics is rapidly evolving, with several promising technologies on the horizon:

• CRISPR-based multiplex assays offering reduced turnaround times (<2 hours) with high accuracy (>95%) [58]
• Artificial intelligence-based metagenomic platforms for enhanced pathogen prioritization and resistance prediction
• Sensitive biosensors with point-of-care applicability for rapid screening
• Digital PCR technologies for absolute quantification of multiple pathogens
• Single-cell sequencing approaches to resolve individual pathogen contributions in complex communities

For the specific context of novel bacterial taxa in immunocompromised patients, research priorities include:

• Establishing comprehensive databases of novel pathogens and their clinical associations
• Developing rapid phenotypic susceptibility testing methods for unculturable organisms
• Validating host response biomarkers for distinguishing colonization from infection
• Creating standardized bioinformatic pipelines for novel pathogen detection
• Implementing prospective studies of immunocompromised cohorts to define the epidemiology of novel taxa

Advanced diagnostic technologies like mNGS and multiplex molecular platforms are revolutionizing our approach to polymicrobial infections, particularly in immunocompromised patients where novel bacterial taxa may be significant contributors to disease. While interpretation requires careful clinical correlation, these methods enable comprehensive pathogen detection that facilitates timely, targeted antimicrobial therapy. This is especially crucial for immunocompromised hosts, where PMIs are associated with significantly worse outcomes. As these technologies continue to evolve and become more accessible, they hold the promise of transforming the management of complex infections, mitigating antimicrobial resistance, and ultimately improving patient survival through precision infectious disease medicine.

Interpreting Antimicrobial Susceptibility for Organisms with Unknown Profiles

The emergence of novel bacterial taxa and strains with undefined antimicrobial susceptibility profiles represents a critical challenge in clinical microbiology, particularly in the management of immunocompromised patients. This population exhibits significantly increased vulnerability to infections due to impairments in both innate and adaptive immune systems, whether from primary immunodeficiency disorders, HIV/AIDS, malignancies, immunosuppressive therapies, or malnutrition [40]. The global burden of antimicrobial resistance (AMR) accounts for millions of deaths annually, with immunocompromised individuals facing elevated risks due to frequent antimicrobial exposure, prolonged healthcare contact, and the potential for rapid disease progression from undetected resistant pathogens [40]. When encountering organisms without established susceptibility interpretative criteria, clinicians and researchers must employ sophisticated methodological frameworks that integrate phenotypic, genotypic, and bioinformatic analyses to guide appropriate therapeutic interventions and advance our understanding of resistance mechanisms in these evolving pathogens.

Methodological Framework: An Integrated Approach

A comprehensive strategy for interpreting susceptibility for organisms with unknown profiles requires a multi-modal approach that correlates traditional phenotypic methods with advanced molecular techniques and epidemiological data. The framework consists of three interconnected pillars: phenotypic characterization, genotypic analysis, and contextual data interpretation.

Table 1: Core Components of the Methodological Framework

Component	Key Methods	Primary Outputs	Application Considerations
Phenotypic Characterization	Broth microdilution (ISO 20776-1), Disk diffusion, MIC determination	Quantitative susceptibility data (MIC values), Resistance phenotypes	Requires standardized inoculum preparation (1-2 × 10⁸ CFU/mL), controlled growth conditions [65]
Genotypic Analysis	Whole genome sequencing, PCR-based detection of ARGs, MLST, Rep-PCR	Identification of resistance determinants, Strain typing, Phylogenetic context	Enables detection of known and novel resistance mechanisms; requires bioinformatic expertise [66] [67]
Contextual Interpretation	Epidemiological cutoffs, Population distributions, Clinical correlation	Categorization of susceptibility profiles, Therapeutic guidance	Utilizes data from related species; considers infection site and patient-specific factors [68]

Phenotypic Characterization Methods

Reference Broth Microdilution Method

The reference method for antimicrobial susceptibility testing follows internationally standardized procedures (BS EN ISO 20776-1:2020) to ensure reproducibility and comparability across laboratories [65]. The protocol involves precise preparation of antimicrobial stock solutions, with concentrations typically starting at 1 g/L or higher depending on compound solubility. Critical steps include:

• Solution Preparation: Antimicrobial powders are weighed using pre-calibrated analytical balances, with concentrations adjusted for powder potency using the equation: m = (V × c)/P, where m is mass (mg), V is volume (mL), c is concentration (μg/mL), and P is potency (μg/mg) [65]. For experimental compounds with unknown extinction coefficients, spectrophotometric quantification at appropriate wavelengths (e.g., 235 nm for ampicillin, 260 nm for ceftazidime) applies the Beer-Lambert law: c = A/(ϵ × l) × DF, where A is absorbance, ϵ is molar extinction coefficient, l is path length, and DF is dilution factor [65].

• Inoculum Standardization: Bacterial cultures are grown in Mueller-Hinton broth at 35±1°C with orbital shaking (170 rpm) for 18-24 hours, then adjusted to a 0.5 McFarland standard (OD₆₂₅ 0.08-0.12), corresponding to approximately 1-2 × 10⁸ CFU/mL. Further dilution to 10⁶ CFU/mL creates the final working inoculum [65].

• Incubation and MIC Determination: Plates containing serial antimicrobial dilutions are inoculated and incubated under standardized conditions. The Minimum Inhibitory Concentration (MIC) represents the lowest antimicrobial concentration preventing visible growth, determined through spectrophotometric methods or visual inspection after 24 hours of incubation [65].

Genomic Characterization and Resistome Analysis

Whole genome sequencing (WGS) has emerged as the definitive method for comprehensive characterization of bacterial isolates with undefined susceptibility profiles, particularly for novel taxa in immunocompromised hosts [66] [67]. The analytical workflow encompasses multiple genomic features that collectively inform susceptibility predictions.

Genomic Techniques for Strain Typing and Characterization

Multiple molecular techniques enable researchers to type microbial isolates beyond species level, providing critical epidemiological and pathogenicity insights [66]. These methods vary in resolution, cost, and technical requirements, allowing selection based on specific research needs and available resources.

Table 2: Molecular Techniques for Microbial Identification and Typing

Technique	Principle	Discriminatory Power	Time to Result	Primary Applications
Pulsed-Field Gel Electrophoresis (PFGE)	Separation of large DNA restriction fragments	High	3+ days	Gold standard for outbreak investigation [66]
Multilocus Sequence Typing (MLST)	Sequencing of 400-500 bp fragments of 7 housekeeping genes	Moderate to High	1-2 days	Epidemiological studies, population genetics [66]
Whole Genome Sequencing (WGS)	Determination of complete or nearly complete DNA sequence	Highest	1-3 days	Comprehensive characterization, novel gene detection [66] [67]
Multilocus Variable Number Tandem Repeat Analysis (MLVA)	PCR amplification and sequencing of repetitive DNA sequences	High	1 day	Outbreak investigation, strain discrimination [66]
Repetitive Sequence-based PCR (rep-PCR)	Amplification of non-coding repetitive sequences	Moderate	1 day	Rapid strain typing, infection control [66]

Genomic Analysis Workflow for Novel Isolates

The characterization of novel multidrug-resistant organisms from immunocompromised patients follows a systematic genomic workflow, as demonstrated in the analysis of a novel esxA-positive Staphylococcus haemolyticus ST-184 isolate from a respiratory infection case [67]:

• DNA Extraction and Sequencing: High-quality genomic DNA is extracted from pure cultures and subjected to whole genome sequencing using next-generation sequencing platforms such as Illumina or Ion Torrent [67].

• In silico Analysis: Sequencing data undergoes comprehensive computational analysis to identify: (1) Antimicrobial resistance genes (ARGs) through comparison with curated resistance databases; (2) Virulence factors; (3) Plasmid-associated genes; (4) Mobile genetic elements (MGEs) including integration/excision elements and prophage-associated regions; (5) Biosynthetic gene clusters [67].

• Pan-resistome Analysis: Comparative genomics with publicly available genomes (e.g., 694 S. haemolyticus genomes from 35 countries in the DUEML1 study) places the novel isolate in global context, identifying unique and shared resistance determinants [67].

• Phylogenetic Placement: Multilocus sequence typing (MLST) identifies novel sequence types (e.g., ST-184 with arcC-38 allele), while single nucleotide polymorphism (SNP) analysis determines phylogenetic relationships to known clinical isolates [67].

This integrated genomic approach identified several antimicrobial resistance genes (fosBx1, mgrA, norC, sdrM, sepA) and virulence genes (esxA, cap8G) in the novel S. haemolyticus isolate, explaining its multidrug-resistant phenotype against levofloxacin, ciprofloxacin, tetracycline, doxycycline, gentamicin, and trimethoprim-sulfamethoxazole [67].

Quantitative Analysis of Antimicrobial Susceptibility Data

Standardized analysis and presentation of cumulative antimicrobial susceptibility test data enables meaningful interpretation for organisms without established breakpoints [68]. The CLSI M39 guideline provides frameworks for data extraction, analysis, and presentation that support susceptibility interpretation for novel organisms.

Antimicrobial Use Evaluation Metrics

Quantitative evaluation of antimicrobial use employs standardized metrics that enable comparison across institutions and tracking of resistance trends [69]. These metrics are particularly valuable when establishing baseline data for novel pathogens.

Table 3: Antimicrobial Use Evaluation Metrics

Metric	Definition	Calculation	Advantages	Limitations
Defined Daily Dose (DDD)	The average daily dose administered to adults for primary treatment indication [69]	Total amount of antimicrobial used (g) / WHO DDD	Easy data collection, no patient-specific data needed	Not applicable to children, inaccurate with renal impairment or combination therapy [69]
Days of Therapy (DOT)	The sum of the number of days patients received antimicrobials [69]	Count of treatment days for each antimicrobial	More intuitive, applicable to all patient populations	Requires patient-specific data, resource-intensive to collect [69]

Antimicrobial Categorization Systems

Classification systems organize antimicrobials based on spectrum of activity and resistance risk, providing framework for empirical therapy decisions when facing novel pathogens [69]:

• WHO AWaRe Classification: Categorizes antimicrobials into Access (narrow-spectrum, good safety profile), Watch (broader-spectrum, higher resistance potential), and Reserve (last-resort options) groups [69].

• Spectrum-Based Classification: Groups antimicrobials by spectrum of activity: (1) Broad-spectrum agents for nosocomial infections; (2) Broad-spectrum agents for community infections; (3) Agents targeting gram-positive resistant bacteria; (4) Non-broad-spectrum β-lactams; (5) Anti-anaerobic agents; (6) Agents targeting gram-negative highly resistant bacteria [69].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Essential Research Reagents for Antimicrobial Susceptibility Testing

Reagent/Material	Specification	Function/Application	Example Sources
Mueller-Hinton Broth	Standardized formulation per CLSI/ISO	Growth medium for broth microdilution assays, ensures reproducible results [65] [67]	Commercial manufacturers
Cation-Adjusted Mueller-Hinton Broth	Divalent cation standardization	Specialized medium for testing Pseudomonas aeruginosa and other non-fermenters	Commercial manufacturers
Antimicrobial Reference Powders	Known potency, purity >95%	Preparation of stock solutions for susceptibility testing [65]	Sigma-Aldrich, Fisher Bioreagents
McFarland Standards	0.5 McFarland (OD₆₂₅ 0.08-0.12)	Turbidity standard for inoculum preparation (1-2 × 10⁸ CFU/mL) [65] [67]	Commercial standards or prepared in-house
DNA Extraction Kits	High-quality genomic DNA	Whole genome sequencing, PCR-based resistance detection [67]	Qiagen, Thermo Fisher
PCR Reagents	Including primers, dNTPs, polymerase	Amplification of specific resistance genes or housekeeping genes for MLST [70] [66]	Various molecular biology suppliers
Next-Generation Sequencing Platforms	Illumina, Ion Torrent systems	Whole genome sequencing for comprehensive resistance determinant identification [66] [67]	Institutional core facilities

Interpretation Strategies and Clinical Correlation

Interpreting susceptibility data for organisms without established breakpoints requires inferential approaches that integrate multiple data sources:

Epidemiological Cutoff Values (ECVs)

ECVs distinguish wild-type populations (without acquired resistance mechanisms) from non-wild-type populations (with acquired resistance mechanisms) based on MIC distribution data from large isolate collections. For novel organisms, ECVs from phylogenetically related species provide preliminary interpretive criteria until species-specific data becomes available [68].

Correlation with Resistance Mechanisms

Identified resistance mechanisms should correlate with observed resistance phenotypes. For example, the detection of norC and sdrM efflux pump genes in S. haemolyticus explains resistance to fluoroquinolones, while fosBx1 correlates with resistance to fosfomycin [67]. Discordance between genotypic predictions and phenotypic results may indicate novel resistance mechanisms or regulatory pathways requiring further investigation.

Therapeutic Decision-Making

In clinical settings, particularly for immunocompromised patients, therapeutic decisions for infections with novel organisms integrate multiple factors: (1) MIC distribution data from related species; (2) Identified resistance mechanisms; (3) Pharmacokinetic/pharmacodynamic (PK/PD) parameters; (4) Infection site penetration; (5) Patient-specific factors including immune status and comorbidities [40] [68]. This multidimensional approach supports personalized antimicrobial therapy while minimizing collateral damage from unnecessarily broad-spectrum regimens.

The interpretation of antimicrobial susceptibility for organisms with unknown profiles demands an integrated methodology that synergistically combines standardized phenotypic testing, comprehensive genomic analysis, and informed contextual interpretation. This approach is particularly crucial for managing infections in immunocompromised patients, where delayed or inappropriate therapy carries grave consequences. As novel bacterial taxa and resistance mechanisms continue to emerge, particularly in vulnerable populations, the framework outlined in this technical guide provides a roadmap for researchers and clinicians to navigate the complexities of susceptibility interpretation, ultimately supporting optimized patient care and strengthened antimicrobial stewardship in the face of evolving microbial threats.

Strategies for Treating Infections with Limited Antibiotic Options

The escalating global crisis of antimicrobial resistance (AMR) presents a formidable challenge to modern medicine, particularly in the treatment of infections in immunocompromised patients. This whitepaper synthesizes current evidence and emerging strategies for managing infections when conventional antibiotic options are depleted. The convergence of advanced diagnostics, novel therapeutic modalities, and personalized medicine approaches outlined herein provides a framework for addressing this critical healthcare challenge within the unique context of immunocompromised hosts, who face disproportionate risks from multidrug-resistant pathogens due to their impaired immune defenses and frequent healthcare exposures [40] [71].

Global Resistance Epidemiology and Burden

Understanding the contemporary landscape of antimicrobial resistance is fundamental to developing effective treatment strategies. Recent data from the World Health Organization (WHO) reveals alarming trends in resistance patterns worldwide.

Regional Variation in Resistance Patterns

According to WHO surveillance data from over 100 countries, approximately one in six laboratory-confirmed bacterial infections in 2023 were resistant to antibiotic treatments. Between 2018 and 2023, antibiotic resistance rose in over 40% of the pathogen-antibiotic combinations monitored, with an average annual increase of 5-15% [72]. The burden of resistance demonstrates significant geographical variation, as detailed in Table 1.

Table 1: Global Regional Variation in Antibiotic Resistance Patterns

WHO Region	Resistance Prevalence	Key Resistance Trends
South-East Asia	1 in 3 infections resistant	Among the highest resistance rates globally
Eastern Mediterranean	1 in 3 infections resistant	Similar to South-East Asian prevalence
African Region	1 in 5 infections resistant	Exceeds 70% for specific pathogen-drug combinations
Global Average	1 in 6 infections resistant	Increasing across >40% of monitored combinations

Resistance is notably more common and worsening in regions where health systems lack capacity for adequate diagnosis and treatment of bacterial pathogens [72]. This disparity highlights the urgent need for strengthened laboratory infrastructure and surveillance systems, particularly in resource-limited settings.

Gram-Negative Resistance Crisis

The WHO report identifies drug-resistant Gram-negative bacteria as presenting one of the most dangerous trends in the AMR landscape. Among these pathogens, E. coli and K. pneumoniae are the leading drug-resistant Gram-negative bacteria found in bloodstream infections, which frequently result in sepsis, organ failure, and death [72].

Table 2: Critical Resistance Patterns in Gram-Negative Pathogens

Pathogen	Resistance to First-Line Therapy	Regional Concerns	Therapeutic Implications
Escherichia coli	>40% resistant to third-generation cephalosporins	Global spread	Limited options for common infections
Klebsiella pneumoniae	>55% resistant to third-generation cephalosporins	African Region >70% resistance	Carbapenems often required
Acinetobacter spp.	Emerging carbapenem resistance	Multiple regions	Relying on last-resort antibiotics
Salmonella spp.	Fluoroquinolone resistance increasing	Foodborne transmission concern	Complicates gastrointestinal infections

Of particular concern is the rise of carbapenem resistance, which was once rare but is becoming more frequent, dramatically narrowing treatment options and forcing reliance on last-resort antibiotics. These reserve antibiotics are often costly, difficult to access, and frequently unavailable in low- and middle-income countries, creating potentially untreatable infections in vulnerable populations [72].

Novel Therapeutic Approaches and Mechanisms

The declining efficacy of conventional antibiotics has catalyzed the development of innovative therapeutic strategies that target bacterial pathogens through novel mechanisms. These approaches aim to overcome existing resistance mechanisms while minimizing the emergence of new resistance.

Targeting Bacterial Gene Regulation and Protein Homeostasis

Emerging therapeutic strategies are focusing on previously unexplored bacterial processes essential for survival and virulence. Among the most promising targets are bacterial riboswitches and proteolytic systems:

Riboswitch Targeting: Riboswitches are non-coding RNA domains that detect specific metabolites and regulate gene expression in bacteria. Recent investigations have demonstrated that targeting flavin mononucleotide (FMN), thiamine pyrophosphate (TPP), and glmS riboswitches with chimeric antisense oligonucleotides can effectively inhibit bacterial growth without exhibiting toxicity on human cell lines [73]. This approach represents a rational and selective strategy against resistant pathogens like Staphylococcus aureus and Escherichia coli.

Experimental Protocol: Riboswitch Inhibition Assay

• Design and Synthesis: Design chimeric antisense oligonucleotides complementary to the target riboswitch sequence (FMN, TPP, or glmS). Incorporate 2'-O-methyl modifications to enhance nuclease resistance.
• Bacterial Strains and Culture: Select target bacterial strains (e.g., Staphylococcus aureus, Escherichia coli) and culture in appropriate medium to mid-log phase.
• Oligonucleotide Delivery: Introduce oligonucleotides into bacterial cells using electroporation or cationic lipid-based transfection. Optimize concentration (typically 1-10 μM) and incubation time.
• Growth Monitoring: Measure bacterial growth kinetics by optical density (OD600) over 24 hours. Compare treatment groups to scrambled oligonucleotide controls.
• Gene Expression Analysis: Extract RNA post-treatment and quantify target gene expression using RT-qPCR to confirm riboswitch engagement.
• Cytotoxicity Assessment: Expose human cell lines (e.g., HEK293, HepG2) to identical oligonucleotide concentrations and assess viability via MTT assay after 48 hours [73].

Protease Activation: The bacterial caseinolytic protease (ClpP) system plays an essential role in maintaining protein homeostasis. A novel class of antibiotics known as activators of self-compartmentalizing proteases (ACPs) has demonstrated potent activity against Gram-negative pathogens that are resistant to traditional antibiotics. These compounds work by dysregulating ClpP activity, leading to uncontrolled proteolysis and bacterial death [73].

Diagram: Bacterial Protease Activation Pathway - ACP antibiotics activate ClpP protease, leading to uncontrolled protein degradation and bacterial death.

Overcoming Gram-Negative Permeability Barriers

The development of effective antibiotics against Gram-negative pathogens has been particularly challenging due to their protective outer membrane, which limits drug penetration and facilitates efflux pump-mediated resistance. Innovative strategies are being pursued to circumvent these barriers:

Membrane Permeabilization: Novel approaches are being developed to alter bacterial membrane permeability, thereby facilitating targeted drug uptake. These include:

• Engineered cationic polymers that disrupt membrane integrity
• Adjuvants that inhibit efflux pump activity
• Trojan horse strategies that exploit bacterial nutrient uptake systems [73]

Combination Therapies: Strategic pairing of antibiotics with complementary agents represents a promising approach to overcoming resistance:

• Antibiotic + Efflux Pump Inhibitors: Restores susceptibility to existing antibiotics
• Antibiotic + Antivirulence Agents: Reduces pathogenicity without direct killing pressure
• Antibiotic + Quorum-Sensing Inhibitors: Disrupts bacterial communication and biofilm formation [73]

Experimental Protocol: Membrane Permeability Assessment

• Bacterial Preparation: Grow Gram-negative test strains to mid-log phase in appropriate medium.
• Membrane Perturbation: Treat bacterial suspensions with candidate permeabilizing agents at varying concentrations.
• Fluorescent Probe Uptake: Add membrane-impermeant fluorescent dyes (e.g., N-phenyl-1-naphthylamine, ethidium bromide) and measure fluorescence increase over time.
• Efflux Inhibition Assay: Combine sub-inhibitory concentrations of efflux pump inhibitors with antibiotics and determine MIC reduction.
• Synergy Testing: Evaluate combination therapies using checkerboard microdilution assays and calculate fractional inhibitory concentration indices.
• Cytoplasmic Leakage Confirmation: Measure release of cytoplasmic components (e.g., ATP, UV-absorbing materials) spectrophotometrically [73].

Advanced Biotherapeutic Interventions

Bacteriophage Therapy: The therapeutic use of bacteriophages (viruses that infect and lyse bacteria) has regained attention as an alternative to conventional antibiotics. Phages offer several advantages, including species-specific targeting, the ability to penetrate biofilms, and mechanisms of action distinct from antibiotics. Recent studies have demonstrated promising activity of bacteriophage K against Staphylococcus aureus isolates from pediatric populations, with elevated susceptibility observed in resistant strains [74] [75].

Experimental Protocol: Bacteriophage Characterization and Therapeutic Assessment

• Phage Isolation and Propagation: Isolate phages from environmental samples using the double-agar overlay method with target bacterial strains as hosts. Amplify high-titer phage stocks.
• Host Range Determination: Spot purified phage lysates on lawns of clinically relevant bacterial isolates to determine specificity.
• Biofilm Penetration Assay: Grow biofilms in vitro, treat with phage preparations, and assess biomass reduction using crystal violet staining and confocal microscopy.
• Time-Kill Kinetics: Co-incubate bacteria with phages at various multiplicities of infection and quantify viable bacteria over 24 hours.
• Resistance Monitoring: Serial passage bacteria with phages and monitor for emerging resistance phenotypes.
• Synergy with Antibiotics: Combine phage therapy with sub-inhibitory antibiotic concentrations and assess enhanced bactericidal activity [74].

Immunomodulatory Approaches: For immunocompromised patients, enhancing host immune responses represents a complementary strategy. Approaches under investigation include:

• Monoclonal antibodies targeting specific virulence factors
• Immune checkpoint modulators to reverse infection-associated immunosuppression
• Cytokine therapies to bolster deficient immune functions [40] [71]

Diagram: Bacteriophage Therapeutic Mechanism - Phages specifically target and lyse antibiotic-resistant bacteria, even within biofilms.

Diagnostic Innovations and Resistance Surveillance

Rapid and accurate diagnostic methods are critical components in the effort to combat antimicrobial resistance, particularly for immunocompromised patients where delayed appropriate therapy significantly increases mortality risk.

Advanced Molecular Detection Technologies

Whole Genome Sequencing (WGS): The implementation of WGS in clinical microbiology laboratories has revolutionized pathogen identification and resistance detection. WGS enables comprehensive analysis of bacterial genomes, allowing for the identification of resistance genes, virulence factors, and phylogenetic relationships between isolates. This approach has proven particularly valuable for investigating outbreaks of carbapenem-resistant Gram-negative bacteria in healthcare settings [74].

CRISPR-Based Diagnostics: CRISPR/Cas systems have been adapted for rapid detection of antimicrobial resistance genes. These platforms offer:

• High sensitivity and specificity for resistance determinant detection
• Rapid turnaround times compared to conventional culture methods
• Potential for point-of-care implementation in resource-limited settings [74]

Machine Learning and Artificial Intelligence: AI-based approaches are being increasingly utilized to predict resistance patterns from complex datasets. Applications include:

• Resistance prediction from genomic data
• Antibiotic recommendation systems based on local epidemiology
• Outbreak detection and transmission tracking [76] [74]

Surveillance Systems and Epidemiology

Robust surveillance is fundamental to understanding and combating AMR. The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) has demonstrated significant expansion, with country participation increasing from 25 nations in 2016 to 104 countries in 2023. However, critical gaps remain, as 48% of countries did not report data to GLASS in 2023, and approximately half of reporting countries lacked systems to generate reliable data [72].

Molecular epidemiology studies have revealed important insights into the dissemination of resistant pathogens. Recent investigations of carbapenem-resistant Gram-negative bacteria in Moldova identified several phylogenetic clusters of K. pneumoniae, A. baumannii, and P. aeruginosa, with demonstrated phylogenetic relationships to isolates from neighboring Ukraine. The study identified diverse carbapenemase genes, including blaKPC-23, blaOXA-72, blaGES-11, blaNDM-1, and blaVIM-2, supporting the hypothesis of regional transmission events driven by evolutionarily successful clonal lineages [74].

The Scientist's Toolkit: Essential Research Reagents and Platforms

Table 3: Key Research Reagents and Platforms for AMR Investigation

Reagent/Platform	Function/Application	Specific Utility in AMR Research
Biocontainers	Standardized bioinformatics software containers	Ensures reproducibility of genomic analyses and tool versions [76]
CRISPR/Cas Systems	Gene editing and diagnostic detection	Identifies and characterizes resistance mechanisms; potential therapeutic application [74]
Whole Genome Sequencing Platforms	Comprehensive genomic analysis	Enables resistance gene identification and phylogenetic tracking [74]
Retrieval Augmented Generation (RAG)	Domain-specific knowledge retrieval	Enhances bioinformatics analysis through dynamic access to current literature and databases [76]
BioAgents Multi-Agent System	Bioinformatics workflow development	Assists in developing complex analysis pipelines for AMR surveillance [76]
Antimicrobial Peptide Libraries	Novel therapeutic candidates	Provides alternatives to conventional antibiotics with lower resistance potential [73]
Microfluidic Culturing Devices	Pathogen isolation and susceptibility testing	Enables rapid phenotypic testing from limited clinical samples [40]
Phage Library Platforms	Bacteriophage isolation and characterization	Supports development of phage therapy against multidrug-resistant pathogens [74]

Concluding Perspectives

The escalating challenge of antimicrobial resistance demands an integrated, multidisciplinary approach that leverages advances in diagnostics, therapeutics, and surveillance. For immunocompromised patients, who face disproportionate risks from multidrug-resistant infections, the strategies outlined in this whitepaper provide a roadmap for navigating the increasingly limited antibiotic landscape. The convergence of novel therapeutic modalities—from riboswitch inhibitors and protease activators to bacteriophage therapy and immunomodulatory approaches—offers hope for addressing infections that are no longer responsive to conventional antibiotics. Continued investment in research and development, strengthened surveillance systems, and enhanced antimicrobial stewardship will be essential to prevent a return to the pre-antibiotic era and protect our most vulnerable patient populations.

The Role of Antimicrobial Stewardship in Preventing Resistance Emergence

Antimicrobial stewardship (AMS) is the coordinated effort to measure and improve how antibiotics are prescribed by clinicians and used by patients. In the specific context of immunocompromised patients, where novel and difficult-to-identify bacterial taxa are increasingly recognized, these efforts are critical for preventing the emergence and spread of resistance [77] [27]. Immunocompromised individuals, including people living with HIV/AIDS, cancer patients, transplant recipients, and those with autoimmune disorders, constitute a growing and diverse population that is disproportionately affected by antimicrobial resistance (AMR) [40] [78]. This vulnerability stems from frequent healthcare encounters, repeated and prolonged antibiotic exposure, and often impaired immune responses that complicate infection diagnosis and management [78].

The discovery of novel bacterial pathogens through advanced diagnostic techniques has further highlighted the urgent need for sophisticated stewardship approaches. Recent studies have identified numerous previously uncharacterized bacterial species in clinical specimens from immunocompromised hosts, with one investigation isolating 35 bacterial strains representing potentially novel species, 7 of which demonstrated clear clinical relevance [27]. These emerging pathogens challenge conventional diagnostic and therapeutic protocols, necessitating stewardship strategies that are both robust and adaptable to accommodate evolving microbiological landscapes.

Core Elements of Antimicrobial Stewardship Programs

The Centers for Disease Control and Prevention (CDC) has established Core Elements for antibiotic stewardship that provide healthcare facilities with a framework for implementing effective programs. These elements emphasize the importance of accountability, drug expertise, action, tracking, reporting, and education [77]. While these principles provide a foundational structure, their application must be tailored to the unique challenges presented by immunocompromised populations and the novel pathogens that affect them.

AMS programs complement existing guidelines and standards from key healthcare partner organizations, including the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), American Society of Health System Pharmacists, and The Joint Commission [77]. The complexity of medical decision-making surrounding antibiotic use in immunocompromised patients, coupled with the variability in facility size and types of care, requires flexible programs and activities rather than a "one size fits all" approach [77].

Special Considerations for Immunocompromised Patients

• Diagnostic Uncertainty: Immunocompromised patients often present with non-specific or atypical features of infection due to blunted inflammatory responses, broadening the differential diagnosis and complicating targeted therapy [78].
• Diagnostic Urgency: The critical need for timely diagnosis in high-risk patients often leads to pan-culture approaches and broad molecular diagnostic testing, which can inadvertently result in detection of contaminants or colonization and excess antibiotic treatment [78].
• Unique Resistance Pressures: The high prevalence of prophylactic and therapeutic antibiotic use in this population, coupled with frequent contact with healthcare facilities, creates selective pressures that favor the emergence of resistant strains [40].

Quantitative and Qualitative Evaluation of Antimicrobial Use

A fundamental aspect of antimicrobial stewardship is the identification of antimicrobial use patterns, which reveals key targets for interventions and facilitates evaluation of intervention effectiveness [69]. Accurate identification of these patterns requires both quantitative and qualitative assessments, which provide complementary information essential for effective ASP implementation [69].

Table 1: Antimicrobial Use Evaluation Metrics

Metric Category	Specific Metric	Definition	Applications	Limitations
Quantitative Evaluation	Defined Daily Dose (DDD)	The average daily dose administered to adults for treating infectious diseases when a specific antimicrobial is the primary indication [69].	- Benchmarking across facilities- Tracking trends over time	- Not applicable to children- Potentially inaccurate in patients with renal impairment or those requiring high-dose/combination therapy [69]
	Days of Therapy (DOT)	The sum of the number of days a patient receives any dose of an antimicrobial [69].	- More intuitive than DDD- Applicable to children	- Requires patient-specific data- Labor-intensive to collect [69]
Qualitative Evaluation	Guideline Adherence	Assessment of prescription compliance with established institutional or national guidelines [69].	- Identifies educational opportunities- Measures intervention effectiveness	- Dependent on guideline quality and accessibility
	Appropriateness Assessment	Evaluation of drug choice, dose, duration, and route based on patient-specific factors and pathogen characteristics [69].	- Directly impacts patient outcomes- Reduces collateral damage	- Requires clinical expertise and time

Antimicrobial Categorization Systems

Effective stewardship utilizes classification systems to guide antimicrobial use evaluation:

• WHO AWaRe System: Categorizes antimicrobials into Access, Watch, and Reserve groups based on the associated risk of developing resistant bacteria [69].
• Spectrum-Based Classification: Groups antimicrobials based on their spectrum of activity rather than traditional class-based categorization (e.g., broad-spectrum antibiotics for nosocomial infections vs. community-acquired infections) [69].

These classification systems enable more precise monitoring and intervention strategies, particularly important in immunocompromised populations where broad-spectrum antimicrobial use is prevalent.

Advanced Diagnostic Approaches and Their Integration with Stewardship

Diagnostic stewardship—improving appropriate diagnosis through processes that ensure the right test is performed on the right specimen at the right time for the right patient—works in concert with antimicrobial stewardship to optimize infectious disease management [78]. This integration is particularly crucial for immunocompromised patients, where diagnostic challenges directly impact antibiotic use.

Algorithm for Novel Pathogen Identification

The NOVA (Novel Organism Verification and Analysis) study established a systematic algorithm for identifying bacterial isolates that cannot be characterized by conventional identification procedures [27]. This approach exemplifies how advanced diagnostics can inform stewardship efforts.

Diagram 1: NOVA novel pathogen identification algorithm. This workflow systematically identifies novel bacterial species that evade conventional identification methods [27].

Diagnostic Stewardship Strategies for Immunocompromised Patients

• Culture-Based Diagnostics: Enhancement of appropriate specimen collection, processing, and interpretation to distinguish colonization from true infection [78].
• Rapid Molecular Diagnostics: Implementation of multiplex PCR panels and other rapid tests to decrease time to optimal therapy and enable early de-escalation [78].
• Advanced Pathogen Detection: Utilization of metagenomic next-generation sequencing (mNGS) for universal pathogen detection and identification of antibiotic resistance genes in complex cases [78].
• Antibiotic Allergy Delabelling: Systematic evaluation of reported antibiotic allergies to remove inappropriate labels that restrict therapeutic options [78].

Experimental Protocols for Antimicrobial Use Assessment

Protocol for Quantitative Antimicrobial Use Evaluation

Objective: To quantify and benchmark antimicrobial use within a healthcare facility using standardized metrics [69].

Materials:

• Pharmacy dispensing data or electronic health record extraction capabilities
• Patient census data
• Standardized antimicrobial classifications (e.g., WHO AWaRe, spectrum-based categories)
• DDD values from WHO Collaborating Centre for Drug Statistics Methodology
• Data analysis software (e.g., R, Python, or specialized antimicrobial use software)

Procedure:

• Data Collection: Extract data on all systemic antimicrobial agents administered to patients during the defined study period, including drug name, formulation, strength, daily dose, and administration dates.
• Patient-Days Calculation: Calculate the total number of patient-days for the population during the same period.
• DDD Calculation: For each antimicrobial agent, divide the total quantity used (in grams) by the appropriate DDD value to obtain the number of DDDs.
• DOT Calculation: For each patient, count the number of days each antimicrobial agent was administered, regardless of dose, then sum these days across all agents and patients.
• Utilization Rate Calculation: Express use as DDD per 1000 patient-days or DOT per 1000 patient-days to enable benchmarking.
• Stratified Analysis: Categorize antimicrobial use by drug class, spectrum of activity, patient care unit, or prescriber specialty to identify targets for intervention.

Analysis: Compare utilization rates to internal benchmarks over time or external benchmarks from similar facilities. Significant deviations from expected ranges should trigger qualitative review of prescribing appropriateness.

Protocol for Qualitative Antimicrobial Use Evaluation

Objective: To assess the appropriateness of antimicrobial prescribing based on established criteria [69].

Materials:

• Explicit criteria for appropriate antimicrobial use (e.g., institutional guidelines, national standards)
• Trained reviewer(s) (e.g., infectious diseases physician, pharmacist)
• Standardized data collection tool
• Access to complete medical records

Procedure:

• Case Selection: Identify cases for review through random sampling, focused review of specific agents (e.g., broad-spectrum antimicrobials), or triggered by certain events (e.g., positive blood culture).
• Data Abstraction: Collect relevant clinical data including patient demographics, comorbidities, signs and symptoms of infection, microbiological results, and antimicrobial regimen details.
• Appropriateness Assessment: Evaluate each antimicrobial regimen against predetermined criteria, considering:
  • Indication (presence of infection, prophylaxis)
  • Drug selection (spectrum, allergies, interactions)
  • Dose (weight, renal/hepatic function)
  • Route of administration
  • Duration of therapy
• Categorization: Classify each regimen as appropriate or inappropriate, with specific rationale for inappropriate classifications.
• Feedback: Provide timely, specific feedback to prescribers when opportunities for improvement are identified.

Analysis: Calculate the proportion of appropriate antimicrobial use overall and within specific categories. Identify common patterns of inappropriate use to guide educational interventions and policy changes.

Innovative Therapeutic Approaches and Research Reagents

The growing threat of AMR has stimulated development of novel therapeutic approaches, particularly for multidrug-resistant pathogens that commonly affect immunocompromised patients.

Bacteriophage Therapy

Recent research has demonstrated the potential of bacteriophage therapy against challenging pathogens such as Stenotrophomonas maltophilia, an opportunistic bacterium with significant multidrug resistance that poses particular threats to immunocompromised individuals [79]. Isolation and characterization of novel phages targeting this pathogen have shown potent lytic activity even at low doses, with genome analysis confirming the absence of lysogeny genes, virulence factors, or antibiotic resistance genes—essential characteristics for therapeutic phages [79].

Table 2: Research Reagent Solutions for Antimicrobial Resistance Research

Reagent/Category	Specific Examples	Function/Application	Research Context
Whole Genome Sequencing Platforms	Illumina MiSeq/NextSeq500	High-resolution bacterial species identification and resistance gene detection [27].	NOVA study algorithm for novel pathogen identification [27].
Mass Spectrometry Systems	MALDI-TOF MS (Bruker Daltonics)	Rapid microbial identification based on protein spectral patterns [27].	Routine bacterial identification prior to advanced molecular methods [27].
Antimicrobial Susceptibility Testing Systems	VITEK 2 AST, Selux AST System	Phenotypic determination of antimicrobial effectiveness against specific bacterial isolates [80].	FDA-cleared systems for clinical susceptibility testing [80].
Bacteriophage Isolation Materials	Bacterial host strains, sewage samples, enrichment cultures	Isolation of novel phages with therapeutic potential against multidrug-resistant pathogens [79].	Characterization of Stenotrophomonas maltophilia phages [79].
Molecular Diagnostic Panels	Multiplex PCR panels for respiratory, gastrointestinal pathogens	Rapid syndromic testing to guide targeted antimicrobial therapy [78].	Stewardship interventions in immunocompromised patients with suspected infection [78].
Bioinformatics Tools	rMLST, TYGS, OrthoANIu	Genomic analysis and comparison for novel species identification [27].	Classification of novel bacterial taxa in clinical specimens [27].

Diagnostic and Digital Innovation

Emerging technologies are creating new opportunities to combat AMR in immunocompromised patients:

• Machine Learning Models: Analysis of metagenomics data, microbiology imaging, and electronic health records to predict risk of multidrug-resistant organisms, sepsis, and patient outcomes [78].
• Rapid Molecular Diagnostics: Platforms that enable same-day pathogen identification and resistance marker detection, facilitating early appropriate therapy [78] [80].
• Metagenomic Next-Generation Sequencing (mNGS): Universal pathogen detection that can identify unconventional or novel pathogens while simultaneously detecting resistance genes [78].

Diagram 2: Diagnostic-stewardship integration cycle. Advanced diagnostics and stewardship interventions form a continuous quality improvement cycle [78].

Antimicrobial stewardship plays an indispensable role in preventing the emergence of resistance, particularly in vulnerable immunocompromised populations where novel bacterial taxa present ongoing challenges. The integration of quantitative and qualitative antimicrobial use evaluation, coupled with advanced diagnostic techniques and innovative therapeutic approaches, creates a comprehensive framework for addressing this critical public health threat. As research continues to reveal new pathogens and resistance mechanisms, stewardship programs must evolve to incorporate novel diagnostic technologies, therapeutic modalities like phage therapy, and digital tools that enable personalized medicine approaches. Protecting the efficacy of existing antimicrobial agents while fostering development of new therapeutic strategies requires sustained commitment to stewardship principles across the healthcare continuum, ensuring these life-saving treatments remain effective for future generations.

Addressing Contamination and Colonization vs. True Infection

In the context of novel bacterial taxa research in immunocompromised patients, distinguishing between contamination, colonization, and true infection represents a fundamental diagnostic challenge with direct implications for therapeutic outcomes and antimicrobial stewardship. Contamination refers to the presence of microbes in a sample that are not truly associated with the patient, often introduced during collection or processing. Colonization describes the presence of microorganisms that have established themselves on or in the body without causing tissue damage or eliciting a host immune response. In contrast, true infection occurs when pathogens invade host tissues, multiply, and provoke a pathological immune response [39] [81].

This distinction becomes particularly critical when investigating novel bacterial taxa in immunocompromised populations, including intensive care unit (ICU) patients, those with malignancies, transplant recipients, and HIV-positive individuals [39]. These patients exhibit increased susceptibility to infections with multidrug-resistant (MDR) organisms due to frequent healthcare exposure, invasive procedures, prolonged antibiotic prophylaxis, and compromised host immunity [39]. Asymptomatic colonization with MDR bacteria typically precedes infection and can persist for extended periods, creating a reservoir for potential systemic invasion when host defenses are most compromised [39].

The emergence of novel bacterial species further complicates this landscape. Recent studies utilizing whole-genome sequencing have identified numerous previously uncharacterized bacterial organisms from clinical specimens, with a significant proportion demonstrating clinical relevance [27]. This expanding microbial diversity necessitates refined diagnostic approaches to accurately differentiate harmless colonization from pathogenic invasion, particularly when dealing with organisms of unknown virulence potential.

Epidemiological Patterns and Clinical Significance in Immunocompromised Patients

Colonization Dynamics and Infection Risk

Immunocompromised patients demonstrate distinct patterns of microbial colonization that significantly influence their infection risk. The gastrointestinal tract serves as a primary reservoir for MDR organisms, with microbiota imbalances caused by antibiotic therapy facilitating intestinal overpopulation with pathogenic species and increasing bacterial translocation potential [39]. Electronic health record analyses of neurological ICU patients reveal that colonization with specific pathogens like Pseudomonas aeruginosa shows significant association with subsequent pneumonia and sepsis development [81].

Table 1: Prevalence of Multidrug-Resistant Bacterial Colonization and Infection in High-Risk Populations

Patient Population	Primary Colonization Sites	Common MDR Pathogens	Colonization Prevalence	Infection Incidence
ICU Patients [39]	Gastrointestinal tract, respiratory system	CRE, ESBL-producing Enterobacterales, MRSA, VRE	50-80% (varies by institution)	15-40% among colonized patients
HIV-Positive Patients [39]	Gastrointestinal tract	ESBL-producing Enterobacterales, MRSA	30-60%	10-25% among colonized patients
Cancer Patients [39]	Gastrointestinal tract, bloodstream	VRE, CRE, MRSA	40-70%	20-45% among colonized patients
Neurological ICU Patients [81]	Respiratory tract, wounds	MDR P. aeruginosa, Acinetobacter baumannii	60-85%	50-60% develop pneumonia

Impact of Novel Bacterial Taxa

Advanced identification techniques have revealed that conventional diagnostic methods frequently miss novel bacterial species. The Novel Organism Verification and Analysis (NOVA) study identified 35 bacterial strains representing potentially novel species, with Corynebacterium species and Schaalia species being predominant [27]. Notably, 27 of these 35 strains were isolated from deep tissue specimens or blood cultures, and 7 were clinically relevant, demonstrating that novel taxa can function as true pathogens rather than mere contaminants [27].

Table 2: Novel Bacterial Species Isolated from Clinical Specimens (NOVA Study) [27]

Genus	Number of Novel Strains	Specimen Sources	Clinical Relevance
Corynebacterium	6	Blood, urine, swabs	Mixed (2/6 clinically relevant)
Schaalia	5	Deep tissue, abscesses	High (3/5 clinically relevant)
Anaerococcus	2	Wounds, deep tissue	Moderate (1/2 clinically relevant)
Clostridium	2	Blood, deep tissue	Low (0/2 clinically relevant)
Other Genera	20	Various sterile sites	Low (1/20 clinically relevant)

Methodological Framework for Differentiation

Diagnostic Algorithm for Novel Pathogen Identification

The NOVA study established a systematic algorithm for identifying novel bacterial organisms that cannot be characterized by conventional methods [27]. This approach is particularly valuable for distinguishing contamination from true infection when dealing with unfamiliar microbial species.

Rapid Pathogen Isolation Protocol

For bloodstream infections, a rapid, low-cost protocol has been developed that significantly reduces diagnostic delays. This method achieves over 70% bacterial isolation efficiency within 30 minutes, remains effective at low bacterial concentrations (1-10 bacteria/0.3 mL blood), and preserves bacterial viability with no notable change in growth lag times [82].

Table 3: Research Reagent Solutions for Bacterial Isolation and Identification

Reagent/Equipment	Application	Function	Protocol Specifications
EZ1 DNA Tissue Kit (Qiagen)	Nucleic acid extraction	DNA purification for WGS	Automated extraction on EZ1 Advanced Instrument [27]
Thioglycolate Medium	Enrichment culture	Supports growth of fastidious and anaerobic organisms	Standard microbiological procedures [27]
CHCA Matrix Solution	MALDI-TOF MS	Enables laser desorption/ionization	Smear technique with 1-µl formic acid overlay [27]
Illumina Sequencing	Whole genome sequencing	High-resolution genomic characterization	MiSeq or NextSeq500 platforms [27]
Blood Lysis Buffer	Rapid pathogen isolation	Selective removal of blood cells	30-minute processing time [82]

Data-Driven Prediction of Colonization Outcomes

Machine learning approaches show promise for predicting colonization outcomes in complex microbial communities. Using baseline microbial community compositions as input, models including Random Forest and Neural Ordinary Differential Equations can predict both binary colonization outcomes (AUROC > 0.8) and steady-state abundance of invading species [83].

Diagnostic Criteria and Interpretation Frameworks

Clinical and Laboratory Differentiation

Accurate distinction between contamination, colonization, and infection requires integration of multiple clinical and microbiological parameters. The following criteria provide a framework for interpretation:

• Clinical Signs of Infection: Presence of systemic inflammatory response syndrome (SIRS) criteria, organ dysfunction, or localized signs of inflammation [81]
• Microbiologic Evidence: Quantitative cultures demonstrating significant microbial loads from sterile sites; repeated isolation of the same organism [81]
• Host Response Markers: Elevated procalcitonin, C-reactive protein, or other inflammation biomarkers [81]
• Radiologic Corroboration: Imaging findings consistent with infection at the site of culture collection [81]

In neurocritical care populations, electronic health record analyses demonstrate that patients with monomicrobial culture are more likely to develop pneumonia than those with polymicrobial culture, despite lower pathogen titers in monoculture, suggesting complex ecological interactions influence infection development [81].

Antimicrobial Resistance Considerations

Multidrug-resistant organisms present particular challenges in immunocompromised patients. Bacterial isolates from neurological ICU patients show high levels of multidrug resistance (Gram-negative bacteria: 88-100%; Gram-positive bacteria: 48-97%), with no significant differences in MDR colonization and infection rates [81]. This high prevalence of resistance necessitates careful antibiotic stewardship guided by accurate differentiation between colonization and infection.

Current ESCMID-EUCIC clinical guidelines do not recommend routine decolonization for MDR bacteria in the intestinal tract, as studies using non-absorbable antibiotics, probiotics, or fecal microbiota transplantation have shown only mild suppression of carriage with rapid reappearance after treatment cessation [39]. However, temporary colonization suppression may be beneficial during periods of maximum vulnerability in immunocompromised patients [39].

The accurate discrimination between contamination, colonization, and true infection represents a cornerstone of effective management in immunocompromised patients, particularly as novel bacterial taxa continue to be identified in clinical settings. Advanced molecular diagnostics, systematic algorithmic approaches, and data-driven predictive models provide powerful tools for addressing this challenge. Integration of these methodologies with conventional clinical assessment enables appropriate therapeutic interventions, reduces unnecessary antibiotic exposure, and ultimately improves outcomes in this vulnerable patient population. Future research should focus on expanding reference databases for novel pathogens, validating machine learning approaches in clinical settings, and developing targeted strategies for modulating the microbiome to prevent transition from colonization to invasion.

Evaluating Novel Therapeutic Avenues and Their Clinical Potential

The escalating global burden of antimicrobial resistance (AMR) presents a formidable challenge to modern medicine, with immunocompromised patients representing a particularly vulnerable population. According to the 2021 Global Burden of Disease study, AMR is directly responsible for an estimated 1.27 million deaths worldwide annually, surpassing deaths from malaria and HIV/AIDS [84]. Immunocompromised individuals—including people living with HIV/AIDS (PLWH), patients with malignancies, transplant recipients, and those with diabetes—face disproportionately high risks of infections from multidrug-resistant (MDR) pathogens due to weakened immune systems and frequent exposure to healthcare settings [40]. The microbiota imbalance caused by antibiotic therapy and decreased host immunity in these patients favors intestinal overpopulation with pathogenic species, leading to increased bacterial translocation and susceptibility to systemic infections [39].

The World Health Organization has classified various MDR bacteria into priority groups based on their threat level, with carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa ranking as critical-priority pathogens [39]. These pathogens frequently colonize immunocompromised patients, often preceding invasive infections that are increasingly difficult to treat with conventional antibiotics [39]. This clinical crisis has catalyzed renewed interest in bacteriophage (phage) therapy as a promising alternative therapeutic approach, evidenced by a fivefold increase in PubMed-indexed clinical case reports over the past decade [85]. Phage therapy offers distinct advantages as a precision antimicrobial, with reported efficacy rates of 50%-70% and an excellent safety profile, positioning it as a transformative approach for combating antimicrobial resistance in this vulnerable population [85].

Bacteriophage Biology and Therapeutic Mechanisms

Fundamental Characteristics of Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect and replicate within bacterial hosts, ultimately causing host cell lysis. First identified by Frederick Twort in 1915 and independently discovered by Félix D'Herelle in 1917, phages typically range from 40-200 nm in size, with filamentous variants extending up to several micrometers [85]. Their host range may be narrow or broad; for instance, phage JHP can infect multiple species (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli), whereas M13 demonstrates high specificity to E. coli [85].

Phages sustain two primary lifestyles, determined by their genetics and interactions with bacterial hosts:

• Lytic (virulent) phages follow the lytic cycle, replicating inside the host, assembling progeny virions, and lysing the cell to release new particles. These are preferred for therapy due to their direct bactericidal activity.
• Temperate phages undergo the lysogenic cycle, integrating their DNA into the host genome as prophages and replicating passively during host cell division. These are generally avoided in therapy due to their potential to transfer antibiotic resistance or virulence genes [86].

Phage infection initiates upon binding to bacterial receptors located on cell walls, capsular polysaccharides, or flagella. The adsorption rate depends on host cell physiology, the phage's mode of action, and local physicochemical variations in the surrounding medium [85].

Antimicrobial Mechanisms of Phage Therapy

Phages mediate antimicrobial activity through three principal mechanisms [85]:

• Direct bacterial lysis: Lytic phages directly infect and lyse pathogenic bacteria via host-specific recognition and replicative cycles, providing precise targeting of MDR pathogens while preserving commensal microbiota.

• Resensitization to antibiotics: Phage-mediated strategies can resensitize antibiotic-resistant bacteria to conventional antibiotics. For example, MDR efflux pumps, which confer resistance through active drug extrusion, are evolutionarily co-opted by phages as entry receptors. This molecular exploitation enables phages to selectively target resistant populations, thereby enriching antibiotic-sensitive subpopulations and restoring therapeutic efficacy when combined with antibiotics.

• Biofilm disruption: Phages disrupt bacterial biofilms by penetrating extracellular matrices and binding selectively to bacterial receptors, thereby mitigating the ~1,000-fold increase in antimicrobial resistance associated with biofilms. Some phages also encode natural depolymerases that degrade bacterial surface polysaccharides, facilitating phage diffusion and subsequent bacterial lysis.

Table 1: Bacteriophage-Derived Enzymes with Therapeutic Potential

Enzyme Type	Mechanism of Action	Target Pathogens	Clinical Advantages
Endolysins	Hydrolyzes peptidoglycan bonds in bacterial cell wall, causing osmotic rupture	Particularly effective against Gram-positive pathogens	Rapid lytic activity; rarely induces bacterial resistance
Depolymerases	Enzymatically hydrolyzes surface polysaccharides and biofilm matrices	Gram-negative and Gram-positive biofilm-forming species	Exposes pathogens to host immunity; disrupts biofilm protection
Exolysins	Degrades extracellular polymeric substances	Pseudomonas aeruginosa and other biofilm-formers	Enhances antibiotic penetration; reduces virulence

Beyond whole-phage therapy, bacteriophage-derived enzymes have emerged as promising alternatives with distinct clinical advantages. Unlike intact phages, these enzymes rarely induce bacterial resistance and demonstrate a narrow activity spectrum, enabling precise targeting of antibiotic-resistant pathogens while preserving commensal microbiota [85].

Phage Therapy Implementation Strategies

Treatment Modalities and Formulation

Phage therapy can be tailored to infection characteristics using different treatment modalities [85]:

• Monophage therapy: For targeted infections involving well-defined pathogens (e.g., carbapenem-resistant A. baumannii [CRAB] pneumonia), monophage therapy enables precise eradication while conserving commensal microbiota. However, monotherapy often rapidly selects for resistant variants, limiting its clinical utility.

• Phage cocktails: Rationally formulated phage cocktails that concurrently target diverse bacterial receptors or species broaden therapeutic coverage while mitigating the likelihood of resistance. Optimal phage cocktail formulation necessitates rigorous assessment of host range breadth, lytic kinetics, formulation stability under physiological conditions, and clinical safety profiles.

• Phage-antibiotic synergy (PAS): PAS arises not only from phage-mediated restoration of antibiotic sensitivity but also from enhanced phage replication in the presence of subinhibitory antibiotic concentrations. A multicenter cohort study of 100 patients with diverse infections demonstrated 70% superior eradication rates with combination therapy compared to phage monotherapy [85].

Genetic Engineering of Therapeutic Phages

Genetic engineering has significantly expanded the therapeutic potential of bacteriophages, enabling the development of customized phage libraries with enhanced capabilities. Targeted modifications include [85]:

• Tail fiber mutations for host range expansion
• Conversion of lysogenic phages into strictly lytic variants
• Deletion of toxin genes for enhanced safety
• Incorporation of reporter genes for diagnostic applications

A representative case demonstrating the successful application of engineered phages involved a 15-year-old cystic fibrosis patient with extensively drug-resistant Mycobacterium abscessus infection. The patient achieved significant clinical improvement following treatment with a phage cocktail comprising both wild-type (Muddy) and engineered variants (ZoeJΔ45, BPsΔ33HTH-HRM10) [85].

Research Methodologies and Experimental Protocols

Phage Isolation and Characterization Workflow

The standard methodology for isolating and characterizing therapeutic phages involves a multi-stage process:

Stage 1: Sample Collection and Enrichment

• Collect environmental samples from phage-rich sources (sewage, soil, water)
• Enrich phages by co-culturing with bacterial host strains
• Filter through 0.22μm membranes to remove bacteria and debris [86]

Stage 2: Plaque Assay and Purification

• Use double overlay method to visualize, isolate, and purify phages by plaque formation
• Pick single plaques and culture them to separate distinct phage species
• Conduct successive rounds of purification (typically 3-5 cycles) to ensure clonal purity
• Enumeration via serial dilution and titration [86]

Stage 3: Morphological and Genomic Characterization

• Visualize phage morphology by transmission electron microscopy
• Extract DNA for whole-genome sequencing (aim for 25× to 100× coverage)
• Assemble genomes using tools like MetaViralSPAdes or ViralFlye
• Assess genome quality and completeness with CheckV [86]

Stage 4: Functional Annotation

• Identify protein-coding sequences with PHANOTATE or Prodigal
• Annotate functions using phage-specific databases (PHROGs, pVOGs)
• Screen for antimicrobial resistance genes and virulence factors using AMRFinderPlus and VFDB
• Predict lifestyle (lytic vs. temperate) with BACPHLIP or PHACTS [86]

Diagram 1: Phage Isolation and Characterization

Research Reagent Solutions for Phage Research

Table 2: Essential Research Reagents for Phage Therapy Development

Reagent/Resource	Primary Function	Application Notes
Double Agar Overlay	Plaque formation and isolation	Standard method for phage quantification and purification
PHANOTATE	Gene prediction in phage genomes	More accurate for phage genomes than Prodigal
PHROGs Database	Functional annotation of phage proteins	Categorizes proteins into functional groups
CheckV	Phage genome quality assessment	Evaluates completeness and identifies contaminants
BACPHLIP	Phage lifestyle prediction	Determines lytic vs. temperate propensity
AMRFinderPlus	Antimicrobial resistance gene detection	Critical for safety screening
VFDB	Virulence factor identification	Ensures therapeutic candidates lack toxin genes

Clinical Applications and Evidence Base

Phage Therapy in Immunocompromised Hosts

Immunocompromised patients represent a population with particularly compelling indications for phage therapy due to their heightened susceptibility to MDR infections and limited antibiotic options. Specific clinical considerations in this population include:

• Altered immune function: Impairments in both innate and adaptive immunity significantly increase vulnerability to bacterial, viral, fungal, and intracellular bacterial pathogens [40].
• Frequent healthcare exposure: Regular contact with healthcare facilities increases colonization pressure with MDR pathogens [39].
• Prolonged antibiotic exposure: Extensive antibiotic use promotes resistance and disrupts protective microbiota [39].

The relationship between colonization and infection is particularly critical in immunocompromised patients. Asymptomatic colonization with MDR bacteria usually precedes infection and tends to persist for long periods. In this vulnerable population, colonization with MDR bacteria is a significant risk factor for subsequent systemic infections [39].

Clinical Evidence and Case Studies

Between 2020 and 2024, 32 phage therapy clinical trials were registered worldwide on ClinicalTrials.gov, reflecting growing research interest [85]. Current clinical applications primarily target MDR infections across multiple systems:

• Respiratory infections: Particularly in cystic fibrosis patients with MDR Pseudomonas aeruginosa and Mycobacterium abscessus
• Wound and burn infections: Including complex soft tissue infections with biofilm formation
• Bloodstream infections: Bacteremia with carbapenem-resistant Enterobacterales
• Urinary tract infections: Especially in transplant and immunocompromised patients [85]

Notable clinical successes include the case of a 15-year-old cystic fibrosis patient with extensively drug-resistant Mycobacterium abscessus infection who achieved significant clinical improvement following treatment with a phage cocktail comprising both wild-type and engineered variants [85]. Additionally, a multicenter cohort study of 100 patients with diverse infections demonstrated 70% superior eradication rates with combination therapy compared to phage monotherapy [85].

Table 3: Clinical Efficacy of Phage Therapy Against ESKAPE Pathogens

Pathogen	Infection Type	Therapeutic Approach	Reported Outcomes
Pseudomonas aeruginosa	Respiratory, wound, UTI	Phage cocktail + antibiotics	50-70% efficacy rates; improved biofilm penetration
Acinetobacter baumannii	CRAB pneumonia, bacteremia	Monophage therapy	Targeted eradication with commensal microbiota preservation
Mycobacterium abscessus	Cystic fibrosis lung infection	Engineered phage cocktail	Significant clinical improvement in drug-resistant case
Klebsiella pneumoniae	UTI, bloodstream infection	Phage-antibiotic synergy	Superior eradication vs. monotherapy
Staphylococcus aureus	MRSA wound infections	Endolysin-antibiotic combinations	Reduced mortality in bloodstream infections

Technical and Regulatory Considerations

Phage-Antibiotic Synergy (PAS) Mechanisms

The interplay between phages and antibiotics reveals complex, often synergistic relationships that can be leveraged for enhanced therapeutic efficacy:

Diagram 2: Phage-Antibiotic Synergy

However, these interactions exhibit significant complexity. Certain ribosome-targeting antibiotics can suppress phage replication by inhibiting virion assembly, thereby compromising therapeutic efficacy. Thus, the outcomes of phage-antibiotic combinations depend critically on treatment parameters—including dosage, frequency, timing, and administration sequence [85].

Regulatory and Manufacturing Challenges

The development of phage therapy faces several significant challenges that must be addressed for widespread clinical adoption:

• Host range limitations: The narrow specificity of many phages necessitates careful matching to bacterial targets
• Bacterial resistance: Bacteria can develop resistance to phages through receptor modification and other mechanisms
• Immunogenicity: Phages can elicit immune responses that may limit repeated administration
• Standardization challenges: Variable phage characterization and production methods complicate regulatory approval
• Regulatory uncertainties: Evolving regulatory frameworks for biologic therapies create uncertainty [85] [87]

Future optimization strategies include AI-driven phage prediction, standardized pharmacokinetic assessment, advanced genetic engineering, and interdisciplinary collaboration to accelerate clinical translation [85].

Bacteriophage therapy represents a promising alternative to conventional antibiotics for managing multidrug-resistant bacterial infections in immunocompromised patients. Its unique mechanisms of action—including direct bacterial lysis, biofilm disruption, and resensitization to antibiotics—offer advantages in addressing the growing crisis of antimicrobial resistance. The precision targeting of phages preserves commensal microbiota, which is particularly beneficial for immunocompromised patients who are vulnerable to microbiota disruption and subsequent opportunistic infections.

Future developments in phage therapy should focus on several key areas:

• Standardization of phage isolation, characterization, and production protocols
• Expansion of well-designed clinical trials to establish efficacy and safety
• Development of phage-antibiotic combination strategies
• Advancement of genetic engineering techniques to enhance therapeutic properties
• Establishment of clear regulatory pathways for phage-based therapeutics

As research continues to address current limitations—including host range constraints, potential resistance development, and manufacturing challenges—phage therapy is positioned to become an increasingly important tool in combating multidrug-resistant infections, particularly in vulnerable immunocompromised populations where conventional treatments are increasingly failing.

Antimicrobial peptides (AMPs) represent a promising frontier in the battle against multidrug-resistant bacterial pathogens, a challenge particularly acute in immunocompromised patient populations. These patients are vulnerable to infections from novel and opportunistic pathogens, complicating treatment outcomes [40]. AMPs, as naturally occurring elements of the innate immune system found across all biological domains, offer a versatile therapeutic alternative due to their broad-spectrum activity and unique mechanisms of action that pose a high barrier for resistance development [88] [89]. This technical guide examines the molecular mechanisms of AMPs, explores advanced discovery methodologies, and evaluates their clinical application, specifically framing these aspects within the research context of novel bacterial threats to immunocompromised hosts.

Mechanisms of Action and Bacterial Resistance

Primary Mechanisms of Antimicrobial Activity

AMPs employ diverse and complex mechanisms to target and eliminate bacterial pathogens. A fundamental characteristic of most AMPs is their cationic nature, which facilitates initial electrostatic interactions with the negatively charged components of bacterial membranes, such as lipopolysaccharides (LPS) in Gram-negative bacteria and teichoic acids in Gram-positive bacteria [89] [90]. This interaction is a key determinant of their selective toxicity against microbial over host cells [90].

Following membrane attachment, AMPs utilize several models to achieve membrane disruption and cell death:

• Carpet Model: Peptides cover the membrane surface in a carpet-like manner, leading to disintegration and micelle formation [91].
• Barrel-Stave Pore: Peptides insert into the membrane bilayer, forming permanent pores that cause leakage of cellular contents [91].
• Toroidal Pore: Peptides induce the lipid monolayers to bend continuously, forming a pore lined by both the peptide and the lipid head groups [89] [90].

Beyond membrane disruption, many AMPs demonstrate significant intracellular targeting capabilities. These mechanisms include:

• Inhibition of cell wall synthesis by binding to essential precursors like Lipid II [89].
• Dysregulation of cellular processes such as protein synthesis and DNA replication [89].
• Modulation of host immune responses, including induction of cytokine expression and immune cell recruitment [88] [91].

The following diagram illustrates the primary mechanisms of AMP activity and corresponding bacterial resistance strategies:

Molecular Mechanisms of Bacterial Resistance

Despite the multifaceted action of AMPs, bacteria have evolved sophisticated resistance mechanisms, a critical consideration when treating infections in immunocompromised patients where pathogen evolution can be rapid [92]. These resistance strategies include:

• Cell Envelope Modification: Bacteria can alter their surface charge through modifications to lipopolysaccharides (LPS) in Gram-negative bacteria (e.g., addition of phosphoethanolamine to lipid A) or teichoic acids in Gram-positive bacteria, reducing the initial electrostatic attraction to AMPs [92].
• Efflux Pump Systems: Specific and multifunctional efflux pumps can export AMPs from the cytoplasm or periplasmic space, effectively reducing intracellular concentrations to sublethal levels [92].
• Proteolytic Degradation: Pathogens secrete proteases and other degrading enzymes that inactivate AMPs through cleavage, a mechanism observed in both Gram-positive and Gram-negative bacteria [92].
• Extracellular Sequestration: Bacteria produce molecules such as polysaccharide capsules or released proteins that bind to and trap AMPs in the extracellular environment, preventing them from reaching their cellular targets [92].

The ongoing co-evolutionary arms race between AMPs and bacterial resistance mechanisms underscores the need for continued research, particularly in clinical settings involving immunocompromised patients where the emergence of novel resistant pathogens is a significant concern [88] [92].

Advanced Discovery and Design Methodologies

Artificial Intelligence and High-Throughput Screening

The discovery of novel AMPs has been revolutionized by computational approaches, particularly artificial intelligence. A recent groundbreaking study established a sequential pipeline using a pre-trained protein large language model (LLM), ProteoGPT, which was further refined into specialized sub-models for specific tasks [93].

The experimental workflow for this AI-driven discovery approach involves:

• Model Pre-training: ProteoGPT was pre-trained on 609,216 non-redundant canonical and isoform sequences from the UniProtKB/Swiss-Prot database to build a foundational understanding of protein sequences [93].
• Transfer Learning for Specialization:
  • AMPSorter: Fine-tuned to classify sequences as AMPs or non-AMPs, achieving an area under the curve (AUC) of 0.99 on test sets and demonstrating robust performance even on sequences with unnatural amino acids [93].
  • BioToxiPept: Fine-tuned to identify peptide cytotoxicity, crucial for selecting therapeutic candidates with favorable safety profiles [93].
  • AMPGenix: Retrained on known AMP datasets to generate novel peptide sequences with predicted antimicrobial activity [93].
• High-Throughput Screening: The pipeline enables rapid screening across hundreds of millions of peptide sequences, balancing antimicrobial potency with minimized cytotoxic risks [93].
• Experimental Validation: Candidates identified through computational methods are validated through in vitro and in vivo models, including thigh infection models in mice against critical pathogens like carbapenem-resistant Acinetobacter baumannii (CRAB) and methicillin-resistant Staphylococcus aureus (MRSA) [93].

This methodology represents a significant advancement over traditional discovery approaches, enabling more efficient exploration of the vast peptide sequence space.

Rational Design and Engineering Strategies

Beyond AI-driven discovery, researchers employ sophisticated rational design strategies to optimize AMP therapeutic potential:

• Fragment Fusion: Hybrid peptides created by combining active fragments from different parent AMPs. For example, 13DKallDab was engineered by fusing fragments from sC184b and MSI-78, demonstrating excellent broad-spectrum activity against clinically isolated multidrug-resistant bacteria with low cytotoxicity and reduced resistance tendency [94].
• Lipidation Strategies: Conjugation of fatty acid chains to enhance membrane interaction and antimicrobial activity. Studies show that double-site lipidated ultra-short AMPs can achieve lower toxicity and maintain activity compared to single-point lipidated variants, offering promising therapeutic potential against resistant pathogens like K. pneumoniae and MRSA [95].
• Amino Acid Substitution: Systematic replacement with non-natural amino acids (e.g., D-amino acids) or specific residues to enhance stability, increase amphipathicity, or reduce proteolytic degradation [88] [94].

The following table summarizes key quantitative findings from recent AMP development studies:

Table 1: Efficacy Data of Recently Developed AMPs Against Resistant Pathogens

Peptide Name	Design Strategy	Target Pathogens	MIC Range	Key Findings	Study
13DKallDab	Fragment fusion	Clinical MDR isolates	8 μg/mL	Higher plasma stability, low resistance tendency	[94]
AI-generated AMPs	LLM pipeline	CRAB, MRSA	Comparable to clinical antibiotics	Reduced resistance development in vitro	[93]
BiF2_5K7K	Synthetic, AA substitution	Gram-positive and Gram-negative	Not specified	Superior pregnancy rates in animal husbandry	[88]
Lipidated peptides	Single/double lipidation	K. pneumoniae, MRSA	Not specified	Double-site modification reduced toxicity	[95]
A-11, AP19	Synthetic AMPs	Gram-negative bacteria	Not specified	No harm to sperm motility/viability	[88]

Experimental Protocols and Methodologies

Standardized Assays for AMP Evaluation

Comprehensive evaluation of AMP efficacy and safety requires standardized experimental protocols:

• Antimicrobial Susceptibility Testing: Minimum Inhibitory Concentration (MIC) assays are performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines using broth microdilution methods against reference strains and clinically isolated multidrug-resistant pathogens [94] [95].
• Cytotoxicity Assessment:
  • Hemolysis assays using mammalian red blood cells to quantify membrane selectivity [94] [95].
  • Cell viability assays (MTT/XTT) on mammalian cell lines (e.g., HEK293, HaCaT) to determine therapeutic indices [94] [95].
• Serum Stability Studies: Peptides are incubated in human or mouse serum at 37°C, with samples taken at time intervals and analyzed by HPLC to quantify remaining intact peptide [94].
• Mechanism of Action Studies:
  • Membrane depolarization assays using fluorescent dyes (e.g., DiSC3-5) [93].
  • Cytoplasmic membrane disruption measured by SYTOX Green uptake [93] [94].
  • Electron microscopy to visualize ultrastructural damage to bacterial cells [94].

In Vivo Efficacy Models

Robust assessment of AMP therapeutic potential necessitates appropriate animal models:

• Mouse Thigh Infection Model: Mice are rendered neutropenic via cyclophosphamide administration, thighs are inoculated with bacterial suspensions (~10^6 CFU), and peptides are administered systemically. Efficacy is determined by quantifying bacterial burden in tissue homogenates after treatment [93].
• Peritonitis Models: Mice are infected intraperitoneally with lethal bacterial inocula, followed by peptide treatment. Survival rates and bacterial counts in blood and organs are primary endpoints [94].
• Wound Infection Models: Created by excision followed by bacterial inoculation. Peptides are applied topically, and wound healing progression and bacterial load are monitored [95].

These standardized protocols enable meaningful comparison across different AMP candidates and facilitate the translation of promising agents toward clinical application.

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Research Reagents for AMP Investigation

Reagent/Category	Specific Examples	Research Function	Experimental Context
Bacterial Strains	CRAB, MRSA, K. pneumoniae, P. aeruginosa ATCC strains	Efficacy screening against priority pathogens	In vitro susceptibility testing; in vivo infection models [93] [95]
Cell Lines	HEK293, HaCaT, RAW 264.7	Cytotoxicity and immunomodulation assessment	MTT/XTT assays; cytokine profiling [94]
Fluorescent Probes	DiSC3-5, SYTOX Green, NPN	Mechanism of action studies	Membrane depolarization; membrane permeability [93] [94]
Solid-Phase Synthesis	Fmoc-protected amino acids, HBTU/HOBt, Rink AM resin	Peptide synthesis and modification	Custom peptide production; structure-activity studies [94] [95]
Analytical Instruments	HPLC, MALDI-TOF MS	Purification and characterization	Peptide purity verification; mass confirmation [94] [95]
Animal Models	Mouse thigh infection, peritonitis, wound models	In vivo efficacy and toxicity evaluation	Translational therapeutic assessment [93] [94]

Clinical Translation and Applications

Approved AMPs and Clinical Trials

Several peptide-based antimicrobials have received regulatory approval, demonstrating the clinical viability of this class:

• FDA-Approved Agents: These include dalbavancin, telavancin, oritavancin, bacitracin, colistin, polymyxin B, vancomycin, and gramicidins, targeting various Gram-positive and Gram-negative infections [89].
• Recent Approvals: Rezafungin, a novel systemic antifungal from the echinocandin class (cyclic lipopeptides), was approved by the FDA in March 2023 [88].
• Clinical Trials: Numerous AMPs are currently undergoing clinical trials targeting drug-resistant pathogens, reflecting active investment in this therapeutic area [88] [89].

Applications in Immunocompromised Patient Populations

The unique vulnerability of immunocompromised patients to multidrug-resistant infections creates a particularly compelling application for AMPs [40]. This population includes people living with HIV/AIDS (PLWH), diabetes, cancer, organ transplant recipients, and those with primary immunodeficiency disorders [40]. Their susceptibility stems from:

• Weakened immune barriers and diminished immune cell function [40].
• Frequent and prolonged antibiotic exposure, selecting for resistant organisms [40].
• High rates of healthcare contact, increasing exposure to nosocomial pathogens [40].

In this context, AMPs offer several distinct advantages:

• Activity Against Novel Pathogens: The NOVA study identified 35 novel bacterial strains from clinical specimens, 7 of which were clinically relevant, highlighting the continuous emergence of new threats that may be less susceptible to conventional antibiotics [27].
• Synergistic Potential: AMPs can work synergistically with conventional antibiotics to restore efficacy against resistant strains, as demonstrated by MV6 reducing the mutant prevention concentration of netilmicin against A. baumannii [88].
• Immunomodulatory Properties: Beyond direct antimicrobial effects, AMPs can modulate host immune responses—a critical feature for patients with impaired immunity [88] [91].

The following diagram illustrates the clinical research workflow for developing AMP therapies, particularly for immunocompromised patients:

Antimicrobial peptides represent a promising therapeutic alternative in an era of escalating antimicrobial resistance, particularly for vulnerable immunocompromised patient populations facing novel and multidrug-resistant bacterial threats. Their diverse mechanisms of action, broad-spectrum activity, and lower propensity for resistance development compared to conventional antibiotics position them as valuable candidates for addressing evolving clinical challenges. Advances in artificial intelligence, rational design strategies, and high-throughput screening methodologies are accelerating the discovery and optimization of novel AMPs with enhanced efficacy and safety profiles. Continued research into their mechanisms of action, resistance development, and immunomodulatory properties will be essential for fully realizing their clinical potential and integrating them into comprehensive strategies for managing infections in the most vulnerable patient populations.

The Promise of AI in Accelerating Novel Antibiotic Discovery

Antimicrobial resistance (AMR) represents one of the most severe public health threats of the 21st century, particularly for immunocompromised patients who are disproportionately vulnerable to infections caused by multidrug-resistant (MDR) pathogens [96]. Recent studies estimate that drug-resistant bacterial infections cause nearly 5 million deaths annually worldwide, with immunocompromised individuals facing significantly higher morbidity and mortality rates due to their limited capacity to combat invasive infections [97] [98]. The discovery of novel bacterial taxa in clinical settings, especially among patient populations with suppressed immune systems, has further complicated the treatment landscape, as these organisms often exhibit intrinsic resistance profiles and evade conventional diagnostic and therapeutic approaches [99].

The traditional antibiotic discovery pipeline has stagnated significantly, with no new classes of antibiotics discovered in decades, while resistance mechanisms continue to evolve and spread at an accelerated pace [100]. This disparity is particularly problematic for immunocompromised patients, where the emergence of novel bacterial taxa and resistant strains outpaces the development of effective therapeutics. Artificial intelligence (AI) emerges as a transformative tool in this context, offering the potential to dramatically compress the timeline for antibiotic discovery from years to months while enabling the identification of compounds with novel mechanisms of action effective against emerging pathogens [96] [100].

AI Approaches in Antibiotic Discovery

Machine Learning Paradigms for Antimicrobial Discovery

Artificial intelligence, particularly machine learning (ML), has revolutionized the approach to antibiotic discovery by enabling the rapid analysis of complex biological and chemical datasets that would be intractable through manual methods. ML models can be broadly categorized into predictive and generative approaches, each with distinct applications in the drug discovery pipeline [100].

Predictive models are trained on known bioactive compounds to identify patterns correlating chemical structures with antimicrobial activity. These models can screen millions of chemical structures in silico, prioritizing candidates with a high probability of efficacy against target pathogens [100]. For instance, researchers from MIT and the Broad Institute employed predictive models to screen libraries of chemical fragments for activity against Neisseria gonorrhoeae, identifying promising starting points for further optimization [97] [98].

Generative models represent a more advanced paradigm, capable of designing entirely novel antibiotic candidates from scratch rather than merely筛选 existing compounds. These models learn the underlying rules of chemical structures and bioactivity from training data, then generate new molecular structures with predicted antimicrobial properties [100] [97]. This approach dramatically expands the explorable chemical space beyond known compound libraries, enabling the discovery of structurally unique antibiotics with novel mechanisms of action [98].

Mining Biological Data for Antimicrobial Peptides

Beyond synthetic chemical libraries, AI approaches are being deployed to mine biological data for naturally inspired antimicrobial compounds. One promising strategy involves identifying antimicrobial peptides (AMPs) from genomic and proteomic sequences of both extant and extinct organisms [100]. Researchers at the University of Pennsylvania have pioneered this approach, developing ML models that scan proteomic databases to identify peptide sequences with predicted antimicrobial properties.

This "molecular de-extinction" strategy has yielded promising results, with researchers identifying functional antimicrobial peptides from the proteomes of Neanderthals, Denisovans, and prehistoric mammals such as the woolly mammoth [100]. When synthesized in the laboratory, these peptides demonstrated efficacy against contemporary pathogens like Acinetobacter baumannii in both in vitro and in vivo models, highlighting the potential of evolutionary information in addressing modern clinical challenges [100].

Table 1: AI-Driven Antimicrobial Peptide Discovery from Biological Data

Source Organism	Pathogen Targeted	Efficacy Findings	Research Institution
Neanderthals & Denisovans	Acinetobacter baumannii	Effective in vitro and in vivo models	University of Pennsylvania
Woolly mammoth, giant sloth, ancient sea cow	Multiple bacterial pathogens	As effective as polymyxin B in mouse infection models	University of Pennsylvania
Human gut microbiome	ESKAPE pathogens	83.8% hit rate for synthesized peptides showing antimicrobial activity	Chinese Academy of Sciences

Generative AI for De Novo Molecular Design

Generative AI represents the cutting edge of AI-driven antibiotic discovery, enabling the creation of completely novel compounds not found in nature or existing chemical libraries. Researchers from MIT, the Whitehead Institute, and the Broad Institute have demonstrated the power of this approach by designing compounds effective against drug-resistant Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus (MRSA) [97] [98].

Their methodology employed two complementary generative algorithms: Chemically Reasonable Mutations (CReM), which generates new molecules by adding, replacing, or deleting atoms and chemical groups from a starting structure; and Fragment-Based Variational Autoencoder (F-VAE), which builds complete molecules from chemical fragments based on patterns learned from large molecular databases [97] [98]. This combined approach generated over 36 million candidate compounds, which were computationally screened for antibacterial activity, synthetic feasibility, and low cytotoxicity.

The top candidates identified through this process—NG1 for N. gonorrhoeae and DN1 for MRSA—demonstrated efficacy in mouse infection models and appeared to work through novel mechanisms of action, primarily involving disruption of bacterial membrane integrity [97] [98]. This represents a significant advancement, as compounds with new mechanisms are crucial for overcoming existing resistance pathways.

Table 2: AI-Designed Antibacterial Compounds with Demonstrated In Vivo Efficacy

Compound	Target Pathogen	Mechanism of Action	Efficacy in Model Systems	Structural Features
NG1	Drug-resistant Neisseria gonorrhoeae	Binds LptA protein, disrupting outer membrane synthesis	Effective in mouse model of gonorrhea infection	Structurally distinct from existing antibiotics
DN1	Methicillin-resistant Staphylococcus aureus (MRSA)	Disrupts bacterial cell membrane	Cleared MRSA skin infection in mouse model	Novel chemical scaffold
Halicin	Broad-spectrum activity	Disrupts electrochemical gradient across cell membrane	Effective in multiple infection models	Originally developed for diabetes

Experimental Protocols and Methodologies

Workflow for Generative AI Antibiotic Discovery

The following diagram illustrates the comprehensive workflow for generative AI-driven antibiotic discovery, integrating both fragment-based and unconstrained design approaches:

Detailed Experimental Methodology

Compound Screening and Validation Protocols

In Vitro Susceptibility Testing: Researchers determined minimum inhibitory concentrations (MICs) using standardized broth microdilution methods according to Clinical and Laboratory Standards Institute (CLSI) guidelines [100] [101]. For AI-designed compounds, testing included reference strains and clinically isolated MDR pathogens, particularly focusing on ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) [101]. Assays were performed in triplicate with appropriate quality control strains to ensure reproducibility.

Cytotoxicity Assessment: Candidate compounds were evaluated for cytotoxicity against human cell lines (typically HEK-293 and HepG2) using MTT or similar viability assays [97]. Compounds showing selective toxicity against bacterial over mammalian cells (therapeutic index >10) were prioritized for further development. Standardization of assay conditions (pH, temperature, media) across experiments was critical for generating comparable data for AI training [100].

Mechanism of Action Studies: For promising candidates, researchers employed multiple approaches to elucidate mechanisms of action, including:

• Bacterial membrane disruption assays using fluorescent dyes that detect membrane depolarization or permeability [97] [98]
• Protein binding studies through cellular thermal shift assays (CETSA) and surface plasmon resonance (SPR) to identify cellular targets [97]
• Transcriptomic analysis via RNA sequencing to examine bacterial response to compound treatment [99]
• Morphological assessment using transmission electron microscopy to visualize ultrastructural changes [98]

In Vivo Efficacy Models

Mouse Infection Models: Promising compounds advanced to in vivo testing using established infection models [97] [98]. For MRSA-targeting compounds like DN1, a skin infection model was employed where mice were shaved, skin was abrasioned, and bacteria were applied topically [98]. Treatment was administered via topical application or systemic delivery, and bacterial load reduction was quantified through tissue homogenization and plating.

For systemic infections, a neutropenic thigh infection model was commonly used, particularly for immunocompromised host simulations [100]. Mice were rendered neutropenic via cyclophosphamide administration, followed by intramuscular injection of the test pathogen. Compound efficacy was determined by comparing bacterial counts in treated versus untreated animals after 24 hours of therapy.

Research Reagent Solutions for AI-Driven Antibiotic Discovery

Table 3: Essential Research Reagents and Resources for AI-Driven Antibiotic Discovery

Reagent/Resource	Function in Research	Application Example
REAL Space Library (Enamine)	Provides synthetically accessible chemical fragments for AI training and validation	Used as starting point for fragment-based generative AI design [97] [98]
ChEMBL Database	Curated bioactive molecules with drug-like properties for model training	Source of >1 million molecules for training F-VAE algorithm [98]
CReM Algorithm	Generates chemically reasonable molecular mutations for exploration of chemical space	Created structural variations of promising fragments [97] [98]
Fragment-Based VAE	Builds complete molecules from chemical fragments based on learned patterns	Generated novel antibiotic candidates from fragment F1 [98]
Specialized Chemical Synthesis Services	Produces AI-designed compounds for experimental validation	Synthesized NG1 and DN1 compounds for biological testing [97]

Addressing the Challenges of Resistance in Immunocompromised Hosts

AI Strategies for Overcoming Gram-Negative Resistance

Gram-negative pathogens pose particular challenges for antibiotic development due to their impermeable outer membrane and efficient efflux systems [102] [103]. These challenges are especially relevant for immunocompromised patients, who are frequently infected with hospital-acquired Gram-negative organisms like Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa [96] [102].

AI approaches are being specifically directed to address these barriers. The Fleming Initiative-GSK collaboration is employing AI to understand the chemical properties that allow compounds to penetrate and accumulate within Gram-negative bacteria [102] [103]. Their approach involves generating novel datasets on diverse molecules' ability to penetrate bacterial membranes, then training AI models to identify the structural features correlated with effective intracellular accumulation [102].

This strategy aims to overcome the long-standing challenge of Gram-negative resistance by explicitly designing compounds that can bypass the bacterial defense systems, rather than relying on serendipitous discovery [102]. The resulting models and data will be made publicly available to accelerate broader antibiotic development efforts [102].

Explainable AI for Mechanism of Action Prediction

A significant limitation of early AI models in drug discovery was their "black box" nature, which provided limited insight into the rationale behind compound selection [104]. This is particularly problematic for antibiotic development, where understanding the mechanism of action is crucial for predicting resistance potential and clinical utility.

Recent advances in explainable AI approaches are addressing this limitation. The InterPred platform demonstrates how interpretable machine learning can not only predict bioactivity but also identify chemical moieties responsible for antimicrobial activity and propose likely mechanisms of action [104]. By analyzing thousands of molecules against bacterial and fungal pathogens, this approach can prioritize compounds with novel mechanisms, reducing the risk of cross-resistance with existing antibiotics [104].

For immunocompromised patients, where empirical broad-spectrum coverage is often initiated before pathogen identification, antibiotics with predictable and novel mechanisms are particularly valuable, as they are less likely to encounter pre-existing resistance [99].

Implementation Challenges and Future Directions

Data Quality and Standardization

The performance of AI models in antibiotic discovery is heavily dependent on the quality, quantity, and relevance of training data [100]. Current limitations include heterogeneous data sources, inconsistent assay methodologies, and limited data on novel bacterial taxa relevant to immunocompromised hosts. Addressing these challenges requires concerted efforts in data standardization and curation [100].

Researchers at the University of Pennsylvania have emphasized the importance of rigorous data curation for AI model training, spending years assembling standardized datasets with consistent experimental conditions (temperature, pH, media) to ensure comparability across results [100]. Such standardized datasets are essential for developing robust models that can generalize to novel clinical isolates.

Integration with Clinical Practice

Beyond compound discovery, AI has potential applications throughout the antibiotic development pipeline and clinical practice. Predictive models could optimize clinical trial design, identify patient populations most likely to benefit from novel agents, and even guide personalized antibiotic selection based on pathogen characteristics [100] [102].

For immunocompromised patients, AI-driven diagnostic approaches could enable rapid identification of novel bacterial taxa and their resistance profiles, guiding targeted therapy selection before conventional culture results are available [99]. The integration of AI across the continuum from discovery to clinical application represents the most promising path forward for addressing the AMR crisis in vulnerable populations.

Artificial intelligence is fundamentally transforming the landscape of antibiotic discovery, offering powerful new tools to address the escalating crisis of antimicrobial resistance. For immunocompromised patients, who bear a disproportionate burden of MDR infections, AI-driven approaches promise more rapid identification of effective therapeutics against both established and emerging pathogens. While significant challenges remain in data standardization, model interpretability, and clinical implementation, the integration of AI across the drug development pipeline represents our most promising strategy for replenishing the antibiotic arsenal and protecting vulnerable patients in the post-antibiotic era.

The escalating crisis of antimicrobial resistance (AMR) poses a critical threat to global health, with projections indicating 10 million annual deaths by 2050 without innovative interventions [105] [106]. Traditional antibiotic development faces significant challenges including lengthy timelines (10-15 years), high costs, and substantial failure rates [106]. Within this landscape, drug repurposing has emerged as a promising strategy to identify new antibacterial applications for existing non-antibiotic drugs with established safety profiles [105] [107]. This approach offers faster, more cost-effective therapeutic development by bypassing early-stage clinical trials and leveraging existing pharmacological and toxicological data [106].

The challenge of novel bacterial pathogens further compounds the AMR threat. Recent studies identifying 35 clinical isolates representing potentially novel bacterial taxa highlight the continuous emergence of previously uncharacterized pathogens, seven of which demonstrated clinical relevance [10]. This expanding spectrum of bacterial pathogens necessitates flexible therapeutic strategies like drug repurposing that can address both known resistant organisms and emerging novel taxa, particularly in immunocompromised patient populations where unconventional pathogens more frequently cause disease.

Mechanisms of Antibacterial Action

Non-antibiotic drugs exert antibacterial effects through diverse mechanisms distinct from traditional antibiotics, offering potential advantages in circumventing existing resistance pathways.

Efflux Pump Inhibition

Bacterial efflux pumps actively export antibiotics from cells, significantly contributing to multidrug resistance. Several drug classes demonstrate efflux pump inhibition:

• Phenothiazine Antipsychotics: Thioridazine and chlorpromazine inhibit efflux in Mycobacterium tuberculosis and Staphylococcus aureus, reversing resistance to isoniazid, rifampicin, and norfloxacin [106].
• Selective Serotonin Reuptake Inhibitors (SSRIs): Sertraline, fluoxetine, and paroxetine enhance antibiotic susceptibility through efflux inhibition, with sertraline showing synergy with fluconazole against Candida albicans (FIC indices <0.5) [106].
• Calcium Channel Blockers: Verapamil demonstrates potent efflux pump inhibition against M. tuberculosis, reducing bedaquiline MIC from 0.5 µM to 0.025 µM (20-fold reduction) with FIC indices as low as 0.06 [106].

Membrane Disruption

Certain non-antibiotic drugs compromise bacterial membrane integrity through:

• Structural Interference: Interaction with membrane phospholipids and proteins
• Permeability Alteration: Increased membrane permeability leading to leakage of cellular contents
• Potential Disruption: Proton motive force dissipation

Biofilm Inhibition and Quorum Sensing Interference

Biofilm formation significantly enhances bacterial resistance to antibiotics. Several repurposed drugs disrupt:

• Matrix Formation: Inhibition of extracellular polymeric substance production
• Adherence: Reduction of surface attachment capabilities
• Cell-Cell Communication: Interference with quorum sensing signaling systems

Table 1: Quantitative Evidence for Efflux Pump Inhibition by Non-Antibiotic Drugs

Drug Class	Specific Drug	Antibiotic Enhanced	MIC Reduction	FIC Index	Bacterial Species
Phenothiazine Antipsychotics	Thioridazine	Ethambutol	8 µg/mL to 2 µg/mL	Not specified	Mycobacterium avium
Phenothiazine Antipsychotics	Chlorpromazine	Norfloxacin	4 µg/mL to 1 µg/mL	Not specified	Staphylococcus aureus RN4220
SSRIs	Sertraline	Fluconazole	MIC90: 3 µM	<0.5	Candida albicans
Calcium Channel Blockers	Verapamil	Bedaquiline	0.5 µM to 0.025 µM	0.06	M. tuberculosis H37Rv

Research Methodologies and Experimental Protocols

Novel Bacterial Taxon Identification Pipeline

The NOVA (Novel Organism Verification and Analysis) algorithm provides a systematic approach for identifying novel bacterial species from clinical isolates [10]:

Detailed Protocol:

• Initial Culture: Process clinical specimens using standard microbiological procedures including aerobic, anaerobic, and thioglycolate enrichment cultures [10]
• MALDI-TOF MS Screening: Perform species identification using MALDI-TOF MS (Bruker Daltonics). Isolates with scores <2.0 proceed to molecular analysis [10]
• 16S rRNA Gene Sequencing: Amplify and sequence approximately 800 bp of the 16S rRNA gene. Compare to NCBI database using BLAST. Isolates with ≤99.0% nucleotide identity (≥7 mismatches) proceed to WGS [10]
• Whole Genome Sequencing: Extract DNA using EZ1 DNA Tissue Kit (Qiagen). Prepare libraries (NexteraXT/Illumina DNA prep). Sequence on Illumina platforms (MiSeq/NextSeq500). Assemble genomes using Unicycler v0.3.0b [10]
• Genomic Analysis: Annotate using Prokka v1.13. Perform rMLST analysis. Use TYGS with 70% dDDH cutoff for species demarcation. Calculate ANI values using OrthoANIu [10]

Synergy Testing Methods

Checkerboard Assay Protocol:

• Preparation: Prepare serial dilutions of both antibiotic and non-antibiotic drug in broth medium
• Combination: Dispense combinations in 96-well plates with varying concentrations of each compound
• Inoculation: Add standardized bacterial suspension (~5×10^5 CFU/mL)
• Incubation: Incubate at appropriate conditions (typically 35°C for 18-24 hours)
• Analysis: Determine MIC for each combination. Calculate Fractional Inhibitory Concentration (FIC) index:
  • FIC index = (MIC antibiotic in combination/MIC antibiotic alone) + (MIC non-antibiotic in combination/MIC non-antibiotic alone)
  • Synergy defined as FIC index ≤0.5 [106]

Time-Kill Assay Protocol:

• Preparation: Prepare tubes containing antibiotic, non-antibiotic drug, combination, and growth control
• Inoculation: Add standardized bacterial suspension (~10^6 CFU/mL)
• Sampling: Remove aliquots at 0, 4, 8, and 24 hours
• Enumeration: Perform serial dilution and plating for viable counts
• Analysis: Synergy defined as ≥2-log10 decrease in CFU/mL with combination compared to most active single agent [106]

Table 2: Key Research Reagent Solutions for Drug Repurposing Studies

Resource Category	Specific Resource	Function/Application	Key Features
Bioinformatics Tools	rMLST	Ribosomal multilocus sequence typing for bacterial classification	53 genes for precise species identification [10]
	TYGS (Type Strain Genome Server)	Digital DNA-DNA hybridization for species demarcation	70% dDDH cutoff for novel species identification [10]
	OrthoANIu	Average Nucleotide Identity calculation	Alternative to DDH with 95-96% species cutoff [10]
Knowledge Bases	OREGANO Knowledge Graph	Computational drug repurposing using link prediction	Integrates natural compounds; machine learning-ready [108]
	Broad Institute Repurposing Hub	Connectivity mapping for drug mechanisms	Transcriptional response data across cell lines [109]
	DrugBank	Drug-target interaction data	Comprehensive drug and target information [110]
Experimental Databases	DrugComb	Drug combination sensitivity screening	466K drug combinations across 2204 cancer cell lines [110]
	LPSN (List of Prokaryotic Names)	Validated bacterial nomenclature	Authoritative source for taxonomic standing [10]

Table 3: Clinically Relevant Novel Bacterial Taxa and Therapeutic Challenges

Novel Taxon	Source	Clinical Relevance	Therapeutic Considerations
Corynebacterium sp. nov. (6 strains)	Various clinical specimens	Established in selected cases	Corynebacterium species often show intrinsic resistance [10]
Streptococcus toyakuensis sp. nov.	Not specified	Not established	Exhibits multi-drug resistance profile [16]
Vibrio paracholerae sp. nov.	Diarrhea and sepsis cases	Established	Co-circulated with pandemic V. cholerae for decades [16]
Schaalia sp. (5 strains)	Various clinical specimens	Not established in most cases	Previously classified as Actinomyces; antibiotic susceptibility variable [10]

Computational Approaches and Knowledge Integration

Artificial intelligence and machine learning are revolutionizing drug repurposing efforts through several approaches:

Knowledge Graph Implementation

The OREGANO knowledge graph represents a comprehensive resource specifically designed for computational drug repurposing [108]:

• Data Integration: Holistic integration of diverse data types including chemical, biological, and clinical information
• Natural Compound Emphasis: Unique focus on herbal and plant-derived compounds, reflecting that >60% of drugs (1981-2010) originated from natural products [108]
• Link Prediction: Machine learning algorithms predict novel drug-target relationships through analysis of existing network topology
• Open Accessibility: Publicly available graph structure and source code facilitate research reproducibility [108]

Multi-Database Strategy

Effective computational repurposing requires strategic database utilization:

• Chemical Databases: DrugBank, ChEMBL, PubChem providing compound structures and properties [110]
• Biomolecular Databases: KEGG, Reactome, STRING offering pathway and interaction data [110]
• Drug-Target Interaction Databases: BindingDB, DrugTargetCommons with curated target affinity data [110]
• Disease Databases: DisGeNET, OMIM containing disease-gene associations [110]

Clinical Translation and Commercialization

Advancing repurposed non-antibiotic drugs to clinical application requires addressing several key considerations:

Pharmacokinetic and Safety Evaluation

While repurposed drugs have established human safety profiles, their application as antimicrobials necessitates specific assessments:

• Tissue Penetration: Evaluation of drug concentrations at infection sites relative to determined MIC values
• Dosing Optimization: Determination of regimens achieving effective antimicrobial concentrations while maintaining safety
• Drug-Drug Interactions: Assessment of interactions with concomitant antimicrobials and patient medications
• Toxicity Re-evaluation: Identification of potential new adverse effects at doses required for antimicrobial activity

Patent and Regulatory Considerations

The unique intellectual property landscape for drug repurposing includes:

• Method-of-Use Patents: Protection of new antimicrobial applications for existing drugs
• Formulation Patents: Novel delivery systems optimizing antimicrobial efficacy
• Combination Therapy Patents: Specific drug combinations demonstrating synergy
• Regulatory Pathways: FDA approval processes leveraging existing safety data to accelerate development

Future Directions and Research Priorities

The field of non-antibiotic drug repurposing faces several critical research challenges and opportunities:

Integration with Novel Pathogen Discovery

The expanding landscape of bacterial pathogens necessitates:

• Rapid Screening Platforms: High-throughput systems evaluating repurposing candidates against novel bacterial taxa
• Mechanistic Studies: Elucidation of resistance mechanisms in emerging pathogens to identify vulnerable targets
• Predictive Modeling: Computational approaches anticipating effective repurposing strategies for newly discovered bacteria

Advanced Delivery Systems

Optimizing targeted delivery represents a promising approach to enhance efficacy and reduce toxicity:

• Nanoparticle Formulations: Targeted delivery to infection sites and bacterial cells
• Antibiotic-Drug Conjugates: Covalent linkage of non-antibiotic drugs with antibiotics for synergistic action
• Bioresponsive Systems: Release of active compounds specifically in response to bacterial environments

Resistance Mitigation Strategies

Proactive approaches to prevent resistance development include:

• Rational Combination Therapies: Systematic identification of non-antibiotic and antibiotic pairings that suppress resistance emergence
• Cycling Protocols: Treatment regimens alternating different repurposed drugs to prevent selection of resistant strains
• Evolutionary Studies: Investigation of bacterial adaptation mechanisms to non-antibiotic antimicrobials

Drug repurposing of non-antibiotic agents represents a promising strategy to address the critical challenges of antimicrobial resistance and emerging novel bacterial pathogens. The diverse mechanisms of action, including efflux pump inhibition, membrane disruption, and biofilm interference, provide opportunities to overcome conventional resistance mechanisms. Integration of computational approaches, particularly knowledge graphs and machine learning, with robust experimental methodologies like the NOVA algorithm for novel pathogen identification, creates a powerful framework for systematic repurposing efforts.

The continuing discovery of novel bacterial taxa, particularly in immunocompromised patients, underscores the importance of flexible therapeutic approaches that can rapidly address emerging pathogens. As the field advances, focus must remain on rigorous mechanistic validation, thoughtful clinical translation, and proactive resistance mitigation to fully realize the potential of non-antibiotic drugs in combating bacterial infections.

The escalating global antimicrobial resistance (AMR) crisis necessitates a critical reevaluation of our therapeutic arsenal. With projections indicating that AMR could cause 10 million deaths annually by 2050, the development of effective antibacterial therapies is more urgent than ever [111]. This challenge is particularly acute for immunocompromised patients, who are disproportionately vulnerable to infections caused by multidrug-resistant (MDR) pathogens and emerging novel bacterial taxa. The traditional antibiotic model, largely reliant on modifying existing chemical classes, is faltering; a 2025 World Health Organization (WHO) report notes a decrease in the clinical antibacterial pipeline and highlights that only 15 of 90 agents in development qualify as innovative [112]. This whitepaper provides a comparative analysis of the efficacy of novel therapeutic approaches against traditional antibiotic regimens. It synthesizes current clinical data, pharmacokinetic insights, and experimental evidence to guide researchers and drug development professionals in navigating this evolving landscape, with particular consideration for the unique vulnerabilities presented by immunocompromised hosts and the pathogens that challenge them.

The Current Landscape of Traditional Antibiotic Regimens

Efficacy and Limitations of Established Drug Classes

Traditional antibiotics, such as beta-lactams, aminoglycosides, and glycopeptides, have long been the cornerstone of anti-infective therapy. Their efficacy is primarily governed by pharmacokinetic/pharmacodynamic (PK/PD) indices, including the time that drug concentration remains above the minimum inhibitory concentration (T > MIC) for time-dependent agents like beta-lactams, and the ratio of the area under the concentration-time curve to the MIC (AUC/MIC) for concentration-dependent agents like aminoglycosides [113]. However, the utility of these established classes is being severely eroded by widespread resistance mechanisms. For instance, the efficacy of third-generation cephalosporins against Escherichia coli has been compromised, with resistance rates rising from 23.8% in 2021 to 26.7% in 2023 in some regions [114]. Similarly, resistance to macrolides in Streptococcus pneumoniae increased from 20.3% to 26.2% between 2018 and 2023 [114].

The clinical pipeline for truly novel traditional antibiotics is scarce. Since 2017, only 17 new antibacterial agents against priority bacterial pathogens have gained marketing authorization, and just two of these represent a new chemical class [112]. This lack of innovation is compounded by a dramatic exit of major pharmaceutical companies from antibiotic research and development (R&D), driven by scientific hurdles and, critically, a lack of economic sustainability given the high development costs and low returns compared to other drug classes [115] [111].

Advances in Next-Generation Traditional Agents

Despite the overall challenging landscape, some advances have been made with next-generation derivatives of traditional classes. These agents often feature enhanced PK/PD properties, such as extended half-lives and improved tissue penetration, which can potentially translate into shorter, more effective treatment regimens [113].

Table 1: Pharmacokinetic/Pharmacodynamic Properties of Novel Traditional Antibiotics

Antimicrobial Class	Example Agents	Key PK/PD Characteristics	Potential Impact on Therapy Duration
Lipoglycopeptides	Dalbavancin, Oritavancin	Long half-life (>7 days), sustained drug exposure, high tissue penetration	Enables single-dose or infrequent dosing, reducing treatment duration [113]
Novel Cephalosporins	Cefiderocol, Ceftazidime-Avibactam	Enhanced activity against MDR organisms, high tissue concentrations, stability against beta-lactamases	May allow shorter therapy for MDR infections [113]
Long-Acting Aminoglycosides	Liposomal Amikacin, Plazomicin	Improved intracellular penetration, prolonged drug release, concentration-dependent killing	Higher AUC/MIC ratios enable reduced dosing frequency [113]
Beta-Lactam/Beta-Lactamase Inhibitors	Meropenem-Vaborbactam, Imipenem-Relebactam	Broad-spectrum activity, effective against carbapenem-resistant pathogens	Potential to shorten therapy for multidrug-resistant infections [113]

Real-world evidence supports the efficacy of some newer agents. The PROSE study, a retrospective analysis of cefiderocol (a siderophore cephalosporin) in over 1,000 patients with serious Gram-negative infections, demonstrated an overall clinical cure rate of 70.1%. Notably, efficacy was significantly higher when the drug was used empirically (73.7%) compared to salvage therapy (54.3%) [116]. Furthermore, in vitro data confirm cefiderocol's activity against pathogens non-susceptible to newer beta-lactam/beta-lactamase inhibitor combinations [116]. Another significant development is the investigational oral carbapenem, tebipenem HBr. Phase 3 trial results demonstrated non-inferiority to intravenous imipenem-cilastatin for complicated urinary tract infections (cUTIs), with success rates of 58.5% versus 60.2%, respectively [116]. This highlights a trend towards developing oral formulations of powerful antibiotic classes, which could facilitate early hospital discharge and outpatient parenteral antibiotic therapy (OPAT).

Emerging Novel Non-Traditional Therapeutic Approaches

Faced with the limitations of traditional antibiotics, the field is exploring a diverse array of non-traditional therapeutic strategies. These approaches aim to circumvent existing resistance mechanisms and provide new ways to combat bacterial infections.

Key Modalities and Mechanisms of Action

• Bacteriophage Therapy: This approach utilizes viruses that specifically infect and lyse bacterial cells. Phages are highly specific, potentially targeting resistant strains without disrupting the commensal microbiome. Their ability to evolve alongside bacteria offers a dynamic countermeasure to resistance.
• Monoclonal Antibodies (mAbs): mAbs can directly neutralize bacterial toxins (e.g., Clostridioides difficile toxin B) or target specific bacterial surface antigens to enhance opsonophagocytosis by the host immune system. This modality offers high specificity and a favorable safety profile.
• Lysins: These are enzymes derived from bacteriophages that degrade the bacterial cell wall, leading to rapid osmotic lysis and bacterial death. Lysins are particularly effective against Gram-positive bacteria and are less likely to induce resistance due to their targeting of highly conserved cell wall structures.
• Microbiome Modulation: This strategy involves restoring a healthy microbiome through fecal microbiota transplantation (FMT) or the administration of defined bacterial consortia to outcompete pathogenic organisms, particularly in recurrent C. difficile infections.
• CRISPR-Cas Systems: This gene-editing technology is being harnessed to specifically target and eliminate antibiotic resistance genes from bacterial populations or to directly induce lethal DNA damage in pathogens.
• Immune Modulators: These agents enhance the host's innate immune response to infections, such as by boosting macrophage phagocytosis, and can be used as adjuvants to antibiotic therapy, especially in immunocompromised patients.

According to the WHO, the clinical pipeline now includes 40 non-traditional antibacterial agents, reflecting growing investment in these alternative modalities [112].

Comparative Efficacy of Novel Therapies

Direct, head-to-head comparisons between novel therapies and traditional antibiotics are still limited, as many non-traditional approaches are in early-stage development. However, accumulating data point to their potential utility, especially in complex scenarios.

For example, antimicrobial photodynamic therapy (aPDT) demonstrates synergistic effects with traditional antibiotics. A recent study against Klebsiella pneumoniae showed that monotherapy with either antibiotics (ciprofloxacin, gentamicin, ceftriaxone) or aPDT resulted in only moderate bacterial killing (1–2 log10 CFU reduction). In contrast, combination treatments achieved significantly enhanced bactericidal activity, with reductions of ≥3–6 log10 CFU [117]. This suggests that aPDT can potentiate the effect of existing antibiotics, potentially lowering the required doses and overcoming resistance.

The clinical relevance of novel taxa further underscores the need for advanced diagnostic and therapeutic solutions. Studies systematically applying whole-genome sequencing (WGS) have identified numerous previously undescribed bacterial species from clinical specimens, a significant proportion of which were isolated from deep tissue or blood cultures and deemed clinically relevant [10]. These novel pathogens, which may lack established susceptibility profiles, represent a domain where pathogen-agnostic or targeted non-traditional therapies could offer distinct advantages over empiric traditional antibiotics.

Direct Comparative Analysis: Efficacy, Applications, and Limitations

A critical assessment of the efficacy of novel versus traditional therapies requires examining their performance across different infection types, patient populations, and against priority pathogens.

Table 2: Comparative Analysis of Traditional vs. Novel Therapeutic Approaches

Feature	Traditional Antibiotics	Novel Non-Traditional Therapies
Mechanism of Action	Primarily target essential bacterial processes (cell wall, protein, DNA synthesis) [111].	Diverse: viral lysis (phages), enzymatic cell wall degradation (lysins), immune modulation, resistance gene targeting (CRISPR) [115].
Spectrum of Activity	Often broad-spectrum, leading to collateral damage to the microbiome.	Can be highly specific (phages, mAbs) or broad-spectrum (some lysins, immune modulators).
Resistance Potential	High; single-point mutations can confer resistance [115].	Variable; lysins target conserved structures (low), while phage resistance can develop rapidly.
Clinical Validation	Extensive historical data and established regulatory pathways.	Limited for most modalities; primarily experimental or compassionate use, though some (FMT) are standard of care for rCDI.
Suitability for Immunocompromised	Critical, but efficacy may be limited by resistance and lack of immune support.	High potential; immune-agnostic (phages, lysins) or immune-boosting (immune modulators) approaches may be advantageous.
Key Challenges	Diminishing pipeline, high development cost, low economic return, rapid resistance emergence [115] [111].	Complex manufacturing (phages, mAbs), regulatory uncertainty, high cost, and need for rapid diagnostics to guide targeted therapies.

Synergistic Combinations and Future Outlook

The future of antibacterial therapy likely lies not in a choice between traditional and novel approaches, but in their strategic combination. The synergistic effect observed between aPDT and antibiotics is a paradigm for this strategy [117]. Similarly, phage-antibiotic combinations (PACs) are being explored to restore susceptibility to traditional drugs. Another promising area is the use of antibiotic potentiators—non-antibiotic compounds that enhance the activity of existing antibiotics—which can break intrinsic resistance and resensitize bacteria to treatment [115].

For immunocompromised patients, this combinatorial approach is particularly compelling. The high prevalence of MDR infections and the potential for invasive disease by novel taxa in this population necessitates a multifaceted therapeutic strategy. Combining rapidly bactericidal traditional or novel agents (e.g., lysins) with immune modulators could help compensate for the impaired host defense, improving clinical outcomes.

Essential Experimental Models and Methodologies for Efficacy Evaluation

Robust preclinical models are essential for accurately comparing the efficacy of novel and traditional therapies and for predicting their clinical performance.

Standard Susceptibility Testing and Its Evolution

Traditional antibiotic development relies heavily on standardized susceptibility testing methods, such as broth microdilution for determining Minimum Inhibitory Concentration (MIC) and disk diffusion, as per guidelines from EUCAST and CLSI [117]. However, these methods have limitations when applied to non-traditional antimicrobials, such as natural extracts, ionic liquids, or ozonated oils. Properties like high viscosity or poor solubility can interfere with assay results, leading to an underestimation of a compound's activity. Therefore, a combined methodological approach—integrating microdilution, disk diffusion, and agar dilution—is recommended for a more accurate preclinical screening of novel substances [117].

The Scientist's Toolkit: Key Reagents for Antimicrobial Efficacy Research

Reagent/Technology	Function in Research
Broth Microdilution Plates	The standard platform for determining Minimum Inhibitory Concentration (MIC) of antimicrobial agents against bacterial pathogens [117].
MALDI-TOF MS	Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry enables rapid and reliable species identification of cultured bacterial isolates [10].
Whole Genome Sequencing (WGS)	Provides high-resolution data for identifying novel bacterial taxa, elucidating resistance mechanisms, and tracking transmission pathways [10].
Photosensitizers	Chemicals like Methylene Blue and Photodithazine used in antimicrobial photodynamic therapy (aPDT) to generate reactive oxygen species upon light activation [117].
Cell Culture Models	In vitro systems using human cell lines to model specific infections (e.g., pneumonia, UTI) and assess host-pathogen interactions and drug penetration.

Advanced Models for Immunocompromised Hosts

To effectively evaluate therapies for immunocompromised patients, researchers must employ advanced models that mimic the host environment. This includes:

• Neutropenic Mouse Models: These animals, rendered neutropenic via cyclophosphamide, are essential for testing the efficacy of antibacterial therapies in the context of a impaired innate immune system, closely mimicking the condition of chemotherapy patients.
• Humanized Mouse Models: Mice engrafted with human immune cells or tissues can provide a more physiologically relevant platform for studying human-specific pathogens and the interaction of therapies with a humanized immune milieu.
• 3D Tissue Culture and Organoids: These complex in vitro systems better replicate the structure and cellular diversity of human tissues (e.g., lung, gut) than traditional 2D cell cultures, allowing for more realistic assessment of bacterial invasion and drug penetration.

Figure 1: NOVA Pipeline for Novel Pathogen Identification. This workflow, based on the Novel Organism Verification and Analysis (NOVA) study, outlines the systematic process for identifying novel bacterial taxa from clinical samples using MALDI-TOF MS, 16S rRNA gene sequencing, and ultimately Whole Genome Sequencing (WGS) when conventional methods fail [10].

The comparative efficacy landscape of antibacterial therapies is in a state of rapid transition. Traditional antibiotic regimens, particularly those leveraging newer agents with optimized PK/PD, remain a vital and effective tool, as evidenced by the real-world success of drugs like cefiderocol [116]. However, the relentless advance of AMR and the barren antibiotic discovery pipeline underscore the inadequacy of relying solely on incremental improvements to existing classes. Novel non-traditional therapies—including phage therapy, lysins, and microbiome modulation—offer groundbreaking mechanisms of action that hold immense promise for treating infections caused by MDR pathogens and emerging novel taxa, especially in immunocompromised hosts.

The path forward is not one of replacement, but of integration. The most promising strategy for mitigating AMR and improving patient outcomes lies in personalized, combinatorial approaches. This includes using rapid diagnostics to guide targeted therapies, combining traditional antibiotics with novel potentiators or phage therapy, and employing immune modulators to support compromised hosts. Future research must focus on generating robust clinical trial data for these novel modalities, developing clear regulatory pathways for combination products, and creating sustainable economic models that incentivize innovation in the antibacterial space. For researchers and drug developers, mastering this complex, integrated arsenal is the key to winning the race against bacterial evolution.

Conclusion

The continuous emergence of novel bacterial taxa in immunocompromised patients represents a significant and evolving challenge in clinical microbiology and infectious diseases. This review underscores that advanced genomic methods are essential for the accurate identification and characterization of these pathogens, revealing a hidden diversity with direct clinical implications. The integration of novel therapeutic strategies, such as phage therapy and antimicrobial peptides, alongside AI-driven drug discovery, presents a promising frontier for addressing infections caused by multi-drug resistant, novel organisms. Future efforts must focus on enhancing global surveillance systems, standardizing diagnostic algorithms for novel organism identification, and fostering interdisciplinary collaboration to rapidly translate these innovative discoveries into clinical applications that can improve outcomes for this vulnerable patient population.

References

• 1. Challenges in the Diagnosis of Invasive Fungal Infections in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7102396/]
• 2. The Evolving Landscape of Viral Infections in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12197315/]
• 3. Editorial: Microbiome in an immunocompromised host [https://pmc.ncbi.nlm.nih.gov/articles/PMC12055538/]
• 4. Dysbiosis of a microbiota–immune metasystem in critical ... [https://www.nature.com/articles/s41591-023-02243-5]
• 5. Clinical features, pathogens, and prognosis of ... [https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1646513/full]
• 6. Performance of broad-spectrum targeted next-generation ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12139122/]
• 7. Intratumoral microbial community profiling identifies ... [https://www.nature.com/articles/s41698-025-01075-5]
• 8. Using bacteria to improve microbiota resistance to pathogens [https://www.inrae.fr/en/news/using-bacteria-improve-microbiota-resistance-pathogens]
• 9. St. Jude On Microbes: 5 Discoveries to Explore [https://www.stjude.org/research/progress/2025/st-jude-on-microbes-5-discoveries-to-explore.html]
• 10. Novel Organism Verification and Analysis (NOVA) study ... [https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-03163-7]
• 11. An update on novel taxa and revised taxonomic status of ... [https://pubmed.ncbi.nlm.nih.gov/41105204/]
• 12. HiBC: a publicly available collection of bacterial strains ... [https://www.nature.com/articles/s41467-025-59229-9]
• 13. The potential of the microbiome as a target for prevention and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12540337/]
• 14. Novel rapid method for identifying and quantifying ... [https://www.nature.com/articles/s41598-023-50864-0]
• 15. Current Applications of Absolute Bacterial Quantification in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8467167/]
• 16. Valid and accepted novel bacterial taxa derived from ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10662342/]
• 17. ESKAPE [https://en.wikipedia.org/wiki/ESKAPE]
• 18. Overview of Antimicrobial Resistant ESKAPEE Pathogens in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11510272/]
• 19. Current Antibiotic Resistance Profile of ESKAPE ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11968158/]
• 20. ESKAPE pathogens [https://www.bioversys.com/medical-needs/eskape-pathogens/]
• 21. The ESKAPE Model [https://eskape.mcmaster.ca/how-to-use/]
• 22. Identifying Reservoirs of Infection: A Conceptual and Practical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2738515/]
• 23. Taxonomic Profiling and Visualization of Metagenomic Data [https://training.galaxyproject.org/training-material/topics/microbiome/tutorials/taxonomic-profiling/tutorial.html]
• 24. A quantitative sequencing framework for absolute ... [https://www.nature.com/articles/s41467-020-16224-6]
• 25. Microbiome in an immunocompromised host- a jungle of ... [https://www.frontiersin.org/research-topics/56795/microbiome-in-an-immunocompromised-host--a-jungle-of-challenges-or-a-glacier-of-hidden-opportunities/magazine]
• 26. Benefits and Limitations of MALDI-TOF Mass Spectrometry ... [https://www.infectiologyjournal.com/articles/benefits-and-limitations-of-malditof-mass-spectrometry-for-the-identification-of-microorganisms.html]
• 27. Novel Organism Verification and Analysis (NOVA) study [https://pmc.ncbi.nlm.nih.gov/articles/PMC10768270/]
• 28. Comparison of MALDI-TOF MS, Housekeeping Gene ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4329371/]
• 29. Why Not Mold? A Meta-Narrative Review of MALDI-TOF MS [https://openworks.mdanderson.org/rmps24/11/]
• 30. Pushing the Limits of MALDI-TOF Mass Spectrometry [https://pmc.ncbi.nlm.nih.gov/articles/PMC5753130/]
• 31. 16S rRNA Next-Generation Sequencing May Not Be Useful for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10890036/]
• 32. 16S Ribosomal RNA Gene PCR and Sequencing ... [https://wwwnc.cdc.gov/eid/article/31/13/24-1101_article]
• 33. Algorithm Identifies Dozens of New Bacterial Species from ... [https://www.genengnews.com/topics/infectious-diseases/algorithm-identifies-dozens-of-new-bacterial-species-from-clinical-isolates/]
• 34. Whole-Genome Sequencing of Klebsiella ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12313781/]
• 35. comparative performance of WGS and MALDI-TOF MS in ... [https://www.frontiersin.org/journals/bacteriology/articles/10.3389/fbrio.2025.1708292/full]
• 36. Combination of Whole Genome Sequencing and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9456280/]
• 37. High-resolution genomic and molecular characterization of ... [https://www.nature.com/articles/s41598-025-23518-6]
• 38. Whole Genome Sequencing (WGS) Quality Control (QC) ... [https://www.ga4gh.org/news_item/whole-genome-sequencing-wgs-quality-control-qc-standards-approved-as-an-official-ga4gh-product/]
• 39. Multidrug-Resistant Bacteria in Immunocompromised Patients [https://pmc.ncbi.nlm.nih.gov/articles/PMC11434862/]
• 40. A Narrative Review of Current Evidence and Challenges [https://www.mdpi.com/2813-0618/4/4/21]
• 41. Serotype [https://en.wikipedia.org/wiki/Serotype]
• 42. Phage typing [https://en.wikipedia.org/wiki/Phage_typing]
• 43. Phage Types and Genotypes of Shiga Toxin-Producing ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC516362/]
• 44. Identifying potential novel widespread determinants of ... [https://pubmed.ncbi.nlm.nih.gov/40376455/]
• 45. Analysis of pathogenicity factors in the highly virulent ... [https://www.sciencedirect.com/science/article/abs/pii/S0044848624014443]
• 46. Rapid Identification of Gram-Negative Bacteria with and ... - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3122828/]
• 47. Machine Learning for Antimicrobial Resistance Prediction [https://pmc.ncbi.nlm.nih.gov/articles/PMC9491192/]
• 48. Towards an interpretable machine learning model for ... [https://www.sciencedirect.com/science/article/pii/S221371652500195X]
• 49. Validation of a Method to Identify Immunocompromised ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5461953/]
• 50. Comprehensive detection of pathogens in ... [https://www.nature.com/articles/s41598-018-22133-y]
• 51. Long-term taxonomic and functional divergence from donor ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182585]
• 52. A comparison of sequencing platforms and bioinformatics ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5598039/]
• 53. High-quality genome assemblies of 152 root commensal ... [https://www.nature.com/articles/s41597-025-06078-2]
• 54. Targeted Assembly of Obligate Intracellular Bacterial ... [https://www.atcc.org/resources/posters/2025-posters/targeted-assembly-of-obligate-intracellular-bacterial-genomes]
• 55. Comparison of Bioinformatics Pipelines and Operating ... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.01262/full]
• 56. SeqVISTA: a graphical tool for sequence feature visualization ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC140037/]
• 57. Jalview Home Page - Jalview [https://www.jalview.org/]
• 58. Polymicrobial Infections: A Comprehensive Review on ... [https://www.mdpi.com/2813-9054/70/4/39]
• 59. Novel Organism Verification and Analysis (NOVA) study [https://pubmed.ncbi.nlm.nih.gov/38178003/]
• 60. Diagnostic Challenges of Six-Pathogen Detected by mNGS ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12415102/]
• 61. Simultaneous detection and quantification of multiple ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10327253/]
• 62. Simultaneous detection and quantification of multiple ... [https://journals.plos.org/water/article?id=10.1371/journal.pwat.0000224]
• 63. Protocol for studying co-infection between SARS-CoV-2 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10258577/]
• 64. Mechanistic Models of Virus–Bacteria Co-Infections in ... [https://www.mdpi.com/2076-0817/14/8/830]
• 65. Protocol to analyze antimicrobial susceptibility data [https://pmc.ncbi.nlm.nih.gov/articles/PMC9641264/]
• 66. Microbial Identification and Strain Typing Using Molecular ... [https://www.rapidmicrobiology.com/test-method/molecular-techniques-for-microbial-identification-and-typing]
• 67. insights from panresistome analysis | BMC Microbiology [https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04406-5]
• 68. CLSI M39 AST Data Analysis Guide | News [https://clsi.org/about/news/clsi-publishes-new-guideline-m39-analysis-and-presentation-of-cumulative-antimicrobial-susceptibility-test-data/]
• 69. Quantitative and qualitative evaluation of antimicrobial usage [https://pmc.ncbi.nlm.nih.gov/articles/PMC11076899/]
• 70. Molecular techniques for detecting and typing of bacteria ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3597138/]
• 71. Antibiotic Resistance and Bacterial Infections in ... [https://www.frontiersin.org/research-topics/68859/antibiotic-resistance-and-bacterial-infections-in-immunocompromised-hostsundefined]
• 72. WHO warns of widespread resistance to common ... [https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide]
• 73. Novel Antibacterial Approaches and Therapeutic Strategies [https://pmc.ncbi.nlm.nih.gov/articles/PMC12024240/]
• 74. Combating Antimicrobial Resistance: Innovations and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12388624/]
• 75. U.S. Actions & Events to Combat Antimicrobial Resistance [https://www.cdc.gov/antimicrobial-resistance/programs/AR-actions-events.html]
• 76. BioAgents: Bridging the gap in bioinformatics analysis with ... [https://www.nature.com/articles/s41598-025-25919-z]
• 77. Core Elements of Antibiotic Stewardship [https://www.cdc.gov/antibiotic-use/hcp/core-elements/index.html]
• 78. Series Tackling antimicrobial resistance in people who are ... [https://www.sciencedirect.com/science/article/abs/pii/S1473309925003111]
• 79. Isolation and characterization of novel bacteriophages ... [https://www.nature.com/articles/s41598-025-14811-5]
• 80. Antimicrobial Resistance [https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance]
• 81. Observational Study of Microbial Colonization and Infection ... [https://www.mdpi.com/2227-9059/13/4/858]
• 82. A simple, low-cost, and highly efficient protocol for rapid ... [https://pubmed.ncbi.nlm.nih.gov/40881281/]
• 83. Data-driven prediction of colonization outcomes for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10944475/]
• 84. Current Clinical Landscape and Global Potential of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10146840/]
• 85. Phage therapy as a revitalized weapon for treating clinical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12540056/]
• 86. Phage Annotation and Nomenclature for Phage Therapy [https://pmc.ncbi.nlm.nih.gov/articles/PMC10627814/]
• 87. Phage treatment of multidrug-resistant bacterial infections ... [https://www.sciencedirect.com/science/article/pii/S2772431X25000073]
• 88. Antimicrobial Peptides: An Emerging Hope in the Era of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12189473/]
• 89. Antimicrobial peptides: a promising frontier to combat ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11981355/]
• 90. Mechanisms of Antimicrobial Peptide Action and Resistance [https://www.sciencedirect.com/science/article/pii/S0031699724015618]
• 91. Antimicrobial peptides: mechanism of action, activity and ... [https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-021-00343-2]
• 92. Molecular Mechanisms of Bacterial Resistance to ... [https://pubmed.ncbi.nlm.nih.gov/39065030/]
• 93. A generative artificial intelligence approach for the ... [https://www.nature.com/articles/s41564-025-02114-4]
• 94. The discovery of novel antimicrobial peptides against drug ... [https://www.sciencedirect.com/science/article/abs/pii/S0223523425002582]
• 95. Single or double lipid-modified ultra-short antimicrobial ... [https://www.sciencedirect.com/science/article/abs/pii/S0223523425000868]
• 96. Utility of Artificial Intelligence in Antibiotic Development [https://pmc.ncbi.nlm.nih.gov/articles/PMC11872168/]
• 97. Using artificial intelligence, researchers design new ... [https://www.broadinstitute.org/news/using-ai-researchers-design-new-compounds-kill-antibiotic-resistant-bacteria]
• 98. Using generative AI, researchers design compounds that ... [https://news.mit.edu/2025/using-generative-ai-researchers-design-compounds-kill-drug-resistant-bacteria-0814]
• 99. Novel Antibacterial Approaches and Therapeutic Strategies [https://www.mdpi.com/2079-6382/14/4/404]
• 100. Harnessing AI to Revolutionize Antibiotic Discovery [https://asm.org/articles/2025/august/ai-next-frontier-antibiotic-discovery]
• 101. 生物技术》：人工智能有望在最短的时间内发现更多新型抗生素 [https://news.bioon.com/article/17b7e267941e.html]
• 102. GSK and Fleming Initiative scientists unite to target AMR ... [https://www.gsk.com/en-gb/media/press-releases/gsk-and-fleming-initiative-scientists-unite-to-target-amr-with-advanced-ai/]
• 103. Major AI project to tackle drug-resistant superbugs [https://www.bbc.com/news/articles/cp97ggrnn35o]
• 104. 一种可解释的机器学习方法，用于识别抗生素的作用机制。 [https://suppr.wilddata.cn/browses/detail/pubmed/35725893]
• 105. Repurposing Non-Antibiotic Drugs as Novel Antibacterial ... [https://pubmed.ncbi.nlm.nih.gov/41155175/]
• 106. Repurposing Non-Antibiotic Drugs as Novel Antibacterial ... [https://www.mdpi.com/1422-0067/26/20/9880]
• 107. Drug repurposing against antibiotic resistant bacterial ... [https://pubmed.ncbi.nlm.nih.gov/39243454/]
• 108. The OREGANO knowledge graph for computational drug ... [https://www.nature.com/articles/s41597-023-02757-0]
• 109. Broad Institute | Repurposing Data Portal [https://repo-hub.broadinstitute.org/repurposing]
• 110. Exploration of databases and methods supporting drug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7986597/]
• 111. Current economic and regulatory challenges in developing ... [https://www.nature.com/articles/s44259-025-00123-1]
• 112. WHO releases new reports on new tests and treatments in ... [https://www.who.int/news/item/02-10-2025-who-releases-new-reports-on-new-tests-and-treatments-in-development-for-bacterial-infections]
• 113. The Changing Landscape of Antibiotic Treatment [https://www.mdpi.com/2079-6382/14/7/727]
• 114. 2025 AIFA Report on Antibiotics [https://www.aifa.gov.it/en/-/rapporto-aifa-2025-sugli-antibiotici]
• 115. Antibiotics re-booted—time to kick back against drug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12125309/]
• 116. Drugmakers announce encouraging new antibiotic data at ... [https://www.cidrap.umn.edu/antimicrobial-stewardship/drugmakers-announce-encouraging-new-antibiotic-data-idweek]
• 117. Antibiotics, Volume 14, Issue 8 (August 2025) – 115 articles [https://www.mdpi.com/2079-6382/14/8]